
<html lang="en"     class="pb-page"  data-request-id="f2d5a534-d048-448c-8899-3d780583dee4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b01046;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model" /></meta><meta name="dc.Creator" content="Kevin R.  Fales" /></meta><meta name="dc.Creator" content="F. George  Njoroge" /></meta><meta name="dc.Creator" content="Harold B.  Brooks" /></meta><meta name="dc.Creator" content="Stefan  Thibodeaux" /></meta><meta name="dc.Creator" content="Alicia  Torrado" /></meta><meta name="dc.Creator" content="Chong  Si" /></meta><meta name="dc.Creator" content="James L.  Toth" /></meta><meta name="dc.Creator" content="Jefferson R.  Mc Cowan" /></meta><meta name="dc.Creator" content="Kenneth D.  Roth" /></meta><meta name="dc.Creator" content="Kenneth J.  Thrasher" /></meta><meta name="dc.Creator" content="Kwame  Frimpong" /></meta><meta name="dc.Creator" content="Matthew R.  Lee" /></meta><meta name="dc.Creator" content="Robert D.  Dally" /></meta><meta name="dc.Creator" content="Timothy A.  Shepherd" /></meta><meta name="dc.Creator" content="Timothy B.  Durham" /></meta><meta name="dc.Creator" content="Brandon J.  Margolis" /></meta><meta name="dc.Creator" content="Zhipei  Wu" /></meta><meta name="dc.Creator" content="Yong  Wang" /></meta><meta name="dc.Creator" content="Shane  Atwell" /></meta><meta name="dc.Creator" content="Jing  Wang" /></meta><meta name="dc.Creator" content="Yu-Hua  Hui" /></meta><meta name="dc.Creator" content="Timothy I.  Meier" /></meta><meta name="dc.Creator" content="Susan A.  Konicek" /></meta><meta name="dc.Creator" content="Sandaruwan  Geeganage" /></meta><meta name="dc.Description" content="A hallmark of cancer is unbridled proliferation that can result in increased demand for de novo synthesis of purine and pyrimidine bases required for DNA and RNA biosynthesis. These synthetic pathw..." /></meta><meta name="Description" content="A hallmark of cancer is unbridled proliferation that can result in increased demand for de novo synthesis of purine and pyrimidine bases required for DNA and RNA biosynthesis. These synthetic pathw..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 9, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01046" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01046" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01046" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01046" /></link>
        
    
    

<title>Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01046" /></meta><meta property="og:title" content="Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0013.jpeg" /></meta><meta property="og:description" content="A hallmark of cancer is unbridled proliferation that can result in increased demand for de novo synthesis of purine and pyrimidine bases required for DNA and RNA biosynthesis. These synthetic pathways are frequently upregulated in cancer and involve various folate-dependent enzymes. Antifolates have a proven record as clinically used oncolytic agents. Our recent research efforts have produced LSN 3213128 (compound 28a), a novel, selective, nonclassical, orally bioavailable antifolate with potent and specific inhibitory activity for aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT), an enzyme in the purine biosynthetic pathway. Inhibition of AICARFT with compound 28a results in dramatic elevation of 5-aminoimidazole 4-carboxamide ribonucleotide (ZMP) and growth inhibition in NCI-H460 and MDA-MB-231met2 cancer cell lines. Treatment with this inhibitor in a murine based xenograft model of triple negative breast cancer (TNBC) resulted in tumor growth inhibition." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01046"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01046">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01046&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01046&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01046&amp;href=/doi/10.1021/acs.jmedchem.7b01046" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9599-9616</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01001" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00974" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of <i>N</i>-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3<i>R</i>)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+R.++Fales">Kevin R. Fales</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-7207-3610" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=F.+George++Njoroge">F. George Njoroge</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Harold+B.++Brooks">Harold B. Brooks</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Thibodeaux">Stefan Thibodeaux</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alicia++Torrado">Alicia Torrado</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chong++Si">Chong Si</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+L.++Toth">James L. Toth</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jefferson+R.++Mc+Cowan">Jefferson R. Mc Cowan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+D.++Roth">Kenneth D. Roth</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+J.++Thrasher">Kenneth J. Thrasher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kwame++Frimpong">Kwame Frimpong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+R.++Lee">Matthew R. Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+D.++Dally">Robert D. Dally</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+A.++Shepherd">Timothy A. Shepherd</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+B.++Durham">Timothy B. Durham</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brandon+J.++Margolis">Brandon J. Margolis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhipei++Wu">Zhipei Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Wang">Yong Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shane++Atwell">Shane Atwell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Wang">Jing Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu-Hua++Hui">Yu-Hua Hui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+I.++Meier">Timothy I. Meier</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan+A.++Konicek">Susan A. Konicek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandaruwan++Geeganage">Sandaruwan Geeganage</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Centro de Investigación Lilly, S. A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#c4a2a5a8a1b79bafa1b2adaa9bb684a8ada8a8bdeaa7aba9"><span class="__cf_email__" data-cfemail="6a0c0b060f1935010f1c030435182a060306061344090507">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01046&amp;href=/doi/10.1021%2Facs.jmedchem.7b01046" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9599–9616</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 26, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 July 2017</li><li><span class="item_label"><b>Published</b> online</span>9 November 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 December 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01046" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01046</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9599%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKevin%2BR.%2BFales%252C%2BF.%2BGeorge%2BNjoroge%252C%2BHarold%2BB.%2BBrooks%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D23%26contentID%3Dacs.jmedchem.7b01046%26title%3DDiscovery%2Bof%2BN-%25286-Fluoro-1-oxo-1%252C2-dihydroisoquinolin-7-yl%2529-5-%255B%25283R%2529-3-hydroxypyrrolidin-1-yl%255Dthiophene-2-sulfonamide%2B%2528LSN%2B3213128%2529%252C%2Ba%2BPotent%2Band%2BSelective%2BNonclassical%2BAntifolate%2BAminoimidazole-4-carboxamide%2BRibonucleotide%2BFormyltransferase%2B%2528AICARFT%2529%2BInhibitor%2BEffective%2Bat%2BTumor%2BSuppression%2Bin%2Ba%2BCancer%2BXenograft%2BModel%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9616%26publicationDate%3DDecember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01046"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1365</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01046" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;R. Fales&quot;},{&quot;first_name&quot;:&quot;F.&quot;,&quot;last_name&quot;:&quot;George Njoroge&quot;},{&quot;first_name&quot;:&quot;Harold&quot;,&quot;last_name&quot;:&quot;B. Brooks&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Thibodeaux&quot;},{&quot;first_name&quot;:&quot;Alicia&quot;,&quot;last_name&quot;:&quot;Torrado&quot;},{&quot;first_name&quot;:&quot;Chong&quot;,&quot;last_name&quot;:&quot;Si&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;L. Toth&quot;},{&quot;first_name&quot;:&quot;Jefferson&quot;,&quot;last_name&quot;:&quot;R. Mc Cowan&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;D. Roth&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;J. Thrasher&quot;},{&quot;first_name&quot;:&quot;Kwame&quot;,&quot;last_name&quot;:&quot;Frimpong&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;R. Lee&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;D. Dally&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;A. Shepherd&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;B. Durham&quot;},{&quot;first_name&quot;:&quot;Brandon&quot;,&quot;last_name&quot;:&quot;J. Margolis&quot;},{&quot;first_name&quot;:&quot;Zhipei&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shane&quot;,&quot;last_name&quot;:&quot;Atwell&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yu-Hua&quot;,&quot;last_name&quot;:&quot;Hui&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;I. Meier&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;A. Konicek&quot;},{&quot;first_name&quot;:&quot;Sandaruwan&quot;,&quot;last_name&quot;:&quot;Geeganage&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;9599-9616&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01046&quot;},&quot;abstract&quot;:&quot;A hallmark of cancer is unbridled proliferation that can result in increased demand for de novo synthesis of purine and pyrimidine bases required for DNA and RNA biosynthesis. These synthetic pathways are frequently upregulated in cancer and involve various folate-dependent enzymes. Antifolates have a proven record as clinically used oncolytic agents. Our recent research efforts have produced LSN 3213128 (compound 28a), a novel, selective, nonclassical, orally bioavailable antifolate with potent and specific inhibitory activity for aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT), an enzyme in the purine biosynthetic pathway. Inhibition of AICARFT with compound 28a results in dramatic elevation of 5-aminoimidazole 4-carboxamide ribonucleotide (ZMP) and growth inhibition in NCI-H460 and MDA-MB-231met2 cancer cell lines. Treatment with this inhibitor in a murine based xenograft model of triple negative breast cancer (TNBC) resulted in tumor growth inhibition.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01046&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01046" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01046&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01046" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01046&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01046" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01046&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01046&amp;href=/doi/10.1021/acs.jmedchem.7b01046" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01046" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01046" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01046%26sid%3Dliteratum%253Aachs%26pmid%3D29072452%26genre%3Darticle%26aulast%3DFales%26date%3D2017%26atitle%3DDiscovery%2Bof%2BN-%25286-Fluoro-1-oxo-1%252C2-dihydroisoquinolin-7-yl%2529-5-%255B%25283R%2529-3-hydroxypyrrolidin-1-yl%255Dthiophene-2-sulfonamide%2B%2528LSN%2B3213128%2529%252C%2Ba%2BPotent%2Band%2BSelective%2BNonclassical%2BAntifolate%2BAminoimidazole-4-carboxamide%2BRibonucleotide%2BFormyltransferase%2B%2528AICARFT%2529%2BInhibitor%2BEffective%2Bat%2BTumor%2BSuppression%2Bin%2Ba%2BCancer%2BXenograft%2BModel%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D23%26spage%3D9599%26epage%3D9616%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292101" title="Nutrition">Nutrition</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/jmcmar.2017.60.issue-23/20171214/jmcmar.2017.60.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A hallmark of cancer is unbridled proliferation that can result in increased demand for de novo synthesis of purine and pyrimidine bases required for DNA and RNA biosynthesis. These synthetic pathways are frequently upregulated in cancer and involve various folate-dependent enzymes. Antifolates have a proven record as clinically used oncolytic agents. Our recent research efforts have produced LSN 3213128 (compound <b>28a</b>), a novel, selective, nonclassical, orally bioavailable antifolate with potent and specific inhibitory activity for aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT), an enzyme in the purine biosynthetic pathway. Inhibition of AICARFT with compound <b>28a</b> results in dramatic elevation of 5-aminoimidazole 4-carboxamide ribonucleotide (ZMP) and growth inhibition in NCI-H460 and MDA-MB-231met2 cancer cell lines. Treatment with this inhibitor in a murine based xenograft model of triple negative breast cancer (TNBC) resulted in tumor growth inhibition.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer requires both DNA and RNA to support unbridled proliferation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> As components in the synthesis of DNA and RNA, the purines adenine and guanine are critical for cell proliferation. Generation of these key elements is directly dependent on one-carbon metabolic processes involving folate-dependent enzymes (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) that were first elucidated in 1959.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The purine biosynthetic sequence initiates with conversion of 5-phosphoribosyl-1-pyrophosphate (PRPP, <b>1</b>) to glycinamide ribonucleotide (GAR, <b>2</b>). The folate-dependent enzyme glycinamide ribonucleotide formyltransferase (GARFT) then adds a single carbon via formylation to generate α-<i>N</i>-formylglycinamide ribonucleotide (FGAR, <b>3</b>). Subsequent transformation steps provide 5-aminoimidazole 4-carboxamide ribonucleotide (ZMP, <b>4</b>), the substrate for the bifunctional human enzyme aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Purine biosynthetic pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ATIC enzyme consists of two domains with separate functions. The first domain, aminoimidazole-4-carboxamide ribonucleotide formyltransferase or AICARFT, facilitates formyl transfer from <i>N</i><sup>10</sup>-formyl-tetrahydrofolate (N<sup>10</sup>-CHO-THF) to ZMP, producing 5-formamidoimidazole-4-carboxamide ribotide (FAICAR, <b>6</b>). Subsequent cyclization of FAICAR in the second domain of ATIC, inosine monophosphate cyclohydrolase (IMPCH), results in inosine 5′-monophosphate (IMP, <b>7</b>).</div><div class="NLM_p">Inhibitors of AICARFT (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) that have been reported include pemetrexed (<b>9</b>, Ptx), the dihydrofolate reductase (DHFR) inhibitor methotrexate (Mtx, <b>10</b>), <i>N</i>-[(4-{[(2-amino-4-oxo-3,4-dihydroquinazolin-6-yl)amino]sulfonyl}phenyl)carbonyl]-<span class="smallcaps smallerCapital">l</span>-glutamic acid (<b>11</b>), 5- and 6-substituted pyrrolo[2,3-<i>d</i>]pyrimidines reported by Gangjee et al., a series of multisubstrate adduct inhibitors including β-DADF, an inhibitor of ATIC homodimerization, and a series of nonclassical antifolates reported by Agouron.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7 ref8">(3-8)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Reported AICARFT inhibitors and binding regions of <b>11</b>. (a) Crystal structure of <b>11</b> was obtained from PDB (code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1pl0">1pl0</a>; BW2315U89UC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ptx is a classical antifolate with primary activity for inhibition of thymidylate synthase (TS) in the pyrimidine biosynthetic pathway and has been approved by the FDA with vitamin supplementation per label for use in combination with cisplatin as a first line treatment of advanced nonsquamous non-small-cell lung cancer. Ptx is also a multitargeting inhibitor, with activity against dihydofolate reductase (DHFR) and GARFT.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> More recently, Moran et al. reported that a secondary target of Ptx is AICARFT, resulting in accumulation of ZMP and activation of AMP-activated protein kinase (AMPK) with additional downstream effects.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a></div><div class="NLM_p">As classical antifolates, Ptx and likewise Mtx are compounds from a class of drugs that have been extensively studied and used with great success for decades.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The biophysical properties of classical antifolates require parenteral administration, followed by active uptake in cells via reduced folate carrier (RFC), folate receptors (FRα, FRβ, FRγ), or the proton-coupled folate transporter (PCFT), and subsequent conversion to the corresponding polyglutamates via folylpolyglutamate synthase (FPGS).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> While the resulting sequestration of the drugs within the cells dramatically enhances potency at the targeted enzyme, a potentially undesirable result of polyglutamation is enhanced activity toward other folate dependent enzymes.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Also, a major mechanism of resistance to classical antifolates is through genetic mutation leading to impairment of the transport and polyglutamation mechanisms.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In contrast, nonclassical antifolates penetrate cells through passive diffusion, require no intracellular modification in order to exert their effects, and thus can overcome resistance due to impaired active uptake.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">As noted above, inhibition of AICARFT results in elevation of ZMP, a key intermediate in the biosynthesis of purines for a wide variety of species. In addition to its role for the synthesis of DNA and RNA, effects of ZMP have been reported in diverse areas of pharmacological research including oncology, inflammation, autoimmune disease, and diabetes.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Due to its broad effects, ZMP has also been touted as a master regulator of one-carbon metabolism in bacteria, having been shown to activate a conserved riboswitch that regulates expression of associated genes.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Aminoimidazole-4-carboxamide ribonucleoside (AICAr, compound <b>5</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) is the corresponding des-phosphorylated analogue of ZMP and as such is freely permeable and orally bioavailable. Once absorbed, AICAr is rapidly phosphorylated by cells yielding ZMP and has been widely used to study systemic metabolic effects of AMPK activation by ZMP.</div><div class="NLM_p">AICAr was also studied clinically as an oncolytic under the trade name Acadesine, for treatment of childhood acute lymphoblastic leukemia (ALL), but required high doses to maintain elevated levels of ZMP, due to rapid metabolic progression of this intermediate through the purine biosynthetic pathway (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Encouraged by the potential pharmacological benefit of extended elevation of ZMP, we hypothesized that selective inhibition of AICARFT with an orally bioavailable, nonclassical antifolate would lead to durable and sustained elevation of ZMP, resulting in anticancer therapeutic activity.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i2" class="anchor-spacer"></div><h3 class="article-section__title" id="_i2"> Strategy and Initial Leads</h3><div class="NLM_p">In 2004, Beardsley et al. reported the structure of ATIC in complex with the bis-arylsulfonamide <b>11</b>, in which the crystal structure revealed four distinct binding regions as highlighted in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> and described here as the pteridine, oxyanion hole, ZMP π-stack, and glutamate binding regions.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">To reiterate from Beardsley’s paper regarding AICARFT, (1) there was no sequence homology with other folate-dependent enzymes, providing a basis for design of selective inhibitors, (2) the oxyanion hole was a major factor in determining the position of the sulfonyl-containing antifolates within the AICARFT active site, and (3) exploitation of the oxyanion hole for design of selective inhibitors was possible since other folate dependent enzymes (GARFT, TS, DHFR, etc.) did not contain this feature.</div><div class="NLM_p">Compound <b>11</b> was reported to be potent enzymatically (<i>K</i><sub>i</sub> = 6 nM),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> but this activity did not translate well in vitro as the reported IC<sub>50</sub> for this compound was between 1 and 5 μM. This relative loss of activity could possibly be due to poor free permeability of the compound due to bis-carboxylic acids present in its glutamate side chain. Activity of this compound for cellular uptake by folate transporters or the reduced folate carrier was not reported. Use of this compound in vivo also has not been described.</div><div class="NLM_p">The background provided through the work reported by Beardsley et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> encouraged us with the possibility of utilizing structure based design in pursuit of AICARFT inhibitors. We began with an in-house screening effort of ∼100 000 compounds that ultimately yielded compound <b>12</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), which demonstrated low inhibitory activity (IC<sub>50</sub> = 35 μM, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Subsequent explorations resulted in <b>13</b>, potentially a minimum pharmacophore since removal of the primary amide from <b>13</b> generating <b>14</b> resulted in no inhibitory activity even at 100 μM.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Initial leads.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Activity of Early SAR Compounds<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">enzyme IC<sub>50</sub> ± SD (nM)</th><th class="colsep0 rowsep0" align="center">cell IC<sub>50</sub> ± SD (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">34800</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">90000 ± 5445</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">>100000</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">608 ± 286</td><td class="colsep0 rowsep0" align="left">567 ± 289</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">18100 ± 12000</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">723 ± 241</td><td class="colsep0 rowsep0" align="left">1811 ± 910</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">With the exception of compound <b>12</b>, all values represent average results from replicates of two or more measurements.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Concentration at 50% maximum inhibition in NCI-H460 cells, grown in low folate media as described in the biological methods.</p></div></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85428" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85428" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our approach in order to identify more potent and drug-like compounds led us to investigate modifications in four distinct areas of the inhibitors, defining the parts in correspondence with the binding elements shown previously for <b>11</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), including the pteridine, oxyanion hole, ZMP π-stack, and glutamate binding regions. Under the aforementioned designations, the exploration of pertinent features will be described systematically in subsequent sections.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Pteridine Binding Region</h3><div class="NLM_p">With <b>13</b> as a design starting point (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), our first target was envisioned to include addition of two carbons and cyclization to generate the isoquinolone <b>15</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). While compounds <b>12</b>–<b>14</b> were available from commercial sources, <b>15</b> was synthesized by coupling of commercially available 7-aminoisoquinolin-1(2<i>H</i>)-one <b>17</b> to 4-cyanobenzenesulfonyl chloride <b>18</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Biochemical testing of <b>15</b> found that it provided a dramatic increase in AICARFT enzymatic inhibition versus <b>13</b> (IC<sub>50</sub> = 608 nM vs 90 μM). Due to the enzymatic potency of <b>15</b>, it was also tested in vitro using NCI-H460 cells. This cell line was chosen based on Moran’s identification of AICARFT as a secondary target for Ptx in NCI-H46O.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> Compound <b>15</b> was found to have enzymatic activity (IC<sub>50</sub>) of 608 ± 290 nM and comparable cell activity (IC<sub>50</sub>) of 567 ± 290 nM. It is relevant and important to note with regard to this cell activity as well as the in vivo studies discussed below that the levels of folate in media used for cell culture are often higher than circulating folate levels in humans and rodents. For example, Roswell Park Memorial Institute (RPMI) 1640 cell culture media contain 2 μM folic acid. Circulating serum folate levels have been reported for several species and are lower than RPMI 1640 media.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> For example, human serum folate levels are in the range of 20 nM, and rodents exhibit ∼10-fold higher levels of ∼200 nM. Since our inhibitors directly competed with <i>N</i><sup>10</sup>-formyltetrahydrofolate (the natural substrate for AICARFT, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), higher folate levels in cell culture media were expected to have a negative impact on antiproliferative response relative to normal in vivo conditions. For this reason, the cell culture assay was run using cells grown under low folate conditions as described in the biological methods.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The reported structure of <b>11</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> showed interactions of the aminoquinazolinone moiety deep within the pteridine pocket, including hydrogen bonds to Asn489, Asp546′, Asn547′, and Ile452′. These interactions were likely comparable to those made by the pteridine ring of the natural substrate. This along with the expectation that the isoquinolone of <b>15</b> similarly bound in the pteridine pocket led us to attempt further binding enhancement by conversion of the isoquinolone to be more pteridine-like through replacement of C4 with nitrogen and addition of an exocyclic amine at C3 (see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> for numbering). Compound <b>16</b> was generated from the corresponding amine <b>20</b>, prepared by reductive hydrogenation of the commercially available 2-amino-6-nitroquinazolinone <b>19</b>. Contrary to our expectations, AICARFT enzyme IC<sub>50</sub> of <b>16</b> was found to be only 18 ± 12 μM, representing a 30-fold loss in potency versus <b>15</b>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Oxyanion Hole</h3><div class="NLM_p">Although crystal structure analysis indicated a sulfonamide group would be ideal for binding to the oxyanion hole in AICARFT, in silico calculations indicated improvements in drug-like properties (solubility, permeability) could be achieved through replacement of this functionality. We investigated numerous reported sulfonamide replacements including common isosteres such as carboxamide and urea, as well as simpler two-atom linkers like alkylamines, each designed to engage key residues in the oxyanion hole (as reviewed below for sulfonamide). In every case the compounds produced were devoid of activity in the enzyme assay (i.e., IC<sub>50</sub> > 100 μM, structures and data not shown). In order to enhance the drug-like properties of the bis-arylsulfonamide in compounds like <b>15</b>, F for H substitution on C6 of the neighboring isoquinolone as in compound <b>25</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was targeted, expecting to lower the p<i>K</i><sub>a</sub> of the neighboring sulfonamide, leading to improved aqueous solubility at or above pH 6. In addition to improved solubility, we hypothesized that intramolecular hydrogen bonding between the C6 fluorine and the sulfonamide NH might lead to improved permeability.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) triphosgene, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N (0 °C) followed by AlCl<sub>3</sub> (0 °C to rt); (b) H<sub>2</sub>SO<sub>4</sub>, KNO<sub>3</sub> (0 °C); (c) MnO<sub>2</sub>, dichloroethane (120 °C); (d) Pd/C, H<sub>2</sub>, MeOH.</p></p></figure><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Crystal structure of <b>28a</b> (white) and ZMP (yellow) in complex with ATIC (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UZ0">5UZ0</a>). (b) Top: Overlay of <b>11</b> (yellow) from PDB (code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1pl0">1pl0</a>) with <b>28a</b> (cyan) and ZMP (majenta) in the AICARFT domain. Middle: <b>28a</b> in the AICARFT domain. Bottom: Two-dimensional representation of key binding interactions. (c) Pteridine binding region detailed interactions. (d) Oxyanion hole detailed interactions. (e) ZMP π-stack and glutamate binding regions detailed interactions. (f) Protein surface representation of the ZMP π-stack and glutamate binding regions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">7-Amino-6-fluoroisoquinolone <b>24</b> was prepared by in situ generation of a carbamoyl chloride from phenylethanamine <b>21</b> and triphosgene, followed by cyclization under Friedel–Crafts conditions to provide dihydroisoquinolone <b>22</b>. Selective nitration afforded the 7-nitro intermediate that was oxidized to yield isoquinolone <b>23</b> by heating overnight in dichloroethane with 10 equiv of MnO<sub>2</sub>. Subsequent hydrogenation provided amine <b>24</b> as a brown solid that was readily crystallized from water. Similar to the synthesis of <b>15</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), coupling of <b>24</b> and <b>18</b> yielded the corresponding 6-fluoro isomer <b>25</b>.</div><div class="NLM_p">As predicted, introduction of fluorine at C6 resulted in p<i>K</i><sub>a</sub> reduction to 5.97 for <b>25</b> in comparison with 6.93 for <b>15</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) with concomitant decrease in log <i>D</i> at neutral pH and above. No significant difference in solubility was found between <b>15</b> and <b>25</b>, and in contrast to our hypothesis, measured permeability in MDCK cells found reduced permeability (0.35 vs 0.55% A-B). This reduction could be due to the increased polarity of the NH bond in <b>25</b> as reflected in the lower p<i>K</i><sub>a</sub> for this compound. Nonetheless, this modification did provide a pharmacokinetic benefit in vivo since after a 10 mg/kg oral dose a 3-fold enhancement of plasma exposure in mice with <b>25</b> was achieved, yielding an AUC of 55 800 ng·h/mL and 79% bioavailability in comparison to an AUC of 16 100 ng·h/mL and 43% bioavailability for <b>15</b>. No differences in enzymatic inhibition were detected between compounds <b>15</b> and <b>25</b>, although a slight loss in cell based activity was measured with <b>25</b>. In subsequent SAR fluorine at quinolone position C6 often yielded improvements in both measures, and this modification was maintained in all later stage compounds.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Beneficial Impact of Fluorine Substitution on Compound <b>25</b> Pharmacokinetic Properties</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0011.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Mean result from <i>n</i> = 3 replicates. Percent CV was <30% for all results.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> ZMP π-Stack</h3><div class="NLM_p">From the reported crystal structure of <b>11</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), a π -stacking interaction of the benzamide with cocrystallized ZMP was noted. Within medicinal chemistry and shown also in antifolate research, thiophene is a common replacement for phenyl, and this same modification proved valuable to our efforts. The chemistry to install thiophene (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) involved coupling of amine <b>24</b> with commercially available 5-Br- or 5-F-thiophene-2-sulfonyl chloride to yield intermediates (<b>26</b> or <b>27</b>). In addition to maintaining a π -stacking interaction with ZMP, as shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>e, C5 of thiophene provided a beneficial trajectory for terminal substitution that afforded a means to gain interactions with Asp339.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) sulfonyl chloride, pyridine; (b) amine, CuBr, CsCO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub>, DMSO, 100 °C, 16 h; (c) amine, pyridine, 110 °C, 40 h; (d) pyridone-boronate, Pd(dppf), K<sub>2</sub>CO<sub>3</sub>, dioxane, water, 140 °C, microwave, 90 min; (e) 2-thienylzinc bromide, Pd(dppf), THF, 60 °C, 17 h; (f) chlorosulfuric acid, dichloromethane, 0 °C to ambient, 90 min; (g) pyridine, 16 h.</p></p></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Glutamate Binding Region</h3><div class="NLM_p">A wide diversity of substitutions at thiophene C5 were explored as documented in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> and <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Synthesis of these compounds proceeded through reaction of 5-halothiophene <b>26</b> or <b>27</b> with cyclic amines under S<sub>N</sub>Ar or Buchwald amination conditions to provide <b>28a</b> and related analogues <b>28b</b>–<b>i</b> or with pyridone boronate to provide <b>29</b>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> While the amines used were commercially available, in related work we developed and recently reported an enantioselective synthesis of 3,3-difluoropyrrolidin-4-ol, as well as RCM-mediated synthesis of the dihydropyridones <b>30a</b>,<b>b</b>.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Intermediates <b>30a</b>,<b>b</b> were reacted with 2-thienylzinc bromide under Negishi conditions to provide thiophenes <b>31a</b>,<b>b</b>. Subsequent chlorosulfonylation and coupling with <b>24</b> produced dihydropyridones <b>32a</b>,<b>b</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biochemical, in Vitro, and Mouse Plasma Exposure of Leading Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Results ± SD from <i>n</i> = 3 or more replicates.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Concentration at 50% maximum inhibition in NCl-H460 cells, grown in low folate media as described in the biological methods.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Mean results from <i>n</i> = 3 replicates. Percent CV was <30% for all results. <span class="NLM_inline-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/jm-2017-01046b_m001.gif" alt="" /></img></span></p></div></div><div></div></div><div class="NLM_p">As noted in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, this effort produced several molecules that were essentially equipotent in both enzymatic (5–30 nM) and cellular activity assays (4–70 nM). Likewise, permeability was also low to moderate for all compounds, with some distinction between the two classes of compounds that emerged from this exploration. The N-linked heterocycles <b>28a</b>–<b>g</b> generally gave better permeability vs the C5-linked pyridone <b>29</b> and dihydropyridones <b>32a</b>,<b>b</b>. The N-linked heterocycles were further characterized by excellent enzyme inhibition that translated well to give potent in vitro activities. For example, <b>28a</b> recorded an IC<sub>50</sub> of 16 nM for AICARFT enzyme inhibition and 19 nM in cells. Interestingly, equipotent in vitro activities were typically observed by enantiomeric pairs in these series (e.g., <b>28a</b>,<b>b</b>, <b>28h</b>,<b>i</b>). By slight contrast, while <b>29</b> and <b>32a</b>,<b>b</b> provided dramatically potent enzymatic inhibition with IC<sub>50</sub> values in every case below the quantitation limit of the assay (<5 nM), their activities neither translated well to target inhibition in cells nor translated ultimately to in vivo activity. This difference could possibly be due to the noted reduced permeability of the pyridone/dihydropyridones relative to their N-linked counterparts.</div><div class="NLM_p">Since in vitro potencies of these late-stage SAR compounds were generally comparable and in order to identify compounds for further study, the compounds in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> were further assessed for single time point oral exposure in vivo. The concentration of each of the 12 compounds was measured in mouse plasma, sampled 1 h after a 10 mg/kg oral dose of compound. These experiments resulted in a range of values from 1.7 μM for pyridone <b>29</b> up to 33 μM for difluorohydroxypyrrolidine <b>28i</b>. Each of the enantiomeric pairs (<b>28a</b>,<b>b</b>; <b>28c</b>,<b>d</b>; <b>28f</b>,<b>g</b>; <b>28h</b>,<b>i)</b> demonstrated similar exposure levels. However, the measured exposures showed a trend toward higher levels upon ring fluorination in hydroxypyrrolidines, including a greater than 2-fold increase effected by addition of <i>gem</i>-difluoride α to the hydroxyl (<b>28a</b> vs <b>28h</b>). Partial saturation and alkylation of the pyridone ring in <b>29</b> resulted in <b>32a</b>,<b>b</b> that likewise produced a 6- to 18-fold increase in measured plasma exposure. The unbound or free fraction in mouse plasma was also determined and was low for all compounds tested, although the dihydropyridones <b>32a</b> and <b>32b</b> were unique in the set for this parameter, returning unbound fractions that were below the limit of quantitation (<0.02–0.03) for the assay.</div><div class="NLM_p last">To distinguish between compounds <b>28</b>–<b>32</b> based on their in vitro activity and their in vivo free drug exposure, we determined cell-based target engagement ratios (cTERs) for each compound, which was calculated as the ratio of its unbound plasma concentration normalized to the corresponding cell-based IC<sub>50</sub>. As noted in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, this evaluation allowed distinction between enantiomeric pairs. For example, while cTER for the <i>R</i>-isomer <b>28a</b> was calculated at 24, that for the <i>S</i>-isomer <b>28b</b> was only 10. Unfortunately, measured unbound fractions for <b>32a</b>,<b>b</b> were below the limit of quantitation for the assay, preventing calculation of the cTER values for these compounds. As a result of this analysis, four compounds (<b>28a</b>, <b>28f</b>, <b>28i</b>, and <b>32a</b>) were selected for additional analysis (vide infra).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Structural Chemistry</h3><div class="NLM_p last"><a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>a illustrates the binding <b>28a</b> in complex with human ATIC, which exists and functions as a homodimer. Successful crystallization of our compounds required the experiment to be performed in the presence of ZMP, and interactions with protein and the ZMP cofactor were clearly present as described below. <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>b (top) shows <b>11</b>, obtained from the PDB (code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=lp10">lp10</a>), overlaid with the crystal structure of <b>28a</b> to demonstrate the two inhibitors occupy the same AICARFT binding pocket and make similar interactions with the protein. For clarity, the representation shown in the top figure is duplicated in the <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>b (middle) except in this case <b>28a</b> is presented alone. <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>c (bottom) provides a two-dimensional representation of the key binding interactions for <b>28a</b>. For clarity in presentation in all figures, only one of the four binding sites observed in the crystal structure is shown. The asymmetric unit of this crystal complex contained two separate homodimers, each bearing two binding sites at the dimeric interface where the ZMP cofactor binds, which altogether resulted in the four discrete binding sites.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pteridine Binding Region</h3><div class="NLM_p last"><a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>c illustrates the pteridine binding region from the crystal structure of <b>28a</b> in complex with human ATIC. Notable interactions for <b>28a</b> in this area include hydrogen bonding from the carboxylate of Asp546 to the isoquinolone NH and 3-position C–H, and hydrogen bonds from the two lone pairs of the isoquinolone carbonyl to the side-chain amide NH of Asn547 and backbone NH of Ile452. In addition, the electron deficient hydrogens at the 4- and 5-positions of the aromatic bicycle hydrogen bond with the Asn489 side chain amide oxygen and Met312 backbone carbonyl oxygen, respectively.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Oxyanion Hole Region</h3><div class="NLM_p last">The central sulfonamide of <b>28a</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>d) binds in the anionic state to Lys266 through a salt bridge, as inferred from both the flat torsion along the aryl–N bond since a neutral sulfonamide sp<sup>3</sup> nitrogen is known to adopt a more tetrahedral geometry. Binding in the anionic state is also indicated due to the close intermolecular N to N proximity. While two of the polarized hydrogens from the protonated primary amine of Lys266 form intraprotein hydrogen bonds with the backbone carbonyl oxygens of Phe31 and Ser313, the third hydrogen forms a bifurcated hydrogen bond to the nitrogen and one oxygen of the sulfonamide. This same oxygen also hydrogen-bonds with the pyramidal, anilinic, exocyclic amine of ZMP and the side chain amide NH of Asn431. The second sulfonamide oxygen does not appear as well satisfied in the bound state, forming a single hydrogen bond to the backbone-NH of Arg451 and a dispersion contact with the β-carbon on the aliphatic portion of the Arg451 side chain.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> ZMP π-Stack and Glutamate Binding Regions</h3><div class="NLM_p">The 1-(thiophene-2-yl)pyrrolidin-3-ol tail of <b>28a</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>e,f) traverses through a shape-complementary channel, forming a π-stack interaction with the ZMP imidazole below and multiple van der Waals’ contacts with Pro543 and Phe315 above. The anilinic nitrogen of the pyrrolidine keeps the adjacent sp<sup>3</sup> carbons at the 2- and 5-positions roughly coplanar with the thiophene in a portion of the binding site where nonplanarity appears sterically tolerable. The hydroxyl group of <b>28a</b> projects axially off from the downward-puckered carbon at the pyrrolidine’s 3-position, hydrogen-bonding with the Asp339 carboxylate side chain. This carboxylate in turn hydrogen-bonds with a ZMP hydroxyl group and forms a salt bridge with Lys358 that is ∼5 Å from the pyrrolidine. The carbon at the 4-position of the saturated heterocycle is completely solvent exposed and forms no dispersion contacts with the protein or ZMP.</div><div class="NLM_p">In a second crystal structure (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>), analysis of pyridone <b>32b</b> in complex with human ATIC revealed some unique interactions in the glutamate region, possibly providing additional binding energy that led to the noted potency of the pyridone series. Similar to the structure for <b>28a</b>, the crystal complex of <b>32b</b> with ATIC also resulted in two homodimers per asymmetric unit and four independent binding sites. <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a> illustrates one the binding sites, with <b>32b</b> binding the same as <b>28a</b> in the buried portion of the structure but differing significantly in the solvent-exposed, glutamate binding region. The amide and olefin of the dihydropyridone, together with the thiophene, comprise a single planar, conjugated system that keeps the adjacent sp<sup>3</sup> carbons at the 4- and 5-positions of the dihydropyridone in the same plane as the ring amide and olefin. The endocyclic amide forms hydrogen bonds with Asp339 in all four of the binding sites but also with Lys358 in two out of the four binding sites. Neither of the two branched α-carbons at the 5-position form contacts with the protein or cofactor, while the terminal β-carbon of the ethyl forms van der Waals contacts with Phe315 in all four of the binding sites and with Val337 in one of the four. The heterogeneity of polar contacts in this solvent-exposed region suggests that the binding efficiency for this region of the molecule may be short of optimal.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Binding interactions of <b>32b</b> in complex with ATIC (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UY8">5UY8</a>). (b) Protein surface representation of <b>32b</b> in complex with ATIC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Biology</h3><div class="NLM_p">With plans to demonstrate the antiproliferative activity of the AICARFT inhibitors in a murine-based xenograft model and given that folate levels in mice are higher (vide supra) than in humans, compound <b>28a</b> was screened in standard RPMI media to identify cell lines that would respond in the presence of higher circulating folate. As noted in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, in MDA-MB-231 cells compound <b>28a</b> exhibited excellent AICARFT inhibition/ZMP elevation as well as strong antiproliferative effects, even in the presence of high folate containing standard RPMI media. To fully demonstrate the impact of folate levels in tissue culture, experiments were conducted in both standard RPMI media and low folate RPMI media, which contained no folic acid, comparing both NCI-H460 cells and MDA-MB-231 cells. As shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, <b>28a</b> appears to be a folate competitive inhibitor in tissue culture since in NCI-H460 the ZMP response was nearly 80 times stronger in low folate media (ZMP EC<sub>50</sub> = 8 nM vs 356 nM for regular media). The same trend was present, though less pronounced in MDA-MB-231 cells with an approximately 10-fold shift noted. This difference was likely due to the lack of reduced folate carrier in MDA-MB-231 cells resulting in lower intracellular folate concentrations. The compound also clearly demonstrated antiproliferative effect in NCI-H460 cells (Alamar Blue GI<sub>50</sub> = 16.4 nM in low folate media) that was likewise impacted when using standard RPMI media (GI<sub>50</sub> = 3470 nM). By comparison, the GI<sub>50</sub> in MDA-MB-231 cells was 44 nM in standard media.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Compound <b>28a</b> Activity in Tissue Culture: Low Folate vs Regular Folate<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">ZMP EC<sub>50</sub> ± SE (nM)</th><th class="rowsep1 colsep0" colspan="2" align="center">Alamar Blue GI<sub>50</sub> ± SE (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">low folate</th><th class="colsep0 rowsep0" align="center">regular folate</th><th class="colsep0 rowsep0" align="center">low folate</th><th class="colsep0 rowsep0" align="center">regular folate</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NCI-H460 (lung)</td><td class="colsep0 rowsep0" align="left">8.0 ± 5.8</td><td class="colsep0 rowsep0" align="left">356 ± 5</td><td class="colsep0 rowsep0" align="left">25 ± 3</td><td class="colsep0 rowsep0" align="left">6580 ± 840</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-231 (mammary)</td><td class="colsep0 rowsep0" align="left">7.6 ± 2.9</td><td class="colsep0 rowsep0" align="left">73 ± 6</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">44 ± 10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Representative curves available in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf" class="ext-link">Supporting Information Figures 1 and 2</a>.</p></div></div></div><div class="NLM_p">In vivo pharmacokinetic analyses of <b>28a</b>, <b>28f</b>, <b>28i</b>, and <b>32a</b> were conducted in mice, and the results are outlined in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. The parent hydroxypyrrolidine <b>28a</b> demonstrated the highest level of unbound intrinsic clearance (Cl<sub>u</sub>) (78 mL min<sup>–1</sup> kg<sup>–1</sup>) and corresponding lowest unbound oral exposure (unbound AUC = 1279 nM·h for a 10 mg/kg dose). Addition of one or two fluorines (<b>28f</b>, <b>28i</b>) provided incremental improvements in both Cl<sub>u</sub> and AUC<sub>u</sub>, as well as increases in plasma half-life (<i>t</i><sub>1/2</sub>) and bioavailability, with <b>28i</b> returning the best plasma half-life result of 3.2 h and overall best bioavailability of 55%. Of the four compounds tested, dihydropyridone <b>32a</b> had the lowest Cl<sub>u</sub> (19 mL min<sup>–1</sup> kg<sup>–1</sup>), highest AUC<sub>u</sub> (2159 nM·h), and longest plasma half-life (5.2 h) but the lowest bioavailability (23%). Unbound peak plasma concentration (<i>C</i><sub>max<sub>u</sub></sub>) after oral dosing was comparable for all four compounds (187–293 nM) Taking into account the difference in dosing levels, compound <b>28a</b> demonstrated the lowest <i>C</i><sub>max<sub>u</sub></sub>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Analysis of Best Compounds<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">compound</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center"><b>28a</b></th><th class="colsep0 rowsep0" align="center"><b>28f</b></th><th class="colsep0 rowsep0" align="center"><b>28i</b></th><th class="colsep0 rowsep0" align="center"><b>32a</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl<sub>u</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>), iv</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vd<sub>ss,u</sub> (L/kg), iv</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>u</sub> (nM·h), po</td><td class="colsep0 rowsep0" align="left">1279</td><td class="colsep0 rowsep0" align="left">1520</td><td class="colsep0 rowsep0" align="left">2110</td><td class="colsep0 rowsep0" align="left">2159</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h), po</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max,u</sub> (nM), po</td><td class="colsep0 rowsep0" align="left">289</td><td class="colsep0 rowsep0" align="left">232</td><td class="colsep0 rowsep0" align="left">293</td><td class="colsep0 rowsep0" align="left">187</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">23</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Reported values are average results from <i>n</i> = 3 animals.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Calculated values assuming Fu = 0.02 (measured Fu was <0.02).</p></div></div></div><div class="NLM_p">In order to establish target related pharmacodynamics response and further to determine which of the most active compounds to carry into in vivo efficacy studies (vide infra), compounds <b>28a</b>, <b>28f</b>, <b>28i</b>, and <b>32a</b> were also evaluated in dose–response target inhibition studies in vivo using nude mice bearing H460 xenografts. Cognizant of the higher circulating folate levels in rodents, in order to better reflect the activity of our compounds in a system that mimicked human circulating folate levels, the mice used for these studies were maintained on a low folate diet for at least 2 weeks prior to study until baseline plasma folate levels were comparable to those reported for humans. The results of these experiments are shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. Compounds <b>28a</b>, <b>28f</b>, and <b>28i</b> exhibited nearly linear exposure increases through the dose range tested (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf" class="ext-link">Supporting Information</a>) with >100-fold enhancement of intratumoral ZMP levels versus tumors obtained from vehicle treated animals (baseline tumor ZMP = 7 μM, <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>a). While ZMP was sequestered within cells, hydrolysis of the phosphate released the freely permeable metabolite AICAr that was readily measured in plasma. Similar to the results with ZMP, compound treated animals exhibited dramatic increases in circulating AICAr with enhancements of up to 80-fold over baseline (0.04 μM). Dosing with <b>28a</b> resulted in higher plasma AICAr levels versus the other inhibitors tested (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>b), and combination of the intracellular ZMP response with the plasma AICAr response indicated overall that of the four compounds tested, <b>28a</b> demonstrated the most robust in vivo inhibition of AICARFT.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Results from in vivo target inhibition studies using H460 xenografts in mice maintained on low folate diet: (a) tumor ZMP concentrations at increasing dose levels of compounds <b>28a</b>, <b>28f</b>, <b>28i</b>, and <b>32a</b>; (b) plasma AICAr concentrations at increasing dose levels of compounds <b>28a</b>, <b>28f</b>, <b>28i</b>, and <b>32a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These results also supported <b>28a</b> as a selective inhibitor for AICARFT versus other upstream enzymes in the purine biosynthetic pathway (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). For example, the robust elevation of ZMP precludes GARFT activity since inhibition of GARFT prevents ZMP production. Compound <b>28a</b> was also tested against other folate dependent enzymes and found to have IC<sub>50</sub> values of >100 μM against thymidylate synthase, serine hydroxymethyltransferase-1, and methylenetetrahydrofolate dehydrogenases 1, 2, and 2L.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">Assessment of physical and in vitro properties of <b>28a</b> found that the compound had excellent microsomal stability (<10% metabolism), acceptable aqueous solubility (0.02 mg/mL pH 7.5) with moderate permeability in MDCK cells, and no significant inhibition of cytochrome P450 isoforms (<10% inhibition in human Cyp isoforms 3A4, 2D6, 2C9 at 10 μM).</div><div class="NLM_p">With good physical properties, PK profile, and potent in vivo target inhibition resulting in dramatic increases in tumor ZMP and plasma AICAr by inhibition with <b>28a</b>, we decided to advance this compound into in vivo murine based human xenograft efficacy studies. As discussed in detail in a companion paper, in vitro testing of <b>28a</b> against 495 cell lines resulted in identification of MDA-MB-231met2, a triple negative breast cancer line, as being most sensitive to antiproliferative effects of our inhibitor (7.6 nM IC<sub>50</sub> by Cell Titer-Glo readout and 85 nM by Alamar Blue).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Breast cancer, a heterogeneous disease, is the most common tumor type in women and 21% of cases occur in individuals that are 70 years and older.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Triple negative breast cancer (TNBC) is characterized by tumors that do not express estrogen receptor (ER) or progesterone receptor (PR) and that do not overexpress human epidermal growth factor receptor 2 (HER2). TNBC accounts for approximately 15% of all breast cancer cases and has poor prognosis with high risk of metastasis and death within 3–5 years of diagnosis. The incidence of TNBC in African American women is 2–3 times higher than in other ethnic groups.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The molecular mechanisms underlying TNBC development are not clear, and a need exists for greater understanding of TNBC at all levels, along with development of effective therapies for this devastating disease, for which there is no current standard of care, reflecting an unmet medical need.</div><div class="NLM_p">In order to test our AICARFT inhibitor for in vivo antiproliferative effects on tumor growth, MDA-MB-231met2 TNBC tumor xenografts were established in nude mice that were fed standard chow since this cell line did not grow well in mice on a low-folate diet. Due to a genetic mutation in the promoter region for reduced folate carrier (RFC), MDA-MB-231met2 cells lack expression of RFC and thus are resistant to the classical antifolate methotrexate (<b>10</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), which is dependent on RFC for active uptake.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> For this reason and since <b>10</b> had been reported as a nonselective inhibitor for AICARFT, we opted to use <b>10</b> as a comparator in this study.</div><div class="NLM_p">After implantation, the MDA-MB-231met2 xenografts were allowed to grow to a volume of ∼250 mm<sup>3</sup> (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>a) before administration of the inhibitors beginning on day 18. Separate dosing groups (<i>n</i> = 6 animals per group) for this study included animals given compound <b>28a</b> orally at 30 or 60 mg/kg (mpk) twice daily (b.i.d.). In a third group, <b>10</b> was dosed intravenously at 5 mpk once a day for 5 days, followed by a rest period of 9 days.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Antiproliferative effects of <b>28a</b> on MDA-MB-231met2. Group size was <i>n</i> = 6 for all dose groups studied. (b) End of study intratumoral metabolite levels.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After a total of 22 days of dosing, the groups treated with <b>28a</b> demonstrated statistically significant (<i>p</i> < 0.05) tumor growth inhibition levels (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>a). Reported as the ratio of average tumor volumes for treated (<i>T</i>) versus control (<i>C</i>) with correction for the tumor size at the start of compound administration (i.e., % Δ<i>T</i>/C = 100 × (<i>T</i> – <i>T</i><sub>0</sub>)/(<i>C</i> – <i>C</i><sub>0</sub>), the group of animals receiving 30 mpk of <b>28a</b> achieved 16% Δ<i>T</i>/C (<i>p</i> < 0.001) and those receiving 60 mpk a remarkable −1.0% Δ<i>T</i>/C (<i>p</i> < 0.001). In contrast, the group dosed with <b>10</b> only showed limited tumor growth inhibition with 39% Δ<i>T</i>/<i>C</i> (<i>p</i> = 0.004). No animals were lost in any of the dose groups nor were any significant weight losses recorded (data not shown).</div><div class="NLM_p last">At the end of the study (day 40), the animals were sacrificed and the tumors harvested for analysis of intratumoral levels of ZMP and AICAr. As shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>b, tumors from vehicle-treated animals had AICAr and ZMP concentrations of ∼1 and 30 μM, respectively. The level difference in these biomolecules is not surprising since AICAr is freely permeable and ZMP, which is phosphorylated, is sequestered within cells. Tumors from animals receiving <b>28a</b> at 30 or 60 mpk recorded dramatic rise of both compounds. Specifically, AICAr was elevated ∼30-fold to 30 μM and ZMP increased ∼10-fold when treated with 30 mpk of <b>28a</b>. At 60 mpk dose level, AICAr concentration was tripled to ∼100 μM and ZMP amplified ∼16-fold to ∼500 μM.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28312" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28312" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In an effort to restrict the supply of building blocks used by cancer cells to synthesize DNA and RNA in support of unbridled proliferation, the current effort targeted a key enzyme in the synthesis of purines, namely, AICARFT. This research resulted in the identification of a potent and selective, nonclassical, orally bioavailable, antifolate inhibitor of AICARFT. Structure-enabled design enabled rapid progression from a small molecule screening hit to a compound that engaged important binding elements uniquely present in AICARFT versus other folate dependent enzymes. High resolution crystal structures of two potent inhibitors in complex with AICARFT displayed extensive engagement of a central sulfonamide within an oxyanion hole as well as interactions of a novel fluoroisoquinolone in the pteridine binding domain, π-stacking of thiophene with ZMP, and hydroxypyrrolidine or dihydropyridone moieties that effectively engaged protein side chains in the glutamate binding domain. In vitro and in vivo characterization of several potent inhibitors (enzyme IC<sub>50</sub> values of <25 nM) led to the identification of <b>28a</b>, which exhibited good drug-like physical features and pharmacokinetic properties. These characteristics further enabled testing in vivo in a murine-based xenograft model utilizing MDA-MB-231met2, a triple negative breast cancer cell line that notably is deficient for expression of reduced folate carrier. This mutation is known to effect resistance of cancer cells toward classical antifolates which require active uptake. In this model, compound <b>28a</b>, a freely permeable compound that does not require active uptake, exhibited excellent dose dependent tumor growth inhibition (TGI). As a single agent dosed at 60 mpk, <b>28a</b> resulted in complete TGI, while methotrexate administered as a single agent failed to yield statistically significant TGI in the same study. These results support the evaluation of <b>28a</b> as an antineoplastic agent. Further details of this study as well as investigations with other tumor cell lines are discussed in a companion paper.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis</h3><div class="NLM_p last">All commercial reagents were used without further purification. All solvents were reagent or HPLC grade. Flash chromatography was carried out using an automated system with prepacked silica columns. All biologically tested compounds had a purity of ≥95% as determined by LCMS. LCMS data were obtained using an Agilent 1100 series HPLC/MS using either an Xbridge C18, 3.5 μm, 50 mm × 2.00 mm column or using a Kinetex Evo C18 2.6 μm, 50 mm × 3.00 mm column. Yields refer to chromatographically and spectroscopically pure compounds. <sup>1</sup>H NMR, <sup>13</sup>C NMR, and <sup>19</sup>F NMR spectra were recorded on 400/500 MHz spectrometers at ambient temperature (<sup>1</sup>H NMR, 400/500 MHz; <sup>19</sup>F NMR, 377/470 MHz; <sup>13</sup>C NMR, 75/100 MHz). High resolution mass spectra were recorded using a time-of-flight mass spectrometer with an atmospheric pressure chemical ionization source. Chiral analysis was performed using either HPLC or supercritical fluid chromatography (SFC). The methods chosen were based upon ability to obtain baseline separation of the racemic mixtures for the compounds of interest.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure A: Preparation of Sulfonamides</h3><div class="NLM_p last">Sulfonyl chloride (0.9–1.2 equiv) was added to a stirred solution of the corresponding aniline (1 equiv) and pyridine in dichloromethane (10 mL/mmol). The resulting mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated to dryness, and the resulting residue was suspended in water. The pH of the slurry was adjusted to 3–5 with 1 N aqueous hydrochloric acid solution, and the mixture was extracted with ethyl acetate (three times). The combined organic layers were dried over sodium sulfate, filtered, and evaporated to dryness. The crude product was purified to provide the desired sulfonamide product.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 4-Cyano-<i>N</i>-(1-oxo-1,2-dihydroisoquinolin-7-yl)benzenesulfonamide (<b>15</b>)</h3><div class="NLM_p last">Compound <b>15</b> was prepared from 7-amino-2<i>H</i>-isoquinolin-1-one (<b>17</b>, 552 mg, 3.4 mmol, 1.1 equiv), 4-cyanobenzenesulfonyl chloride (<b>18</b>, 655 mg, 3.2 mmol, 1 equiv), and pyridine (1.1 mL, 13.6 mmol, 4.3 equiv) according to general procedure A. The crude product was suspended in diethyl ether. The product was collected by filtration and washed with diethyl ether, dried under vacuum to provide <b>15</b> (748 mg, 2.3 mmol, 71%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.21–11.20 (m, 1H), 10.74 (s, 1H), 7.99–7.97 (m, 2H), 7.85–7.80 (m, 3H), 7.51 (d, <i>J</i> = 8.6 Hz, 1H), 7.39 (dd, <i>J</i> = 2.4, 8.6 Hz, 1H), 7.04–7.01 (m, 1H), 6.41–6.39 (m, 1H). HRMS (ESI) calcd for C<sub>16</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup> = 326.0599, found 326.0586.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-(2-Amino-4-oxo-3<i>H</i>-quinazolin-6-yl)-4-cyanobenzenesulfonamide (<b>16</b>)</h3><div class="NLM_p last">Compound <b>16</b> was prepared from 2,6-diamino-3<i>H</i>-quinazolin-4-one (<b>20</b>, 0.137 g, 0.778 mmol, 1 equiv), 4-cyanobenzenesulfonyl chloride (<b>18</b>, 0.163 g, 0.808 mmol, 1.03 equiv), and pyridine (0.5 mL, 6.2 mmol, 8.0 equiv) according to general procedure A. The crude product was purified by silica gel chromatography, eluting with 0–10% methanol/dichloromethane. Appropriate fractions were concentrated and dried to provide <b>16</b> (0.030 g, 11%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.99–10.85 (m, 1H), 10.41–10.28 (m, 1H), 8.00–7.98 (m, 2H), 7.80–7.79 (m, 2H), 7.49–7.48 (m, 1H), 7.28–7.25 (m, 1H), 7.08–7.06 (m, 1H), 6.35–6.20 (m, 2H). <i>m</i>/<i>z</i> (ESI+) 342.0 (M + H<sup>+</sup>). HRMS (ESI) calcd for C<sub>15</sub>H<sub>11</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> = 342.0661, found 342.0656.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2,6-Diamino-3<i>H</i>-quinazolin-4-one (<b>20</b>)</h3><div class="NLM_p last">10% palladium on carbon (Degussa 50 wt % water, 1.12 g) was added to a suspension of 2-amino-6-nitro-3<i>H</i>-quinazolin-4-one (4.92 g, 23.9 mmol) in methanol (400 mL) and tetrahydrofuran (200 mL). The mixture was heated to 60 °C, then the reaction was placed under 1 atm of hydrogen gas and stirred for 4 h. The suspension was filtered through diatomaceous earth and the filter cake washed with methanol. The filtrate was evaporated under reduced pressure to provide 2,6-diamino-3<i>H</i>-quinazolin-4-one (2.92 g, 69%) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO): δ 4.81 (bs, 2H), 6.25 (bs, 2H), 6.82 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 6.89 (d, <i>J</i> = 8.6 Hz, 1H), 7.01 (d, <i>J</i> = 2.5 Hz, 1H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 6-Fluoro-3,4-dihydro-2<i>H</i>-isoquinolin-1-one (<b>22</b>)</h3><div class="NLM_p last">To a 0 °C solution of triphosgene (852.4 g, 2.87 mol, 0.4 equiv) in dichloromethane (5000 mL) was added a solution of 2-(3-fluorophenyl)ethanamine (1000 g, 7.18 mol, 1 equiv) in dichloromethane (2000 mL) followed by dropwise addition of triethylamine (2000 mL, 14.36 mol, 2 equiv). The resulting mixture was stirred for 2 h at 0 °C and then filtered through a pad of Celite. The pad was further washed with dichloromethane, and the filtrate was added into a suspension of AlCl<sub>3</sub> (3820 g, 28.72 mol, 4 equiv) in dichloromethane (6000 mL) at 0 °C. The resulting mixture was allowed to warm to room temperature gradually and stirred for 18 h. The reaction was then quenched by addition of water followed by 10% aqueous hydrochloric acid. The organic layer was separated, and the aqueous layer was further extracted with dichloromethane. The combined organic layers were washed with saturated sodium bicarbonate solution and brine, dried over sodium sulfate, and evaporated to dryness. The residue was purified on silica gel, eluting with petroleum ether/ethyl acetate (2:1) to provide <b>22</b> (474.73 g, 40%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.09–8.05 (m, 1H), 7.04–7.02 (m, 1H), 6.92–6.90 (m, 1H), 6.77 (br s, 1H), 3.59–3.55 (m, 2H), 3.00–2.97 (m, 2H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 6-Fluoro-7-nitro-3,4-dihydro-2<i>H</i>-isoquinolin-1-one</h3><div class="NLM_p last">A solution of 6-fluoro-3,4-dihydro-2<i>H</i>-isoquinolin-1-one (<b>22</b>, 5.0 g, 30 mmol, 1 equiv) in sulfuric acid (40 mL, 750 mmol) was cooled to 0 °C, and potassium nitrate (3.24 g, 32 mmol, 1.1 equiv) was added portionwise. The resulting mixture was stirred in the ice bath for 20 min. The mixture was poured into ice–water and the resulting precipitate filtered. The precipitate was washed with water and air-dried to give 6-fluoro-7-nitro-3,4-dihydro-2<i>H</i>-isoquinolin-1-one (5.80 g, 26 mmol, 87%) as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41–8.38 (d, <i>J</i> = 7.7 Hz, 1H), 8.26 (br, s 1H), 7.57–7.54 (d, <i>J</i> = 11.8 Hz, 1H), 3.38–3.35 (m, 2H), 2.97 (t, <i>J</i> = 6.4 Hz, 2H); <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) δ −114.98 to −115.03 (m).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 6-Fluoro-7-nitro-2<i>H</i>-isoquinolin-1-one (<b>23</b>)</h3><div class="NLM_p last">A mixture of 6-fluoro-7-nitro-3,4-dihydro-2<i>H</i>-isoquinolin-1-one (3.0 g, 14 mmol, 1 equiv) and manganese(IV) oxide (11.9 g, 136 mmol, 10 equiv) in 1,2-dichloroethane (30 mL) was placed in a microwave vial. The vial was sealed and the mixture purged with nitrogen. The mixture was heated in a microwave at 150 °C for 5 min. The vial was opened, and manganese(IV) oxide (11.9 g, 136 mmol, 10 equiv) was added. The vial was resealed and purged with nitrogen. The mixture was heated in microwave at 150 °C for 5 min. The combined mixtures was filtered and washed with 1:1:1 mixture of methanol/dichloromethane/acetone. The filtrate was evaporated under reduced pressure to yield the title compound <b>22</b> (1.70 g, 7.1 mmol, 52%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88–11.84 (br, s 1H), 8.77–8.75 (m, 1H), 7.78 (d, <i>J</i> = 12.5 Hz, 1H), 7.44–7.41 (m, 1H), 6.60–6.58 (m, 1H); <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) −115.21 (dd, <i>J</i> = 8.0, 12.6 Hz).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 7-Amino-6-fluoro-2<i>H</i>-isoquinolin-1-one (<b>24</b>)</h3><div class="NLM_p last">To a solution of <b>23</b> (100 g, 0.48 mol, 1 equiv) in methanol (1500 mL) was added carefully wetted palladium (20 g, 0.18 mol, 0.38 equiv). The vessel was sealed and purged three times with H<sub>2</sub>, and then the mixture was stirred under 50 psi of H<sub>2</sub> for 2.5 h at 60 °C. LCMS showed the reaction was finished. The mixture was filtered and rinsed with MeOH several times. The filtrate was concentrated to dryness, and the residue was suspended in methyl <i>tert</i>-butyl ether. The resulting precipitate was filtered, rinsed with methyl <i>tert</i>-butyl ether, and dried to afford <b>23</b> (81.2 g, 95%) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.87 (broad s, 1H), 7.50 (d, 1H, <i>J</i> = 9.2 Hz), 7.27 (d, 1H, <i>J</i> = 12.4 Hz), 6.9–6.8 (m, 1H), 6.33 (d, 1H, <i>J</i> = 7.2 Hz), 5.52 (s, 2H).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-Cyano-<i>N</i>-(6-fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)benzenesulfonamide (<b>25</b>)</h3><div class="NLM_p last">Compound <b>25</b> was prepared from 7-amino-6-fluoro-2<i>H</i>-isoquinolin-1-one (<b>24</b>, 1.4 g, 7.4 mmol, 1 equiv), 4-cyanobenzenesulfonyl chloride (<b>18</b>, 1.52 g, 7.4 mmol, 1 equiv), and pyridine (1.8 mL, 22 mmol, 3.0 equiv) according to general procedure A. The crude product was dissolved in a mixture of dichloromethane and dimethylformamide. Water was added to the mixture and stirred for 30 min. The resulting precipitate was filtered, washed with water, and dried to afford the title compound <b>25</b> (370 mg, 1.1 mmol, 15%) as a cream solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.36–11.33 (m, 1H), 10.66–10.64 (m, 1H), 8.03–8.00 (m, 2H), 7.94–7.92 (m, 1H), 7.83–7.81 (m, 2H), 7.44 (d, <i>J</i> = 11.1 Hz, 1H), 7.15–7.13 (m, 1H), 6.42–6.40 (m, 1H); <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) −117.23--117.28 (m); HRMS (ESI) calcd for C<sub>16</sub>H<sub>10</sub>FN<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup> = 344.0505, found 344.0492.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 5-Bromo-<i>N</i>-(6-fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)thiophene-2-sulfonamide (<b>26</b>)</h3><div class="NLM_p last">Compound <b>26</b> was prepared from <b>24</b> (30.0 g, 168 mmol, 1.0 equiv), 5-bromothiophenesulfonyl chloride (54.5 g, 202 mmol, 1.2 equiv), and pyridine (210 mL) according to general procedure A. The crude product was washed with water, 1 N aqueous hydrochloric acid, water, and methyl <i>tert</i>-butyl ether, dried in a vacuum oven at 40 °C for 18 h to give the title compound as a light brown solid (53.6 g, 79%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.38 (broad s, 1H), 10.72 (broad s, 1H), 8.05 (d, 1H, <i>J</i> = 8.5 Hz), 7.55 (d, 1H, <i>J</i> = 11.2 Hz), 7.33 (app s, 2H), 7.21 (t, 1H, <i>J</i> = 7.5 Hz), 6.50 (d, 1H, <i>J</i> = 6.8 Hz). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>): δ −117.09 (s).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 5-Fluoro-<i>N</i>-(6-fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)thiophene-2-sulfonamide (<b>27</b>)</h3><div class="NLM_p last">Compound <b>26</b> was prepared from <b>24</b> (8.80 g, 25.7 mmol, 1.0 equiv), 5-fluorothiophene-2-sulfonyl chloride (5.67 g, 28.3 mmol, 1.1 equiv), and pyridine (64 mL) according to general procedure A. The crude product was wash with water (3×), dried in a vacuum oven at 40 °C for 18 h to give the title compound as a light brown solid (13.2 g, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.38 (broad s, 1H), 10.64 (s, 1H), 8.05 (d, 1H, <i>J</i> = 8.1 Hz), 7.55 (d, 1H, <i>J</i> = 11.3 Hz), 7.28 (t, 1H, <i>J</i> = 4.0 Hz), 7.22 (t, 1H, <i>J</i> = 6.4 Hz), 6.88 (d, 1H, <i>J</i> = 4.2 Hz), 6.50 (d, 1H, <i>J</i> = 7.2 Hz). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>): δ −117.09 (s), −120.63 (s).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure B: Copper(I) Catalyzed Coupling of <b>25</b> and Amine</h3><div class="NLM_p last">A mixture of 5-bromo-<i>N</i>-(6-fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)thiophene-2-sulfonamide (<b>25</b>, 1 equiv), amine (2 equiv), copper(I) bromide (0.2–0.4 equiv), hydroxyproline (0.4–0.8 equiv), and cesium carbonate or potassium carbonate (2–4 equiv) in dimethyl sulfoxide (5.5 mL/mol) in a sealed vial was heated at 100 °C for 16 h. The reaction mixture was suspended in water. The pH of the slurry was adjusted to 3–5 with 1 N aqueous hydrochloric acid solution, and the mixture was extracted with ethyl acetate and subsequently with dichloromethane containing a small amount of methanol. The combined organic layers were dried over sodium sulfate, filtered, and evaporated to dryness. The crude product was purified by silica gel chromatography to provide the desired product.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3<i>R</i>)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (<b>28a</b>)</h3><div class="NLM_p last">Compound <b>28a</b> was prepared from <b>26</b> (0.59 g, 1.47 mmol), (<i>R</i>)-3-pyrrolidinol (0.265 g, 3.04 mmol, 2.07 equiv), copper(I) bromide (0.052 g, 0.36 mmol, 0.24 equiv), hydroxyproline (0.10 g, 0.8 mmol, 0.54 equiv), and cesium carbonate (1.03 g, 3.16 mmol, 2.15 equiv) according to general procedure B. The crude product was purified by silica gel chromatography, eluting with 0–10% methanol/dichloromethane. Isolated product was concentrated to provide <b>28a</b> (0.16 g, 27%) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.27–11.26 (m, 1H), 10.06 (s, 1H), 8.10 (m, 1H), 7.45 (m, 1H), 7.14–7.11 (m, 2H), 6.44–6.42 (m, 1H), 5.66 (m, 1H), 5.05 (m, 1H), 4.40–4.30 (m, 1H), 3.40–2.90 (m, 4H), 2.10–1.80 (m, 2H). [α]<sub>D</sub><sup>20</sup> 5.29 (<i>c</i> 10, CH<sub>3</sub>OH). HRMS (ESI) calcd for C<sub>17</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 410.0645, found 410.0632.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3<i>R</i>)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (<b>28b</b>)</h3><div class="NLM_p last">Compound <b>28b</b> was prepared from <b>26</b> (0.415 g, 1.03 mmol, 1 equiv), (<i>S</i>)-3-pyrrolidinol (0.185 g, 2.12 mmol, 2.06 equiv), copper(I) bromide (0.04 g, 0.28 mmol, 0.27 equiv), hydroxyproline (0.079 g, 0.6 mmol, 0.58 equiv), and potassium carbonate (0.284 g, 2.05 mmol, 2 equiv) according to general procedure B. The resulting residue was purified by silica gel chromatography, eluting with 0–5% methanol/dichloromethane. Appropriate fractions were concentrated and dried to provide <b>28b</b> (0.12 g, 28%) as a cream colored solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.26–11.24 (m, 1H), 10.06–10.05 (m, 1H), 8.10–8.00 (m, 1H), 7.46–7.45 (m, 1H), 7.14–7.12 (m, 2H), 6.43–6.35 (m, 1H), 5.70–5.60 (m, 1H), 5.05–5.04 (m, 1H), 4.40–4.25 (m, 1H), 3.40–2.90 (m, 4H), 2.04–1.80 (m, 2H). [α]<sub>D</sub><sup>20</sup> −6.30 (<i>c</i> 10, CH<sub>3</sub>OH). HRMS (ESI) calcd for C<sub>17</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 410.0645, found 410.0639.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(6-Fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)-5-[(3<i>R</i>)-3-hydroxy-1-piperidyl]thiophene-2-sulfonamide (<b>28c</b>)</h3><div class="NLM_p last">Compound <b>28c</b> was prepared from <b>26</b> (0.546 g, 1.35 mmol, 1 equiv), (3<i>R</i>)-piperidin-3-ol hydrochloride (0.374 g, 2.72 mmol, 2 equiv), copper(I) bromide (0.046 g, 0.32 mmol, 0.24 equiv), hydroxyproline (0.098 g, 0.75 mmol, 0.56 equiv), and cesium carbonate (0.965 g, 2.96 mmol, 1.1 equiv) according to general procedure B. Resulting residue was purified by silica gel chromatography eluting with 0–10% methanol/dichloromethane to provide <b>27c</b> (0.136 g, 24%) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.30–11.28 (m, 1H), 10.14 (s, 1H), 8.10–8.05 (m, 1H), 7.50–7.45 (m, 1H), 7.17–7.13 (m, 2H), 6.50–6.40 (m, 1H), 6.07–6.00 (m, 1H), 4.95–4.85 (m, 1H), 3.60–3.50 (m, 1H), 3.40–3.20 (m, 2H), 2.92–2.82 (m, 1H), 2.76–2.71 (m, 1H), 1.82–1.70 (m, 2H), 1.58–1.40 (m, 1H), 1.35–1.20 (m, 1H). [α]<sub>D</sub><sup>20</sup> −0.83 (<i>c</i> 3.0, CH<sub>3</sub>OH). HRMS (ESI) calcd for C<sub>18</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 424.0801, found 424.0786.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(6-Fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)-5-[(3<i>S</i>)-3-hydroxy-1-piperidyl]thiophene-2-sulfonamide (<b>28d</b>)</h3><div class="NLM_p last">Compound <b>28d</b> was prepared from <b>26</b> (0.51 g, 1.26 mmol, 1 equiv), (3<i>S</i>)-piperidin-3-ol (0.356 g, 2.79 mmol, 2 equiv), copper(I) bromide (0.056 g, 0.39 mmol, 0.31 equiv), hydroxyproline (0.108 g, 0.82 mmol, 0.65 equiv), and cesium carbonate (0.89 g, 2.73 mmol, 2 equiv) according to general procedure B. The resulting residue was purified by silica gel chromatography, eluting with 0–10% methanol/dichloromethane to provide <b>28d</b> (0.208 g, 39%) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.29–11.28 (m, 1H), 10.14 (s, 1H), 8.10–8.05 (m, 1H), 7.50–7.45 (m, 1H), 7.19–7.15 (m, 2H), 6.48–6.40 (m, 1H), 6.05–6.00 (m, 1H), 4.98–4.90 (m, 1H), 3.60–3.50 (m, 1H), 3.40–3.20 (m, 2H), 2.95–2.82 (m, 1H), 2.75–2.70 (m, 1H), 1.80–1.70 (m, 2H), 1.58–1.40 (m, 1H), 1.38–1.20 (m, 1H). LCMS (1.75 min) <i>t</i><sub>R</sub> = 0.81 min; <i>m</i>/<i>z</i> (ESI<sup>+</sup>) 424.0 (M + H<sup>+</sup>). [α]<sub>D</sub><sup>20</sup> 0.99 (<i>c</i> 3.0, CH<sub>3</sub>OH). HRMS (ESI) calcd for C<sub>18</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 424.0801, found 424.0788.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-(4-hydroxypiperidin-1-yl)thiophene-2-sulfonamide (<b>28e</b>)</h3><div class="NLM_p last">Compound <b>28e</b> was prepared from <b>26</b> (0.53 g, 1.31 mmol), 4-hydroxypiperidine (0.36 g, 2.71 mmol), copper(I) bromide (0.078 g, 0.54 mmol), hydroxyproline (0.106 g, 0.81 mmol), and cesium carbonate (0.95 g, 2.92 mmol) according to general procedure B. The resulting residue was purified by silica gel chromatography, eluting with 0–10% methanol/dichloromethane to provide <b>28e</b> (0.159 g, 29%) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.28–11.26 (m, 1H), 10.12 (s, 1H), 8.10–8.00 (m, 1H), 7.50–7.42 (m, 1H), 7.15–7.12 (m, 2H), 6.45–6.40 (m, 1H), 6.06–6.00 (m, 1H), 4.75–4.70 (m, 1H), 3.65–3.60 (m, 1H), 3.50–3.40 (m, 2H), 2.99–2.93 (m, 2H), 1.77–1.70 (m, 2H), 1.47–1.38 (m, 2H). HRMS (ESI) calcd for C<sub>18</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 424.0801, found 424.0791.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 5-[(<i>cis</i>-3-Fluoro-4-hydroxypyrrolidin-1-yl]-<i>N</i>-(6-fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)thiophene-2-sulfonamide (<b>28f</b> and <b>28g</b>)</h3><div class="NLM_p">To a stirred solution of <i>tert</i>-butyl (<i>cis</i>)-3-fluoro-4-hydroxypyrrolidine-1-carboxylate (1.0 g, 4.87 mmol, 2 equiv) in dichloromethane (12 mL) was added TFA (6 mL). The resulting mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated to dryness and the resulting residue dried on high vacuum. The TFA salt was used to couple with <b>26</b> (1.0 g, 2.48 mmol, 1 equiv) in the presence of copper bromide (0.11 g, 0.74 mmol, 0.30 equiv), hydroxyproline (0.2 g, 1.5 mmol, 0.60 equiv), and potassium carbonate (1.37 g, 9.92 mmol, 4 equiv) according to general procedure B. The crude product was purified by reverse phase chromatography (mobile phase A, 0.1% trifluoroacetic acid in water; mobile phase B, 0.1% trifluoroacetic acid in acetonitrile; elution with 5–45% B in A) to provide the racemic product as a yellow oil (244 mg, 0.57 mmol, 23.0%).</div><div class="NLM_p">The racemic product (244 mg, 0.57 mmol) was purify by chiral chromatography on Chiralpak AD-H column (150 mm × 21.2 mm; flow rate of 70 mL/min), eluting with 40% MeOH in CO<sub>2</sub>.</div><div class="NLM_p">Collect the first eluting peak as title compound 5-[(3<i>S</i>,4<i>R</i>)-3-fluoro-4-hydroxypyrrolidin-1-yl]-<i>N</i>-(6-fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)thiophene-2-sulfonamide (<b>28f</b>, 75 mg, 30.8%; <i>t</i><sub>R</sub> = 2.20 min; 96.8% ee). ES/MS (<i>m</i>/<i>z</i>): 428 (M + H). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.27–11.25 (m, 1H), 10.18–10.16 (m, 1H), 8.09–8.07 (m, 1H), 7.46–7.45 (m, 1H), 7.14–7.11 (m, 2H), 6.44–6.42 (m, 1H), 5.74–5.72 (m, 1H), 5.57 (d, J= 6.4 Hz, 1H), 5.14–5.12 (m, 1H), 4.41–4.40 (m, 1H), 3.59–3.55 (m, 3H), 3.08–3.04 (m, 1H). [α]<sub>D</sub><sup>20</sup> 29.03 (<i>c</i> 10.0, CH<sub>3</sub>OH). HRMS (ESI) calcd for C<sub>17</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 428.0550, found 428.0534.</div><div class="NLM_p last">Collect the second eluting peak as title compound 5-[(3<i>R</i>,4<i>S</i>)-3-fluoro-4-hydroxypyrrolidin-1-yl]-<i>N</i>-(6-fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)thiophene-2-sulfonamide (<b>28g</b>, 71 mg, 29.2%; <i>t</i><sub>R</sub> = 3.31 min; 99% ee). ES/MS (<i>m</i>/<i>z</i>): 428 (M + H). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.28–11.26 (m, 1H), 10.15–10.13 (m, 1H), 8.09 (d, J= 8.3 Hz, 1H), 7.45 (d, <i>J</i> = 11.0 Hz, 1H), 7.15–7.11 (m, 2H), 6.43 (d, <i>J</i> = 7.1 Hz, 1H), 5.74 (d, J= 4.3 Hz, 1H), 5.57 (d, <i>J</i> = 6.4 Hz, 1H), 5.13–5.12 (m, 1H), 4.41–4.40 (m, 1H), 3.59–3.55 (m, 3H), 3.08–3.04 (m, 1H). [α]<sub>D</sub><sup>20</sup> −30.54 (<i>c</i> 10.0, CH<sub>3</sub>OH). HRMS (ESI) calcd for C<sub>17</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 428.0550, found 428.0541.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 5-(3,3-Difluoro-4-hydroxypyrrolidin-1-yl)-<i>N</i>-(6-fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)thiophene-2-sulfonamide (<b>28h</b> and <b>28i</b>)</h3><div class="NLM_p">A mixture of <b>27</b> (2.50 g, 7.30 mmol, 1.0 equiv) and 4,4-difluoropyrrolidin-3-ol (1.90 g, 15.4 mmol, 2 equiv) in pyridine (50 mL) was heated at 110 °C for 40 h and cooled to ambient temperature. Solvents were removed under reduced pressure. The residue was purified by low pH reverse phase chromatography: mobile phase A, 0.1% trifluoroacetic acid in water; mobile phase B, 0.1% trifluoroacetic acid in acetonitrile. Elution was with 10–45% B in A. The product fractions were concentrated under reduced pressure to give the title compound as a light brown solid (1.70 g, 52%).</div><div class="NLM_p">The two enantiomers were separated by chiral chromatography using Lux Amylose-2, 50 mm × 150 mm column, eluting with 30% methanol/carbon dioxide at flow rate of 300 g/min at 40 °C.</div><div class="NLM_p">Collect the first eluted peak (<i>t</i><sub>R</sub> = 1.99 min) and concentrate under reduced pressure to give 5-(3,3-difluoro-4-(<i>S</i>)-hydroxypyrrolidin-1-yl)-<i>N</i>-(6-fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)thiophene-2-sulfonamide (<b>28h</b>, 0.650 g, 1.46 mmol, >99% ee). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.31 (br d, <i>J</i> = 6.1 Hz, 1H), 10.22 (s, 1H), 8.12 (d, <i>J</i> = 8.1 Hz, 1H), 7.50 (d, <i>J</i> = 10.7 Hz, 1H), 7.21 (d, <i>J</i> = 4.1 Hz, 1H), 7.18 (t, <i>J</i> = 6.2 Hz, 1H), 6.47 (d, <i>J</i> = 7.1 Hz, 1H), 6.24 (d, <i>J</i> = 5.5 Hz, 1H), 5.87 (d, <i>J</i> = 4.1 Hz, 1H), 4.41–4.33 (m, 1H), 3.78–3.58 (m, 3H), 3.26–3.15 (m, 1H). [α]<sub>D</sub><sup>20</sup> 13.77 (<i>c</i> 10.0, CH<sub>3</sub>OH). HRMS (ESI) calcd for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 446.0456, found 446.0439.</div><div class="NLM_p last">Collect the second eluted peak (<i>t</i><sub>R</sub> = 2.81 min) and concentrate under reduced pressure to give 5-(3,3-difluoro-4-(<i>R</i>)-hydroxypyrrolidin-1-yl)-<i>N</i>-(6-fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)thiophene-2-sulfonamide (<b>28i</b>, 0.660 g, 1.48 mmol, >99% ee). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 11.31 (br d, <i>J</i> = 6.1 Hz, 1H), 10.22 (s, 1H), 8.12 (d, <i>J</i> = 8.1 Hz, 1H), 7.50 (d, <i>J</i> = 10.7 Hz, 1H), 7.21 (d, <i>J</i> = 4.1 Hz, 1H), 7.18 (t, <i>J</i> = 6.2 Hz, 1H), 6.47 (d, <i>J</i> = 7.1 Hz, 1H), 6.24 (d, <i>J</i> = 5.5 Hz, 1H), 5.87 (d, <i>J</i> = 4.1 Hz, 1H), 4.41–4.33 (m, 1H), 3.78–3.58 (m, 3H), 3.26–3.15 (m, 1H). [α]<sub>D</sub><sup>20</sup> −17.90 (<i>c</i> 10.0, CH<sub>3</sub>OH). HRMS (ESI) calcd for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 446.0456, found 446.0455.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-(6-Fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)-5-(6-oxo-1<i>H</i>-pyridin-3-yl)thiophene-2-sulfonamide (<b>29</b>)</h3><div class="NLM_p last">A mixture of <b>26</b> (100 mg, 0.248 mmol, 1 equiv), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1<i>H</i>)-one (110 mg, 0.496 mmol, 2 equiv), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (15 mg, 0.025 mmol, 0.1 equiv), potassium carbonate (137 mg, 0.992 mmol, 4 equiv) in dioxane (1 mL) and water (0.25 mL) was heated in a microwave reactor at 140 °C for 90 min and cooled to ambient temperature. The reaction mixture was suspended in water. The pH of the slurry was adjusted to 3 with 1 N aqueous hydrochloric acid solution, and the mixture was extracted with ethyl acetate (three times). The combined organic layers were dried over sodium sulfate, filtered, and evaporated to dryness. The crude product was purified by flash chromatography, eluting with 0–10% methanol/dichloromethane to give the title compound (40 mg, 39%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.96 (br s, 1H), 11.31 (br d, <i>J</i> = 6.1 Hz, 1H), 10.56 (s, 1H), 8.05 (d, <i>J</i> = 7.5 Hz, 1H), 7.80 (d, <i>J</i> = 2.7 Hz, 1H), 7.70 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.49 (d, <i>J</i> = 11.5 Hz, 1H), 7.39 (d, <i>J</i> = 3.7 Hz, 1H), 7.30 (d, <i>J</i> = 3.6 Hz, 1H), 7.15 (t, <i>J</i> = 6.2 Hz, 1H), 6.44 (d, <i>J</i> = 7.1 Hz, 1H), 6.37 (d, <i>J</i> = 9.6 Hz, 1H). HRMS (ESI) calcd for C<sub>18</sub>H<sub>12</sub>FN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 418.0332, found 418.0314.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> General Procedure C: Negishi Coupling</h3><div class="NLM_p last">A mixture of iodide (1 equiv), 2-thienylzinc bromide (2.0 equiv), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (0.1 equiv) in tetrahydrofuran (20 mL) was degassed by sparging with nitrogen for 10 min and heated at 60 °C for 17 h. The reaction mixture was quenched by adding 2 N aqueous hydrogen chloride solution and extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue, which was purified by flash chromatography to give the title compound.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> General Procedure D: Sulfonyl Chlorination and Coupling with <b>23</b></h3><div class="NLM_p last">Chlorosulfuric acid (4–6 equiv) was added to an ice-cooled solution of the corresponding thiophene (1–2 equiv) in dichloromethane (10 mL) at 0 °C. After 15 min, the cooling bath was removed and the reaction mixture was allowed to warm up to ambient temperature. After 1.5 h, the reaction mixture was poured into ice-cooled brine and extracted four times with dichloromethane. The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give the crude sulfonyl chloride. To the crude sulfonyl chloride were added <b>24</b> (1 equiv) and pyridine (5 mL). After 16 h, the reaction mixture was concentrated under reduced pressure and the residue was suspended in water. The pH of the slurry was adjusted to 3 with 1 N aqueous hydrochloric acid solution, and the mixture was extracted with 4:1 dichloromethane/isopropyl alcohol (three times). The combined organic layers were dried over sodium sulfate, filtered, and evaporated to dryness. The crude product was purified by flash chromatography to give the title compound.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 3,3-Dimethyl-5-(thiophen-2-yl)-3,4-dihydropyridin-2(1<i>H</i>)-one (<b>31a</b>)</h3><div class="NLM_p last">Compound <b>31a</b> was prepared from <i>tert</i>-butyl 5-iodo-3,3-dimethyl-2-oxo-3,4-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>30a</b>, 950 mg, 2.71 mmol) and 0.5 M 2-thienylzinc bromide solution in THF (10.8 mL, 5.4 mmol) according to general procedure C. The resulting residue was purified by silica gel chromatography, eluting with 0–50% ethyl acetate/hexanes to provide <b>31a</b> (450 mg, 80%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.41 (br s, 1H), 7.12 (dd, <i>J</i> = 5.1, 1.1 Hz, 1H), 7.01–6.97 (m, 1H), 6.91 (dd, <i>J</i> = 3.6, 1.1 Hz, 1H), 6.59 (d, <i>J</i> = 5.0 Hz, 1H), 2.60 (s, 2H), 1.28 (s, 6H). Mass spectrum (<i>m</i>/<i>z</i>): 208 (M + H).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 5-(5,5-Dimethyl-6-oxo-1,4-dihydropyridin-3-yl)-<i>N</i>-(6-fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)thiophene-2-sulfonamide (<b>32a</b>)</h3><div class="NLM_p last">Compound <b>32a</b> was prepared from <b>31a</b> (450 mg, 2.17 mmol), chlorosulfuric acid (0.430 mL, 6.51 mmol), and <b>24</b> (194 mg, 1.09 mmol) according to general procedure D. The resulting residue was purified by silica gel chromatography, eluting with 0–10% methanol/dichloromethane to give the title compound as a white solid (280 mg, 57%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (br d, <i>J</i> = 5.5 Hz, 1H), 10.54 (s, 1H), 9.50 (d, <i>J</i> = 5.1 Hz, 1H), 8.10 (d, <i>J</i> = 8.0 Hz, 1H), 7.53 (d, <i>J</i> = 11.3 Hz, 1H), 7.36 (d, <i>J</i> = 3.8 Hz, 1H), 7.19 (t, <i>J</i> = 6.2 Hz, 1H), 7.04 (d, <i>J</i> = 4.2 Hz, 1H), 6.75 (d, <i>J</i> = 5.3 Hz, 1H), 6.49 (d, <i>J</i> = 6.9 Hz, 1H), 2.48 (s, 2H), 1.09 (s, 6H). HRMS (ESI) calcd for C<sub>20</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + Na]<sup>+</sup> = 470.0620, found 470.0617.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3-Ethyl-3-methyl-5-(2-thienyl)-1,4-dihydropyridin-2-one (<b>31b</b>)</h3><div class="NLM_p last">Compound <b>31b</b> was prepared from <i>tert</i>-butyl 3-ethyl-5-iodo-3-methyl-2-oxo-3,4-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>30b</b>, 400 mg, 1.10 mmol) and 0.5 M 2-thienylzinc bromide solution in THF (4.38 mL, 2.19 mmol) according to general procedure C. The resulting residue was purified by silica gel chromatography, eluting with 0–50% ethyl acetate/hexanes to provide <b>31b</b> (450 mg, 80%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.62 (br s, 1H), 7.09 (dd, <i>J</i> = 5.1, 1.1 Hz, 1H), 6.98–6.95 (m, 1H), 6.88 (dd, <i>J</i> = 3.6, 1.1 Hz, 1H), 6.51 (d, <i>J</i> = 4.9 Hz, 1H), 2.66 (d, <i>J</i> = 16.7 Hz, 1H), 2.51 (dd, <i>J</i> = 16.6, 1.3 Hz, 1H), 1.74–1.58 (m, 2H), 0.93 (t, <i>J</i> = 7.5 Hz, 3H). Mass spectrum (<i>m</i>/<i>z</i>): 222 (M + H).</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 5-(5-Ethyl-5-methyl-6-oxo-1,4-dihydropyridin-3-yl)-<i>N</i>-(6-fluoro-1-oxo-2<i>H</i>-isoquinolin-7-yl)thiophene-2-sulfonamide (<b>32b</b>)</h3><div class="NLM_p last">Compound <b>32b</b> was prepared from <b>31b</b> (180 mg, 0.813 mmol), chlorosulfuric acid (0.108 mL, 1.63 mmol), and <b>24</b> (145 mg, 0.813 mmol) according to general procedure D. The resulting residue was purified by silica gel chromatography, eluting with 0–10% methanol/dichloromethane to give the title compound as a white solid (240 mg, 64%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (br d, <i>J</i> = 5.5 Hz, 1H), 10.52 (s, 1H), 9.49 (d, <i>J</i> = 5.4 Hz, 1H), 8.09 (d, <i>J</i> = 8.2 Hz, 1H), 7.53 (d, <i>J</i> = 11.0 Hz, 1H), 7.36 (d, <i>J</i> = 4.0 Hz, 1H), 7.19 (t, <i>J</i> = 6.2 Hz, 1H), 7.06 (d, <i>J</i> = 4.2 Hz, 1H), 6.73 (d, <i>J</i> = 5.3 Hz, 1H), 6.49 (d, <i>J</i> = 6.9 Hz, 1H), 2.54 (d, <i>J</i> = 16.3 Hz, 1H), 2.41 (d, <i>J</i> = 16.3 Hz, 1H), 1.54–1.42 (m, 2H), 0.80 (t, <i>J</i> = 7.5 Hz, 3H). HRMS (ESI) calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup> = 462.0958, found 462.0940.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Aqueous Solubility Measurement</h3><div class="NLM_p last">Equilibrium aqueous solubility was measured by dissolving solid in DMSO and evaporating the solutions to dryness. The resulting powders or films were then added to aqueous pH 2, 6, or 7.5 buffer, targeting 2 mM concentration and rotating the resulting mixtures at room temperature for 20 h. The samples were filtered through a 0.7 μm filter and analyzed via HPLC for concentration against a DMSO standard curve.</div></div><div id="sec4_29_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Biological Methods. Mouse Pharamacokinetics Studies</h3><div class="NLM_p last">Male CD-1 mice purchased from Charles River Laboratories (Indianapolis, IN) were dosed with compounds <b>15</b>, <b>25</b>, and <b>28a</b> at 1 mg/kg intravenously or 10 mg/kg orally in 20% 2-hydroxypropyl-β-cyclodextrin in 25 mM phosphate buffer with 1 molar equvalent NaOH solution formulation in a cross-over design with 3-day wash period in between two arms. Compounds <b>28f</b>, <b>28i</b>, and <b>32a</b> were dosed at 5 mg/kg intravenously and orally. Blood samples were obtained through tail clip at 0, 0.08 (iv only), 0.25, 0.75, 2, 4, 8, and 24 h where approximately 20 μL of blood was collected to capacity into EDTA-coated capillary tubes (Fisher Scientific, Pittsburgh, PA) and spotted onto Whatman DMPK-C DBS collection cards obtained from GE Healthcare Bio-Sciences (Piscataway, NJ). Once spotted, the cards were allowed to dry for 2 h, placed in Ziploc bags (S. C. Johnson & Son, Inc.) and shipped to the bioanalytical facility at ambient temperature. Punches (3 mm) from DBS cards that represented samples or standards were extracted with 180 μL of a 20 ng/mL analog IS (internal standard) (proprietary Lilly compound) in methanol/acetonitrile (1:1, v/v) solution in 96-well plates. Samples were quantitated using LC–MSMS analysis (AB Sciex API 4000 triple-quadrupole mass spectrometer (Life Technologies Corporation). PK parameters were calculated for concentration–time profiles using Watson LIMS (version 7.4) from Thermo Scientific (Billerica, MA).</div></div><div id="sec4_29_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Cloning and Enzyme Purification</h3><div class="NLM_p">Human ATIC (accession number NM_004044.6) cDNA was purchased from Openbiosystem Co. (catalog number MHS1011-62310, clone identifier 4300570, accession number BC008879). Human TS (accession number NM_001071.2) cDNA was purchased from Invitrogen (clone identifer 3138877). Human SHMT (accession number NM_004169.3) cDNA was purchased from Openbiosystem Co. (catalog number MHS1010-9204609, clone identifier 4523709, accession number BC038598). Human MTHFD1 (accession number NM_005956.3) cDNA was purchased from Openbiosystem Co. (catalog number MHS1011-169900, clone identifier 3508998, accession number BC009806), which contained two mutations and was fixed by PCR-based mutagenesis. The human MTHFD2 (accession number NM_006636.3) and MTHFD2L (accession number NM_001144978.1) cDNAs were synthesized at GenScript. The nucleotide sequences encoding full-length human AICARFT, TS, SHMT, MTHFD1, and partial sequences MTHFD2(32–350) and MTHFD2L(46–347) were inserted into pET21d (Novagen) vector with an N-terminal HIS tag. Bacterial BL21(DE3) (Novagen) was used as an expression host, and protein purification is described in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div class="NLM_p last">The induction of protein expression was carried out in 2xTY media with 1 mM IPTG at 18 °C overnight. Cell pellets were stored at −80 °C for subsequent protein purification. Protein purification was conducted at 4 °C. Frozen cell pellets were lysed by incubation with stirring in 50 mL of cold lysis buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10% glycerol, 0.1% Triton X-100, 0.5 mg/mL lysozyme, 5 U/mL benzonase, 1 mM DTT, 10 mM imidazole, and Roche complete EDTA-free protease inhibitor) per liter cell pellet and sonication. Cell lysates were clarified by centrifugation for 45 min at 23 000<i>g</i>. The supernatant was incubated with Ni-NTA agarose resin (Qiagen) for 3 h, followed by an initial batch wash with 10 resin volumes of buffer A (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10% glycerol, 1 mM DTT, 10 mM imidazole) containing 0.1% Triton X-100. The resin was then packed onto a column and washed with buffer A. The HIS-tagged protein was eluted with 10–500 mM imidazole gradient in buffer A. Pooled HIS-tagged protein containing fractions were concentrated, loaded onto a HiLoad 26/600 Superdex 200 column (GE Healthcare Biosciences), and eluted with storage buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl, 1 mM DTT, 10% glycerol). Fractions containing the HIS-tagged protein were pooled and protein concentration determined by the Bradford assay using BSA as standard. The protein was aliquoted and stored at −80 °C.</div></div><div id="sec4_29_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 10-Formyltetrahydrofolate Substrate Synthesis</h3><div class="NLM_p last">Preparation of the 10-formyltetrahydrofolate substrate used in the ATIC enzyme assay is a two-step process starting from folinic acid (Sigma CAS 1492-18-8).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Final conversion of substrate to 10-formyl-tetrahydrofolate is only stable for same day use.</div></div><div id="sec4_29_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> ATIC Enzyme Assay</h3><div class="NLM_p last">25 μM ZMP (Sigma-Aldrich CAS 3031-94-5), 100 μM 10-formyltetrahydrofolate, 3 nM ATIC enzyme, 20 μM ammonium bicarbonate, and 5% DMSO reaction was carried out at room temperature for 1 h in the presence of compound and stopped with 2 volumes of ACN. The IMP response was measured by mass spectrometer, operated in negative ion TurboIonSpray multiple reaction monitoring mode with a source temperature of 750 °C. The precursor and fragment ions for each analyte were IMP (347 → 79) and ZMP (337 → 79). Peak areas for IMP and ZMP were determined using AB Sciex MultiQuant version 2.1.</div></div><div id="sec4_29_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> ZMP in Vitro Assay</h3><div class="NLM_p last">Cells were acquired from ATCC and were grown in folate free RPMI-1640 media (Gibco number 27016-021) supplemented with 5 mL of 1 M Hepes, 5 mL of 100 mM Na pyruvate, 2.5 mg/mL glucose, and 10% defined FBS (Hyclone number SH30070) for 5–7 days to deplete intracellular folate levels prior to the start of the experiment.</div></div><div id="sec4_29_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> MS Detection of ZMP in Cultured Cells</h3><div class="NLM_p">ZMP was detected in cultured cells via mass spectrometry analysis. Cells were plated at 25 000 cells per well in 100 μL with either high or low folate RPMI media and incubated overnight at 37 °C with 5% CO<sub>2</sub>. Cells were treated with inhibitor compounds for 16 h, 0.5% DMSO final concentration. Growth medium was decanted, and cells were lysed for 10 min at room temperature with 50 μL per well of 1× SureFire lysis buffer (PerkinElmer, SureFire kit component). Aliquots (40 μL) of standard or sample were combined in a deep 96-well plate with 160 μL of internal standard solution containing 13C5-ZMP (custom synthesis) and 13C5-AICAr (custom synthesis) at 100 ng/mL in 40 mM ammonium acetate, pH 4. An aliquot (400 μL) of DCM was added to each sample. Samples were sealed, vortexed for 5 min, then placed in the refrigerator for 30 min. The samples were centrifuged at 4 °C for 10 min at 16 600<i>g</i>, and 75 μL of the aqueous layer was transferred to a clean 96-well plate and sealed prior to analysis.</div><div class="NLM_p">The LC–MS method utilizes a Shimadzu Prominence 20A HPLC system connected to an AB Sciex 5500 or an AB Sciex 6500 triple quadrupole mass spectrometer. Extracted samples were separated using a Thermo Hypercarb Javelin guard column (2.1 mm × 20 mm, 5 μm) with an injection volume of 15 μL and a flow rate of 1 mL/min.</div><div class="NLM_p last">ZMP, AICAr, and dUMP were detected using positive ion TurboIonSpray multiple reaction monitoring mode, and the data were processed with AB Sciex MultiQuant. Back-calculated ZMP concentrations were fit to a four-parameter logistic equation using ACTIVITYBASE 4.0 to determine EC<sub>50</sub> values relative to the maximum observed metabolite levels.</div></div><div id="sec4_29_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Antitumor Efficacy in Human Carcinoma Mouse Xenograft Model</h3><div class="NLM_p last">The in vivo anticancer activity of <b>28a</b> was studied in breast adenocarcinoma cell line MDA-MB-231met2. In vivo studies were performed using female athymic nude mice (Harlan) fed normal chow. The MDA-MB-231met2 cells used for implantation were harvested during log phase growth and suspended in serum-free media and then diluted 1:1 with Matrigel matrix (BD 354234). Cells were injected in the right flank with 5 × 10<sup>6</sup> cells. Compound <b>28a</b> was formulated weekly in 20% 2-hydroxypropyl-β-cyclodextrin (HPBCD) in phosphate buffer, pH 8, with 1 molar equivalent NaOH added. The formulated compound was administered at the doses and schedules indicated by oral gavage (0.2 mL). Tumor volume is determined by caliper measurements (mm) using the formula for an ellipsoid sphere: tumor volume (mm<sup>3</sup>) = length × width2/2, where length and width refer to the larger and smaller perpendicular dimensions collected at each measurement. Tumors were collected and stored frozen for subsequent metabolite analysis. The log volume data were analyzed with a two-way repeated measures analysis of variance by time and treatment using the MIXED procedures in SAS software (version 9.3). The correlation model for the repeated measures was Spatial Power. Treated groups were compared to the control group at each time point. The MIXED procedure was also used separately for each treatment group to calculate adjusted mean values and standard errors at each time point accounting for the autocorrelation and produces <i>p</i>-values. The in vivo effects of AICARFT inhibition on the concentrations of pathway-related analytes were determined by liquid chromatography–mass spectrometry (LC–MS) analysis of tumor xenografts as described below.</div></div><div id="sec4_29_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Metabolite Assays</h3><div class="NLM_p">Frozen tumor xenograft samples were weighed on an analytical balance, transferred to 2 mL Eppendorf Safe-Lock tube containing a 5 mm steel bead, and placed on dry ice. For every milligram of tissue, 10 μL of internal standard solution containing 13C5-ZMP and 13C5-AICAr (1000 ng/mL) in ascorbic acid/formic acid/methanol/dichloromethane (0.1:0.1:80:20) was added. Samples were homogenized on a TissueLyser II (Qiagen) for 5 min at 15 Hz. Lysates were cleared by centrifugation at 4 °C for 10 min at 16 600<i>g</i>. Aliquots of each supernatant (200 μL) were transferred to a deep 96-well plate containing 600 μL of dichloromethane and 200 μL of 0.1% ascorbic acid solution per well. The plate was sealed, vortexed for 5 min, and centrifuged at 4 °C for 5 min at 16 600<i>g</i>. An aliquot (75 μL) of the top layer was transferred to a clean 96-well plate. An equal volume of 40 mM ammonium acetate, pH 4, and seal plate was added. The LC–MS method utilized a Shimadzu Prominence 20A HPLC system connected to an AB Sciex 5500 or an AB Sciex 6500 triple-quadrupole mass spectrometer running Analyst software. Extracted samples were separated using two Thermo Hypercarb Javelin guard columns (2.1 mm × 20 mm, 5 μm) connected in series with an injection volume of 15 μL and a flow rate of 0.75 mL/min. ZMP, AICAR, and dUMP were analyzed in positive ion TurboIonSpray multiple reaction monitoring mode, and the data were processed with AB Sciex MultiQuant.</div><div class="NLM_p last">Stable-isotope labeling of 13C2, 15N2-hypoxanthine, 13C5-adenosine, d4-guanine, 15N5-GTP, 13C5-AMP, and other nucleotide metabolites were obtained from Cambridge Isotope Laboratories. LC/ESI/MS/MS analysis of nucleotide metabolites was performed using AB Sciex 6500 mass spectrometer with an ESI probe and interfaced with an LC system. The UPLC system consisted of an Agilent 1290 binary pump, thermostat, TCC, and sampler. Plasma extracted was separated with Hypercarb 5 μm, 40 mm × 2.1 mm Javelin HTS (Thermo Scientific, PN 35005-022135). Mobile phase A was water/acetonitrile (95/5)/50 mM ammonium formate, pH 4.0, and mobile phase B was acetonitrile/methanol (45/50)/50 mM ammonium bicarbonate/0.1% NH<sub>4</sub>OH. Mass spectrometric analyses were performed online using electrospray ionization tandem mass spectrometry in the positive multiple reaction monitoring (MRM) mode. Plasma samples were extracted with methanol/water (80/20) with internal standards. Different nucleotide metabolites were quantified using standard curves and ratios of the peak areas of analytes to internal standard.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01046">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87661" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87661" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01046" class="ext-link">10.1021/acs.jmedchem.7b01046</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">In vitro assays used to characterize the enzymatic selectivity of AICARFT inhibitors, ZMP response for compound <b>28a</b> showing effect of low vs high folate in NCI-H460 cells, Alamar Blue response of compound <b>28a</b> after 7 days of treatment in NCI-H460 and MDA-MB-231 cells, dose–response in vivo target inhibition results (H460, low folate diet, 4 h), and protein expression and purification of AICARFT (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf">jm7b01046_si_001.pdf (351.07 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_002.csv">jm7b01046_si_002.csv (2.34 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes for <b>28a</b> and <b>32b</b> in complex with human ATIC are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UZ0">5UZ0</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UY8">5UY8</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01046" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin R. Fales</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7207-3610" title="Orcid link">http://orcid.org/0000-0001-7207-3610</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1670777a7365497d73607f784964567a7f7a7a6f3875797b"><span class="__cf_email__" data-cfemail="accacdc0c9dff3c7c9dac5c2f3deecc0c5c0c0d582cfc3c1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">F. George Njoroge</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harold B. Brooks</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Thibodeaux</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alicia Torrado</span> - <span class="hlFld-Affiliation affiliation">Centro
de Investigación Lilly, S. A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chong Si</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James L. Toth</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jefferson R. Mc Cowan</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth D. Roth</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth J. Thrasher</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kwame Frimpong</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew R. Lee</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert D. Dally</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy A. Shepherd</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy B. Durham</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brandon J. Margolis</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhipei Wu</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Wang</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shane Atwell</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Wang</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu-Hua Hui</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy I. Meier</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan A. Konicek</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandaruwan Geeganage</span> - <span class="hlFld-Affiliation affiliation">Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i58" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i58"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i59" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i59"> Abbreviations Used</h2><tr><td class="NLM_term">AICARFT</td><td class="NLM_def"><p class="first last">aminoimidazole-4-carboxamide ribonucleotide formyltransferase</p></td></tr><tr><td class="NLM_term">ZMP</td><td class="NLM_def"><p class="first last">5-aminoimidazole 4-carboxamide ribonucleotide</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple negative breast cancer</p></td></tr><tr><td class="NLM_term">PRPP</td><td class="NLM_def"><p class="first last">5-phosphoribosyl-1-pyrophosphate</p></td></tr><tr><td class="NLM_term">GAR</td><td class="NLM_def"><p class="first last">glycinamide ribonucleotide</p></td></tr><tr><td class="NLM_term">FGAR</td><td class="NLM_def"><p class="first last">α-<i>N</i>-formylglycinamide ribonucleotide</p></td></tr><tr><td class="NLM_term">ATIC</td><td class="NLM_def"><p class="first last">aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase</p></td></tr><tr><td class="NLM_term">N<sup>10</sup>-CHO-THF</td><td class="NLM_def"><p class="first last"><i>N</i><sup>10</sup>-formyltetrahydrofolate</p></td></tr><tr><td class="NLM_term">FAICAR</td><td class="NLM_def"><p class="first last">5-formamidoimidazole-4-carboxamide ribotide</p></td></tr><tr><td class="NLM_term">IMPCH</td><td class="NLM_def"><p class="first last">inosine monophosphate cyclohydrolase</p></td></tr><tr><td class="NLM_term">IMP</td><td class="NLM_def"><p class="first last">inosine 5′-monophosphate</p></td></tr><tr><td class="NLM_term">Ptx</td><td class="NLM_def"><p class="first last">pemetrexed</p></td></tr><tr><td class="NLM_term">DHFR</td><td class="NLM_def"><p class="first last">dihydrofolate reductase</p></td></tr><tr><td class="NLM_term">Mtx</td><td class="NLM_def"><p class="first last">methotrexate</p></td></tr><tr><td class="NLM_term">TS</td><td class="NLM_def"><p class="first last">thymidylate synthase</p></td></tr><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">AMP-activated protein kinase</p></td></tr><tr><td class="NLM_term">RFC</td><td class="NLM_def"><p class="first last">reduced folate carrier</p></td></tr><tr><td class="NLM_term">FRα, FRβ, FRγ</td><td class="NLM_def"><p class="first last">folate receptors α, β, γ</p></td></tr><tr><td class="NLM_term">PCFT</td><td class="NLM_def"><p class="first last">proton-coupled folate transporter</p></td></tr><tr><td class="NLM_term">FPGS</td><td class="NLM_def"><p class="first last">folylpolyglutamate synthase</p></td></tr><tr><td class="NLM_term">AICAr</td><td class="NLM_def"><p class="first last">aminoimidazole-4-carboxamide ribonucleoside</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">RPMI</td><td class="NLM_def"><p class="first last">Roswell Park Memorial Institute</p></td></tr><tr><td class="NLM_term">cTER</td><td class="NLM_def"><p class="first last">cell-based target engagement ratio</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ealick, S. E.</span><span> </span><span class="NLM_article-title">Structural Biology of the Purine Biosynthetic Pathway</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3699</span><span class="NLM_x">–</span> <span class="NLM_lpage">3724</span><span class="refDoi"> DOI: 10.1007/s00018-008-8295-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1007%2Fs00018-008-8295-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=18712276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGgs7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=3699-3724&author=Y.+Zhangauthor=M.+Morarauthor=S.+E.+Ealick&title=Structural+Biology+of+the+Purine+Biosynthetic+Pathway&doi=10.1007%2Fs00018-008-8295-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural biology of the purine biosynthetic pathway</span></div><div class="casAuthors">Zhang, Y.; Morar, M.; Ealick, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3699-3724</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Purine biosynthesis requires 10 enzymic transformations to generate IMP.  Enzymes PurF, PurD, PurL, PurM, PurC, and PurB are common to all pathways, whereas PurN or PurT, PurK/PurE-I or PurE-II, PurH or PurP, and PurJ or PurO catalyze the same steps in different organisms.  X-ray crystal structures are available for all 15 purine biosynthetic enzymes, including 7 ATP-dependent enzymes, 2 amidotransferases, and 2 tetrahydrofolate-dependent enzymes.  Here, the authors summarize the structures of the purine biosynthetic enzymes, discuss similarities and differences, and present arguments for pathway evolution.  Four of the ATP-dependent enzymes belong to the ATP-grasp superfamily and 2 to the PurM superfamily.  The amidotransferases are unrelated, with one utilizing an N-terminal nucleophile-glutaminase and the other utilizing a triad glutaminase.  Likewise, the tetrahydrofolate-dependent enzymes are unrelated.  Ancestral proteins may have included a broad specificity enzyme instead of PurD, PurT, PurK, PurC, and PurP, and a sep. enzyme instead of PurM and PurL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUjcyeLGRkBLVg90H21EOLACvtfcHk0lgJtX_5d3UvuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGgs7jM&md5=da182c0690aa7642a26dcd9f2573afbe</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs00018-008-8295-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-008-8295-8%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMorar%26aufirst%3DM.%26aulast%3DEalick%26aufirst%3DS.%2BE.%26atitle%3DStructural%2520Biology%2520of%2520the%2520Purine%2520Biosynthetic%2520Pathway%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2008%26volume%3D65%26spage%3D3699%26epage%3D3724%26doi%3D10.1007%2Fs00018-008-8295-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Buchanan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, S. C.</span><span> </span><span class="NLM_article-title">Enzymic Reactions in the Synthesis of the Purines</span> <span class="citation_source-journal">Adv. Enzymol. Relat. Areas Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1002/9780470122662.ch5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1002%2F9780470122662.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=199-261&author=J.+M.+Buchananauthor=S.+C.+Hartman&title=Enzymic+Reactions+in+the+Synthesis+of+the+Purines&doi=10.1002%2F9780470122662.ch5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2F9780470122662.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9780470122662.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BC.%26atitle%3DEnzymic%2520Reactions%2520in%2520the%2520Synthesis%2520of%2520the%2520Purines%26jtitle%3DAdv.%2520Enzymol.%2520Relat.%2520Areas%2520Mol.%2520Biol.%26date%3D2006%26volume%3D21%26spage%3D199%26epage%3D261%26doi%3D10.1002%2F9780470122662.ch5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Baggott, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, B. B.</span><span> </span><span class="NLM_article-title">Inhibition of 5-Aminoimidazole-4-carboxamide Ribotide Transformylase, Adenosine Deaminase and 5′-Adenylate Deaminase by Polyglutamates of Methotrexate and Oxidized Folates and by 5-Aminoimidazole-4-carboxamide Riboside and Ribotide</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span><span class="refDoi"> DOI: 10.1042/bj2360193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1042%2Fbj2360193" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=1986&pages=193-200&author=J.+E.+Baggottauthor=W.+H.+Vaughnauthor=B.+B.+Hudson&title=Inhibition+of+5-Aminoimidazole-4-carboxamide+Ribotide+Transformylase%2C+Adenosine+Deaminase+and+5%E2%80%B2-Adenylate+Deaminase+by+Polyglutamates+of+Methotrexate+and+Oxidized+Folates+and+by+5-Aminoimidazole-4-carboxamide+Riboside+and+Ribotide&doi=10.1042%2Fbj2360193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2Fbj2360193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2360193%26sid%3Dliteratum%253Aachs%26aulast%3DBaggott%26aufirst%3DJ.%2BE.%26aulast%3DVaughn%26aufirst%3DW.%2BH.%26aulast%3DHudson%26aufirst%3DB.%2BB.%26atitle%3DInhibition%2520of%25205-Aminoimidazole-4-carboxamide%2520Ribotide%2520Transformylase%252C%2520Adenosine%2520Deaminase%2520and%25205%25E2%2580%25B2-Adenylate%2520Deaminase%2520by%2520Polyglutamates%2520of%2520Methotrexate%2520and%2520Oxidized%2520Folates%2520and%2520by%25205-Aminoimidazole-4-carboxamide%2520Riboside%2520and%2520Ribotide%26jtitle%3DBiochem.%2520J.%26date%3D1986%26volume%3D236%26spage%3D193%26epage%3D200%26doi%3D10.1042%2Fbj2360193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mitchell-Ryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravindra, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matherly, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">Discovery of 5-Substituted Pyrrolo[2,3-<i>d</i>]pyrimidine Antifolates as Dual-Acting Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase in De Novo Purine Nucleotide Biosynthesis: Implications of Inhibiting 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase to AMPK Activation and Antitumor Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">10016</span><span class="NLM_x">–</span> <span class="NLM_lpage">10032</span><span class="refDoi"> DOI: 10.1021/jm401328u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401328u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVajur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=10016-10032&author=S.+Mitchell-Ryanauthor=Y.+Wangauthor=S.+Raghavanauthor=M.+P.+Ravindraauthor=E.+Halesauthor=S.+Orrauthor=C.+Cherianauthor=Z.+Houauthor=L.+H.+Matherlyauthor=A.+Gangjee&title=Discovery+of+5-Substituted+Pyrrolo%5B2%2C3-d%5Dpyrimidine+Antifolates+as+Dual-Acting+Inhibitors+of+Glycinamide+Ribonucleotide+Formyltransferase+and+5-Aminoimidazole-4-carboxamide+Ribonucleotide+Formyltransferase+in+De+Novo+Purine+Nucleotide+Biosynthesis%3A+Implications+of+Inhibiting+5-Aminoimidazole-4-carboxamide+Ribonucleotide+Formyltransferase+to+AMPK+Activation+and+Antitumor+Activity&doi=10.1021%2Fjm401328u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates as Dual-Acting Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase in De Novo Purine Nucleotide Biosynthesis: Implications of Inhibiting 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase to AMPK Activation and Antitumor Activity</span></div><div class="casAuthors">Mitchell-Ryan, Shermaine; Wang, Yiqiang; Raghavan, Sudhir; Ravindra, Manasa Punaha; Hales, Eric; Orr, Steven; Cherian, Christina; Hou, Zhanjun; Matherly, Larry H.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10016-10032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We synthesized 5-substituted pyrrolo-[2,3-d]-pyrimidine antifolates (compds. 5-10) with one-to-six bridge carbons and a benozyl ring in the side chain as antitumor agents.  Compd. 8 with a 4-carbon bridge was the most active analog and potently inhibited proliferation of folate receptor (FR) α-expressing Chinese hamster ovary and KB human tumor cells.  Growth inhibition was reversed completely or in part by excess folic acid, indicating that FRα is involved in cellular uptake, and resulted in S-phase accumulation and apoptosis.  Antiproliferative effects of compd. 8 toward KB cells were protected by excess adenosine but not thymidine, establishing de novo purine nucleotide biosynthesis as the targeted pathway.  However, 5-aminoimidazole-4-carboxamide (AICA) protection was incomplete, suggesting inhibition of both AICA ribonucleotide formyltransferase (AICARFTase) and glycinamide ribonucleotide formyltransferase (GARFTase).  Inhibition of GARFTase and AICARFTase by compd. 8 was confirmed by cellular metabolic assays and resulted in ATP pool depletion.  To our knowledge, this is the first example of an antifolate that acts as a dual inhibitor of GARFTase and AICARFTase as its principal mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCWR5x3a4Wo7Vg90H21EOLACvtfcHk0lhax7Iq0V_t3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVajur7I&md5=0870603cc284cf81c44388c7c3cd162f</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1021%2Fjm401328u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401328u%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell-Ryan%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRavindra%26aufirst%3DM.%2BP.%26aulast%3DHales%26aufirst%3DE.%26aulast%3DOrr%26aufirst%3DS.%26aulast%3DCherian%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DZ.%26aulast%3DMatherly%26aufirst%3DL.%2BH.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25205-Substituted%2520Pyrrolo%255B2%252C3-d%255Dpyrimidine%2520Antifolates%2520as%2520Dual-Acting%2520Inhibitors%2520of%2520Glycinamide%2520Ribonucleotide%2520Formyltransferase%2520and%25205-Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Formyltransferase%2520in%2520De%2520Novo%2520Purine%2520Nucleotide%2520Biosynthesis%253A%2520Implications%2520of%2520Inhibiting%25205-Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Formyltransferase%2520to%2520AMPK%2520Activation%2520and%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D10016%26epage%3D10032%26doi%3D10.1021%2Fjm401328u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell-Ryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matherly, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">Novel 5-Substituted Pyrrolo[2,3-<i>d</i>]pyrimidines as Dual Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase and as Potential Antitumor Agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span><span class="refDoi"> DOI: 10.1021/jm501787c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501787c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1479-1493&author=Y.+Wangauthor=S.+Mitchell-Ryanauthor=S.+Raghavanauthor=C.+Georgeauthor=S.+Orrauthor=Z.+Houauthor=L.+H.+Matherlyauthor=A.+Gangjee&title=Novel+5-Substituted+Pyrrolo%5B2%2C3-d%5Dpyrimidines+as+Dual+Inhibitors+of+Glycinamide+Ribonucleotide+Formyltransferase+and+5-Aminoimidazole-4-carboxamide+Ribonucleotide+Formyltransferase+and+as+Potential+Antitumor+Agents&doi=10.1021%2Fjm501787c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1021%2Fjm501787c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501787c%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMitchell-Ryan%26aufirst%3DS.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DOrr%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DZ.%26aulast%3DMatherly%26aufirst%3DL.%2BH.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DNovel%25205-Substituted%2520Pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520Dual%2520Inhibitors%2520of%2520Glycinamide%2520Ribonucleotide%2520Formyltransferase%2520and%25205-Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Formyltransferase%2520and%2520as%2520Potential%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1479%26epage%3D1493%26doi%3D10.1021%2Fjm501787c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 6-Substituted Pyrrolo[2,3-d]pyrimidines as Dual Inhibitors of TS and AICARFTase and as Potential Antitumor Agents</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.ejmech.2016.03.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2016&pages=245-256&author=Y.+Liuauthor=M.+Liauthor=H.+Zhangauthor=J.+Yuanauthor=C.+Zhangauthor=K.+Zhangauthor=H.+Guoauthor=L.+Zhaoauthor=Y.+Duauthor=L.+Wangauthor=L.+Ren&title=Design%2C+Synthesis+and+Biological+Evaluation+of+6-Substituted+Pyrrolo%5B2%2C3-d%5Dpyrimidines+as+Dual+Inhibitors+of+TS+and+AICARFTase+and+as+Potential+Antitumor+Agents&doi=10.1016%2Fj.ejmech.2016.03.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DL.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25206-Substituted%2520Pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520Dual%2520Inhibitors%2520of%2520TS%2520and%2520AICARFTase%2520and%2520as%2520Potential%2520Antitumor%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D115%26spage%3D245%26epage%3D256%26doi%3D10.1016%2Fj.ejmech.2016.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Cheong, C.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolan, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greasley, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beardsley, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. A.</span><span> </span><span class="NLM_article-title">Crystal Structures of Human Bifunctional Enzyme Aminoimidazole-4-carboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase in Complex with Potent Sulfonyl-Containing Antifolates</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">18034</span><span class="NLM_x">–</span> <span class="NLM_lpage">18045</span><span class="refDoi"> DOI: 10.1074/jbc.M313691200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1074%2Fjbc.M313691200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=14966129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Gms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=18034-18045&author=C.-G.+Cheongauthor=D.+W.+Wolanauthor=S.+E.+Greasleyauthor=P.+A.+Hortonauthor=G.+P.+Beardsleyauthor=I.+A.+Wilson&title=Crystal+Structures+of+Human+Bifunctional+Enzyme+Aminoimidazole-4-carboxamide+Ribonucleotide+Transformylase%2FIMP+Cyclohydrolase+in+Complex+with+Potent+Sulfonyl-Containing+Antifolates&doi=10.1074%2Fjbc.M313691200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Human Bifunctional Enzyme Aminoimidazole-4-carboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase in Complex with Potent Sulfonyl-containing Antifolates</span></div><div class="casAuthors">Cheong, Cheom-Gil; Wolan, Dennis W.; Greasley, Samantha E.; Horton, Patricia A.; Beardsley, G. Peter; Wilson, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">18034-18045</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase/IMP cyclohydrolase (ATIC) is a bifunctional enzyme with folate-dependent AICAR transformylase and IMP cyclohydrolase activities that catalyzes the last two steps of purine biosynthesis.  The AICAR transformylase inhibitors BW1540 and BW2315 are sulfamido-bridged 5,8-dideazafolate analogs with remarkably potent Ki values of 8 and 6 nM, resp., compared with most other antifolates.  Crystal structures of ATIC at 2.55 and 2.60 Å with each inhibitor, in the presence of substrate AICAR, revealed that the sulfonyl groups dominate inhibitor binding and orientation through interaction with the proposed oxyanion hole.  These agents then appear to mimic the anionic transition state and now implicate Asn431 in the reaction mechanism along with previously identified key catalytic residues Lys266 and His267.  Potent and selective inhibition of the AICAR transformylase active site, compared with other folate-dependent enzymes, should therefore be pursued by further design of sulfonyl-contg. antifolates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp3qimqqvhSrVg90H21EOLACvtfcHk0lhax7Iq0V_t3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Gms7Y%253D&md5=4d61d94453eee4e6f22c42f3799436b2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M313691200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M313691200%26sid%3Dliteratum%253Aachs%26aulast%3DCheong%26aufirst%3DC.-G.%26aulast%3DWolan%26aufirst%3DD.%2BW.%26aulast%3DGreasley%26aufirst%3DS.%2BE.%26aulast%3DHorton%26aufirst%3DP.%2BA.%26aulast%3DBeardsley%26aufirst%3DG.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26atitle%3DCrystal%2520Structures%2520of%2520Human%2520Bifunctional%2520Enzyme%2520Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Transformylase%252FIMP%2520Cyclohydrolase%2520in%2520Complex%2520with%2520Potent%2520Sulfonyl-Containing%2520Antifolates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D18034%26epage%3D18045%26doi%3D10.1074%2Fjbc.M313691200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Wall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benkovic, S. J.</span><span> </span><span class="NLM_article-title">A Multisubstrate Adduct Inhibitor of AICAR Transformylase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3421</span><span class="NLM_x">–</span> <span class="NLM_lpage">3424</span><span class="refDoi"> DOI: 10.1021/jm990323+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990323%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3421-3424&author=M.+Wallauthor=J.+H.+Shimauthor=S.+J.+Benkovic&title=A+Multisubstrate+Adduct+Inhibitor+of+AICAR+Transformylase&doi=10.1021%2Fjm990323%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm990323%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990323%252B%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DM.%26aulast%3DShim%26aufirst%3DJ.%2BH.%26aulast%3DBenkovic%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Multisubstrate%2520Adduct%2520Inhibitor%2520of%2520AICAR%2520Transformylase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3421%26epage%3D3424%26doi%3D10.1021%2Fjm990323%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Spurr, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birts, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benkovic, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaydes, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavassoli, A.</span><span> </span><span class="NLM_article-title">Targeting Tumour Proliferation with a Small-Molecule Inhibitor of AICAR Transformylase Homodimerization</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1628</span><span class="NLM_x">–</span> <span class="NLM_lpage">1634</span><span class="refDoi"> DOI: 10.1002/cbic.201200279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1002%2Fcbic.201200279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=22764122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVelt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1628-1634&author=I.+B.+Spurrauthor=C.+N.+Birtsauthor=F.+Cudaauthor=S.+J.+Benkovicauthor=J.+P.+Blaydesauthor=A.+Tavassoli&title=Targeting+Tumour+Proliferation+with+a+Small-Molecule+Inhibitor+of+AICAR+Transformylase+Homodimerization&doi=10.1002%2Fcbic.201200279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting tumor proliferation with a small-molecule inhibitor of AICAR transformylase homodimerization</span></div><div class="casAuthors">Spurr, Ian B.; Birts, Charles N.; Cuda, Francesco; Benkovic, Stephen J.; Blaydes, Jeremy P.; Tavassoli, Ali</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1628-1634, S1628/1-S1628/44</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) is a bifunctional homodimeric enzyme that catalyzes the last two steps of de novo purine biosynthesis.  Homodimerization of ATIC, a protein-protein interaction with an interface of over 5000 Å2, is required for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity, with the active sites forming at the interface of the interacting proteins.  Here, we report the development of a small-mol. inhibitor of AICAR transformylase that functions by preventing the homodimerization of ATIC.  The compd. is derived from a previously reported cyclic hexapeptide inhibitor of AICAR transformylase (with a Ki of 17 μM), identified by high-throughput screening.  The active motif of the cyclic peptide is identified as an arginine-tyrosine dipeptide, a capped analog of which inhibits AICAR transformylase with a Ki value of 84 μM.  A library of nonnatural analogs of this dipeptide was designed, synthesized, and assayed.  The most potent compd. inhibits AICAR transformylase with a Ki value of 685 nM, a 25-fold improvement in activity from the parent cyclic peptide.  The potential for this AICAR transformylase inhibitor in cancer therapy was assessed by studying its effect on the proliferation of a model breast cancer cell line.  Using a nonradioactive proliferation assay and live cell imaging, a dose-dependent redn. in cell nos. and cell division rates was obsd. in cells treated with our ATIC dimerization inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbzH_QElMmLbVg90H21EOLACvtfcHk0lgAEDtyDZOC3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVelt7k%253D&md5=4c1437a368f2fd3ac0303918b8b30a73</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201200279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201200279%26sid%3Dliteratum%253Aachs%26aulast%3DSpurr%26aufirst%3DI.%2BB.%26aulast%3DBirts%26aufirst%3DC.%2BN.%26aulast%3DCuda%26aufirst%3DF.%26aulast%3DBenkovic%26aufirst%3DS.%2BJ.%26aulast%3DBlaydes%26aufirst%3DJ.%2BP.%26aulast%3DTavassoli%26aufirst%3DA.%26atitle%3DTargeting%2520Tumour%2520Proliferation%2520with%2520a%2520Small-Molecule%2520Inhibitor%2520of%2520AICAR%2520Transformylase%2520Homodimerization%26jtitle%3DChemBioChem%26date%3D2012%26volume%3D13%26spage%3D1628%26epage%3D1634%26doi%3D10.1002%2Fcbic.201200279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tatlock, J. H.; Linton, M. A.; Condon, B.; Davies, J. F.,  II; Escobar, J. A.; Kumpf, R. A.; Lundgren, K.; Price, S.; Romines, W. H.,  III; Sisson, W.; Varney, M. D.; Worland, S. T.</span><span> </span><span class="NLM_article-title">Design, Synthesis and Evaluation of Novel 6-Arylsulfonylamino-3-chloro-benzo[b]thiophene-2-carboxylic Acid Amides: Potent, Lipophilic Inhibitors of 5-Aminoimidazole-4-carboxamide Ribonucleotide Transformylase</span>. Presented at the 217th National Meeting of the American Chemical Society, Anaheim, CA, March<span class="NLM_x"> </span><span class="NLM_year">1999</span><span class="NLM_x">; </span>Poster MEDI-041.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=J.+H.+Tatlock&author=M.+A.+Linton&author=B.+Condon&author=J.+F.+Davies&author=J.+A.+Escobar&author=R.+A.+Kumpf&author=K.+Lundgren&author=S.+Price&author=W.+H.+Romines&author=W.+Sisson&author=M.+D.+Varney&author=S.+T.+Worland&title=Design%2C+Synthesis+and+Evaluation+of+Novel+6-Arylsulfonylamino-3-chloro-benzo%5Bb%5Dthiophene-2-carboxylic+Acid+Amides%3A+Potent%2C+Lipophilic+Inhibitors+of+5-Aminoimidazole-4-carboxamide+Ribonucleotide+Transformylase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DTatlock%26aufirst%3DJ.%2BH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Evaluation%2520of%2520Novel%25206-Arylsulfonylamino-3-chloro-benzo%255Bb%255Dthiophene-2-carboxylic%2520Acid%2520Amides%253A%2520Potent%252C%2520Lipophilic%2520Inhibitors%2520of%25205-Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Transformylase%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Pearce, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. A.</span><span> </span><span class="NLM_article-title">The Evolution of Cancer Research and Drug Discovery at Lilly Research Laboratories</span> <span class="citation_source-journal">Adv. Enzyme Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1016/j.advenzreg.2005.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.advenzreg.2005.02.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=229-255&author=H.+L.+Pearceauthor=M.+A.+Miller&title=The+Evolution+of+Cancer+Research+and+Drug+Discovery+at+Lilly+Research+Laboratories&doi=10.1016%2Fj.advenzreg.2005.02.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.advenzreg.2005.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.advenzreg.2005.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DPearce%26aufirst%3DH.%2BL.%26aulast%3DMiller%26aufirst%3DM.%2BA.%26atitle%3DThe%2520Evolution%2520of%2520Cancer%2520Research%2520and%2520Drug%2520Discovery%2520at%2520Lilly%2520Research%2520Laboratories%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D2005%26volume%3D45%26spage%3D229%26epage%3D255%26doi%3D10.1016%2Fj.advenzreg.2005.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Racanelli, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothbart, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R. G.</span><span> </span><span class="NLM_article-title">Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">5467</span><span class="NLM_x">–</span> <span class="NLM_lpage">5474</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1158%2F0008-5472.CAN-08-4979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=19549896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFajsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=5467-5474&author=A.+C.+Racanelliauthor=S.+B.+Rothbartauthor=C.+L.+Heyerauthor=R.+G.+Moran&title=Therapeutics+by+Cytotoxic+Metabolite+Accumulation%3A+Pemetrexed+Causes+ZMP+Accumulation%2C+AMPK+Activation%2C+and+Mammalian+Target+of+Rapamycin+Inhibition&doi=10.1158%2F0008-5472.CAN-08-4979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition</span></div><div class="casAuthors">Racanelli, Alexandra C.; Rothbart, Scott B.; Heyer, Cortney L.; Moran, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5467-5474</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pemetrexed represents the first antifolate cancer drug to be approved by the Food and Drug Administration in 20 years; it is currently in widespread use for first line therapy of mesothelioma and non-small cell lung cancer.  Pemetrexed has more than one site of action; the primary site is thymidylate synthase.  We now report that the secondary target is the downstream folate-dependent enzyme in de novo purine synthesis, aminoimidazolecarboxamide ribonucleotide formyltransferase (AICART).  The substrate of the AICART reaction, ZMP, accumulated in intact pemetrexed-inhibited tumor cells, identifying AICART as the step in purine synthesis that becomes rate-limiting after drug treatment.  The accumulating ZMP causes an activation of AMP-activated protein kinase with subsequent inhibition of the mammalian target of rapamycin (mTOR) and hypophosphorylation of the downstream targets of mTOR that control initiation of protein synthesis and cell growth.  We suggest that the activity of pemetrexed against human cancers is a reflection of its direct inhibition of folate-dependent target proteins combined with prolonged inhibition of the mTOR pathway secondary to accumulation of ZMP.  [Cancer Res 2009;69(13):5467-74].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlnjGOCRvlVLVg90H21EOLACvtfcHk0lgAEDtyDZOC3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFajsrc%253D&md5=6cd2a5e107455ab99524d8ed2ed3fc2d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4979%26sid%3Dliteratum%253Aachs%26aulast%3DRacanelli%26aufirst%3DA.%2BC.%26aulast%3DRothbart%26aufirst%3DS.%2BB.%26aulast%3DHeyer%26aufirst%3DC.%2BL.%26aulast%3DMoran%26aufirst%3DR.%2BG.%26atitle%3DTherapeutics%2520by%2520Cytotoxic%2520Metabolite%2520Accumulation%253A%2520Pemetrexed%2520Causes%2520ZMP%2520Accumulation%252C%2520AMPK%2520Activation%252C%2520and%2520Mammalian%2520Target%2520of%2520Rapamycin%2520Inhibition%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D5467%26epage%3D5474%26doi%3D10.1158%2F0008-5472.CAN-08-4979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Rothbart, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racanelli, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R. G.</span><span> </span><span class="NLM_article-title">Pemetrexed Indirectly Activates the Metabolic Kinase AMPK in Human Carcinomas</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">10299</span><span class="NLM_x">–</span> <span class="NLM_lpage">10309</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1158%2F0008-5472.CAN-10-1873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=21159649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10299-10309&author=S.+B.+Rothbartauthor=A.+C.+Racanelliauthor=R.+G.+Moran&title=Pemetrexed+Indirectly+Activates+the+Metabolic+Kinase+AMPK+in+Human+Carcinomas&doi=10.1158%2F0008-5472.CAN-10-1873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pemetrexed Indirectly Activates the Metabolic Kinase AMPK in Human Carcinomas</span></div><div class="casAuthors">Rothbart, Scott B.; Racanelli, Alexandra C.; Moran, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10299-10309</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The chemotherapeutic drug pemetrexed, an inhibitor of thymidylate synthase, has an important secondary target in human leukemic cells, aminoimidazolecarboxamide ribonucleotide formyltransferase (AICART), the second folate-dependent enzyme of purine biosynthesis.  The purine intermediate aminoimidazolecarboxamide ribonucleotide (ZMP), which accumulates behind this block, transmits an inhibitory signal to the mTORC1 complex via activation of the cellular energy sensor AMP-activated kinase (AMPK).  Given that the PI3K-AKT-mTOR pathway is frequently deregulated during carcinogenesis, we asked whether the indirect activation of AMPK by pemetrexed offers an effective therapeutic strategy for carcinomas with defects in this pathway.  Activation of AMPK by ZMP in pemetrexed-treated colon and lung carcinoma cells and the downstream consequences of this activation were strikingly more robust than previously seen in leukemic cells.  Genetic expts. demonstrated the intermediacy of AICART inhibition and the centrality of AMPK activation in these effects.  Whereas AMPK activation resulted in marked inhibition of mTORC1, other targets of AMPK were phosphorylated that were not mTORC1-dependent.  Whereas AMPK activation is thought to require AMPKα T172 phosphorylation, pemetrexed also activated AMPK in carcinoma cells null for LKB1, the predominant AMPKα T172 kinase whose deficiency is common in lung adenocarcinomas.  Like rapamycin analogs, pemetrexed relieved feedback suppression of PI3K and AKT, but the prolonged accumulation of unphosphorylated 4E-BP1, a tight-binding inhibitor of cap-dependent translation, was seen following AMPK activation.  Our findings indicate that AMPK activation by pemetrexed inhibits mTORC1-dependent and -independent processes that control translation and lipid metab., identifying pemetrexed as a targeted therapeutic agent for this pathway that differs significantly from rapamycin analogs.  Cancer Res; 70(24); 10299-309.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS06UXoSFlg7Vg90H21EOLACvtfcHk0lgm_t0Rlus_4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7fF&md5=06fb664e3b1713aff6bdde1ccbadf23a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1873%26sid%3Dliteratum%253Aachs%26aulast%3DRothbart%26aufirst%3DS.%2BB.%26aulast%3DRacanelli%26aufirst%3DA.%2BC.%26aulast%3DMoran%26aufirst%3DR.%2BG.%26atitle%3DPemetrexed%2520Indirectly%2520Activates%2520the%2520Metabolic%2520Kinase%2520AMPK%2520in%2520Human%2520Carcinomas%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10299%26epage%3D10309%26doi%3D10.1158%2F0008-5472.CAN-10-1873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Goldman, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chattopadhyay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R.</span><span> </span><span class="NLM_article-title">The Antifolates: Evolution, New Agents in the Clinic, and how Targeting Delivery via Specific Membrane Transporters is Driving the Development of a Next Generation of Folate Analogs</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1423</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1409-1423&author=I.+D.+Goldmanauthor=S.+Chattopadhyayauthor=R.+Zhaoauthor=R.+Moran&title=The+Antifolates%3A+Evolution%2C+New+Agents+in+the+Clinic%2C+and+how+Targeting+Delivery+via+Specific+Membrane+Transporters+is+Driving+the+Development+of+a+Next+Generation+of+Folate+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DI.%2BD.%26aulast%3DChattopadhyay%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DR.%26atitle%3DThe%2520Antifolates%253A%2520Evolution%252C%2520New%2520Agents%2520in%2520the%2520Clinic%252C%2520and%2520how%2520Targeting%2520Delivery%2520via%2520Specific%2520Membrane%2520Transporters%2520is%2520Driving%2520the%2520Development%2520of%2520a%2520Next%2520Generation%2520of%2520Folate%2520Analogs%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D11%26spage%3D1409%26epage%3D1423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Visentin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, I. D.</span><span> </span><span class="NLM_article-title">The Antifolates</span> <span class="citation_source-journal">Hematol. Oncol. Clin. N. Am.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span><span class="refDoi"> DOI: 10.1016/j.hoc.2012.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.hoc.2012.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=22520983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A280%3ADC%252BC38rmslyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=629-648&author=M.+Visentinauthor=R.+Zhaoauthor=I.+D.+Goldman&title=The+Antifolates&doi=10.1016%2Fj.hoc.2012.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">The antifolates</span></div><div class="casAuthors">Visentin Michele; Zhao Rongbao; Goldman I David</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-48, ix</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics.  New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTs6Vk1KGWrT_h3YQQtAhNufW6udTcc2ebldStJhwpD-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rmslyiuw%253D%253D&md5=516c6432e647418b245aba234c1dd545</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2012.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2012.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DVisentin%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DGoldman%26aufirst%3DI.%2BD.%26atitle%3DThe%2520Antifolates%26jtitle%3DHematol.%2520Oncol.%2520Clin.%2520N.%2520Am.%26date%3D2012%26volume%3D26%26spage%3D629%26epage%3D648%26doi%3D10.1016%2Fj.hoc.2012.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Visentin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diop-Bove, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, D. I.</span><span> </span><span class="NLM_article-title">The Intestinal Absorption of Folates</span> <span class="citation_source-journal">Annu. Rev. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span><span class="refDoi"> DOI: 10.1146/annurev-physiol-020911-153251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1146%2Fannurev-physiol-020911-153251" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=251-274&author=M.+Visentinauthor=N.+Diop-Boveauthor=R.+Zhaoauthor=D.+I.+Goldman&title=The+Intestinal+Absorption+of+Folates&doi=10.1146%2Fannurev-physiol-020911-153251"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1146%2Fannurev-physiol-020911-153251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-physiol-020911-153251%26sid%3Dliteratum%253Aachs%26aulast%3DVisentin%26aufirst%3DM.%26aulast%3DDiop-Bove%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DGoldman%26aufirst%3DD.%2BI.%26atitle%3DThe%2520Intestinal%2520Absorption%2520of%2520Folates%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2014%26volume%3D76%26spage%3D251%26epage%3D274%26doi%3D10.1146%2Fannurev-physiol-020911-153251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Faessel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slocum, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boritzki, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustum, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, W. R.</span><span> </span><span class="NLM_article-title">Super <i>in Vitro</i> Synergy Between Inhibitors of Dihydrofolate Reductase and Inhibitors of Other Folate-requiring Enzymes: The Critical Role of Polyglutamylation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3036</span><span class="NLM_x">–</span> <span class="NLM_lpage">3050</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=3036-3050&author=H.+M.+Faesselauthor=H.+K.+Slocumauthor=R.+C.+Jacksonauthor=T.+J.+Boritzkiauthor=R.+M.+Rustumauthor=M.+G.+Nairauthor=W.+R.+Greco&title=Super+in+Vitro+Synergy+Between+Inhibitors+of+Dihydrofolate+Reductase+and+Inhibitors+of+Other+Folate-requiring+Enzymes%3A+The+Critical+Role+of+Polyglutamylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaessel%26aufirst%3DH.%2BM.%26aulast%3DSlocum%26aufirst%3DH.%2BK.%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DBoritzki%26aufirst%3DT.%2BJ.%26aulast%3DRustum%26aufirst%3DR.%2BM.%26aulast%3DNair%26aufirst%3DM.%2BG.%26aulast%3DGreco%26aufirst%3DW.%2BR.%26atitle%3DSuper%2520in%2520Vitro%2520Synergy%2520Between%2520Inhibitors%2520of%2520Dihydrofolate%2520Reductase%2520and%2520Inhibitors%2520of%2520Other%2520Folate-requiring%2520Enzymes%253A%2520The%2520Critical%2520Role%2520of%2520Polyglutamylation%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D3036%26epage%3D3050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Allegra, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drake, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolivet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabner, B. A.</span><span> </span><span class="NLM_article-title">Inhibition of Phosphoribosylaminoimidazolecarboxamide Transformylase by Methotrexate and Dihydrofolic Acid Polyglutamates</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">4881</span><span class="NLM_x">–</span> <span class="NLM_lpage">4885</span><span class="refDoi"> DOI: 10.1073/pnas.82.15.4881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1073%2Fpnas.82.15.4881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=3860829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADyaL2MXltFGrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=4881-4885&author=C.+J.+Allegraauthor=J.+C.+Drakeauthor=J.+Jolivetauthor=B.+A.+Chabner&title=Inhibition+of+Phosphoribosylaminoimidazolecarboxamide+Transformylase+by+Methotrexate+and+Dihydrofolic+Acid+Polyglutamates&doi=10.1073%2Fpnas.82.15.4881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates</span></div><div class="casAuthors">Allegra, Carmen J.; Drake, James C.; Jolivet, Jacques; Chabner, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4881-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The enhanced inhibitory potency of methotrexate polyglutamate (MTX polyglutamate)  [82334-40-5] and dihydrofolate pentaglutamate  [98204-33-2] on the catalytic activity of phosphoribosylaminoimidazolecarboxamide transformylase (AICAR transformylase)  [9032-03-5] purified from MCF-7 human breast cancer cells was detd.  MTX  [59-05-2] and dihydrofolate  [4033-27-6] both monoglutamates, were weak competitive inhibitors of AICAR transformylase with Ki of 143 and 63 μM, resp., and their inhibitory capacity was largely unaffected by the glutamated state of the folate cosubstrate.  In contrast, MTX polyglutamates were potent competitive inhibitors, with an ≈10-fold increase in inhibitory potency with the addn. of each glutamate group up to 4 (i.e., the pentaglutamate deriv.  [80801-53-2]).  MTX tetraglutamate  [80801-54-3] and MTX pentaglutamates were the most potent, with equiv. Kis of 5.6 × 10-8 M; they were 2500-fold more potent than MTX.  Dihydrofolate pentaglutamate was as potent an inhibitor as MTX pentaglutamate, with a Ki of 4.3 × 10-8 M.  The potent inhibitory effects demonstrated by the polyglutamate compds., when tested against the folate monoglutamate substrate were sharply curtailed when folate pentaglutamate was used as the substrate.  MTX and dehydrofolate pentaglutamates were only 7- and 25-fold more potent than their monoglutamate counterparts under these conditions.  A model depicting these complex interactions is postulated.  These findings have significant implications regarding the antitumor mechanism of action of MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsdj6Jb-DzFrVg90H21EOLACvtfcHk0lgetV5oZeOd3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltFGrt7k%253D&md5=2e89e65beda64b5972a7dd689b928311</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.82.15.4881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.82.15.4881%26sid%3Dliteratum%253Aachs%26aulast%3DAllegra%26aufirst%3DC.%2BJ.%26aulast%3DDrake%26aufirst%3DJ.%2BC.%26aulast%3DJolivet%26aufirst%3DJ.%26aulast%3DChabner%26aufirst%3DB.%2BA.%26atitle%3DInhibition%2520of%2520Phosphoribosylaminoimidazolecarboxamide%2520Transformylase%2520by%2520Methotrexate%2520and%2520Dihydrofolic%2520Acid%2520Polyglutamates%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1985%26volume%3D82%26spage%3D4881%26epage%3D4885%26doi%3D10.1073%2Fpnas.82.15.4881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span> </span><span class="NLM_article-title">Molecular Basis of Antifolate Resistance</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1007/s10555-007-9049-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1007%2Fs10555-007-9049-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=17333344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1KqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=153-181&author=Y.+G.+Assaraf&title=Molecular+Basis+of+Antifolate+Resistance&doi=10.1007%2Fs10555-007-9049-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of antifolate resistance</span></div><div class="casAuthors">Assaraf, Yehuda G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153-181</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Folates play a key role in one-carbon metab. essential for the biosynthesis of purines, thymidylate and hence DNA replication.  The antifolate methotrexate has been rationally-designed nearly 60 years ago to potently block the folate-dependent enzyme dihydrofolate reductase (DHFR) thereby achieving temporary remissions in childhood acute leukemia.  Recently, the novel antifolates raltitrexed and pemetrexed that target thymidylate synthase (TS) and glycineamide ribonucleotide transformylase (GARTF) were introduced for the treatment of colorectal cancer and malignant pleural mesothelioma. (Anti)folates are divalent anions which predominantly use the reduced folate carrier (RFC) for their cellular uptake. (Anti)folates are retained intracellularly via polyglutamylation catalyzed by folylpoly-γ-glutamate synthetase (FPGS).  As the intracellular concn. of antifolates is crit. for their pharmacol. activity, polyglutamylation is a key determinant of antifolate cytotoxicity.  However, anticancer drug resistance phenomena pose major obstacles towards curative cancer chemotherapy.  Pre-clin. and clin. studies have identified a plethora of mechanisms of antifolate-resistance; these are frequently assocd. with qual. and/or quant. alterations in influx and/or efflux transporters of (anti)folates as well as in folate-dependent enzymes.  These include inactivating mutations and/or down-regulation of the RFC and various alterations in the target enzymes DHFR, TS and FPGS.  Furthermore, it has been recently shown that members of the ATP-binding cassette (ABC) superfamily including multidrug resistance proteins (MRP/ABCC) and breast cancer resistance protein (BCRP/ABCG2) are low affinity, high capacity ATP-driven (anti)folate efflux transporters.  This transport activity is in addn. to their established facility to extrude multiple cytotoxic agents.  Hence, by actively extruding antifolates, overexpressed MRPs and/or BCRP confer antifolate resistance.  Moreover, down-regulation of MRPs and/or BCRP results in decreased folate efflux thereby leading to expansion of the intracellular folate pool and antifolate resistance.  This chapter reviews and discusses the panoply of mol. modalities of antifolate-resistance in pre-clin. tumor cell systems in vitro and in vivo as well as in cancer patients.  Currently emerging novel strategies for the overcoming of antifolate-resistance are presented.  Finally, exptl. evidence is provided that the identification and characterization of the mol. mechanisms of antifolate-resistance may prove instrumental in the future development of rationally-based novel antifolates and strategies that could conceivably overcome drug-resistance phenomena.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4aMyulwdVTrVg90H21EOLACvtfcHk0lgetV5oZeOd3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1KqtL8%253D&md5=bb228ef0ef439e83c57d606d17ad216c</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1007%2Fs10555-007-9049-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-007-9049-z%26sid%3Dliteratum%253Aachs%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26atitle%3DMolecular%2520Basis%2520of%2520Antifolate%2520Resistance%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2007%26volume%3D26%26spage%3D153%26epage%3D181%26doi%3D10.1007%2Fs10555-007-9049-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gonen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span> </span><span class="NLM_article-title">Antifolates in Cancer Therapy: Structure, Activity, and Mechanisms of Drug Resistance</span> <span class="citation_source-journal">Drug Resist. Updates</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1016/j.drup.2012.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.drup.2012.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=22921318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWqsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=183-210&author=N.+Gonenauthor=Y.+G.+Assaraf&title=Antifolates+in+Cancer+Therapy%3A+Structure%2C+Activity%2C+and+Mechanisms+of+Drug+Resistance&doi=10.1016%2Fj.drup.2012.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance</span></div><div class="casAuthors">Gonen, Nitzan; Assaraf, Yehuda G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">183-210</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In the past 65 years, antifolates targeting folate metab. played a pivotal role in drug treatment of malignant, microbial, parasitic and chronic inflammatory diseases.  Drug discovery of novel antifolates with improved properties and superior activities remains an attractive strategy both in academia and in the pharmaceutical industry.  Among novel antifolates are pemetrexed which primarily targets thymidylate synthase as well as pralatrexate which blocks dihydrofolate reductase, and displays enhanced transport and cellular retention properties.  The present review describes the evolution and pharmacol. activity of antifolates and prospects for the development of the next generation antifolates.  Pre-clin. and clin. studies identified a plethora of mechanisms of antifolate resistance that are a primary hindrance to curative cancer chemotherapy; these are frequently assocd. with qual. and/or quant. alterations in influx and/or efflux transporters of antifolates and in folate-dependent enzymes.  Current advances including for example the deciphering of the dominant folate transporter proton-coupled folate transporter (PCFT/SLC46A1) facilitated the synthesis of exptl. antifolates aimed at selectively targeting solid tumor cells, which reside in an acidic microenvironment where PCFT supposedly functions optimally.  Moreover, drugs that are structurally and mechanistically distinct from folates were conjugated to folic acid (e.g.  Vintafolide/EC145, a folic acid desacetylvinblastine conjugate) to facilitate endocytosis via the folate receptor (FR) which is markedly overexpressed in various solid tumors.  In an alternative approach, novel antifolates selectively targeting the FR but not other folate transporters are being developed (e.g.  BGC 945). Hence, targeting mechanisms of antifolate-resistance could facilitate the development of rationally-based novel antifolates and strategies that overcome chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVjP1iploMdbVg90H21EOLACvtfcHk0lgetV5oZeOd3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWqsrnO&md5=e9f7f1742c26c72a96a2fdeb2d118f1a</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2012.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2012.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DGonen%26aufirst%3DN.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26atitle%3DAntifolates%2520in%2520Cancer%2520Therapy%253A%2520Structure%252C%2520Activity%252C%2520and%2520Mechanisms%2520of%2520Drug%2520Resistance%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2012%26volume%3D15%26spage%3D183%26epage%3D210%26doi%3D10.1016%2Fj.drup.2012.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurup, S.</span><span> </span><span class="NLM_article-title">Recent Advances in Classical and Non-Classical Antifolates as Antitumor and Antiopportunistic Infection Agents: Part I</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">524</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.2174/187152007781668724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.2174%2F187152007781668724" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=524-542&author=A.+Gangjeeauthor=H.+D.+Jainauthor=S.+Kurup&title=Recent+Advances+in+Classical+and+Non-Classical+Antifolates+as+Antitumor+and+Antiopportunistic+Infection+Agents%3A+Part+I&doi=10.2174%2F187152007781668724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F187152007781668724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152007781668724%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DH.%2BD.%26aulast%3DKurup%26aufirst%3DS.%26atitle%3DRecent%2520Advances%2520in%2520Classical%2520and%2520Non-Classical%2520Antifolates%2520as%2520Antitumor%2520and%2520Antiopportunistic%2520Infection%2520Agents%253A%2520Part%2520I%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D524%26epage%3D542%26doi%3D10.2174%2F187152007781668724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Daignan-Fornier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinson, B.</span><span> </span><span class="NLM_article-title">5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl 5′-Monophosphate (AICAR), a Highly Conserved Purine Intermediate with Multiple Effects</span> <span class="citation_source-journal">Metabolites</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.3390/metabo2020292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.3390%2Fmetabo2020292" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=292-302&author=B.+Daignan-Fornierauthor=B.+Pinson&title=5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl+5%E2%80%B2-Monophosphate+%28AICAR%29%2C+a+Highly+Conserved+Purine+Intermediate+with+Multiple+Effects&doi=10.3390%2Fmetabo2020292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.3390%2Fmetabo2020292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmetabo2020292%26sid%3Dliteratum%253Aachs%26aulast%3DDaignan-Fornier%26aufirst%3DB.%26aulast%3DPinson%26aufirst%3DB.%26atitle%3D5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl%25205%25E2%2580%25B2-Monophosphate%2520%2528AICAR%2529%252C%2520a%2520Highly%2520Conserved%2520Purine%2520Intermediate%2520with%2520Multiple%2520Effects%26jtitle%3DMetabolites%26date%3D2012%26volume%3D2%26spage%3D292%26epage%3D302%26doi%3D10.3390%2Fmetabo2020292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Beckers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Organe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmermans, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderhoydonc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deboel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waelkens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brusselmans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoeven, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinnen, J.</span><span> </span><span class="NLM_article-title">Methotrexate Enhances the Antianabolic and Antiproliferative Effects of 5-Aminoimidazole-4-carboxamide Riboside</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2217</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1158%2F1535-7163.MCT-06-0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=16985054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1yns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=2211-2217&author=A.+Beckersauthor=S.+Organeauthor=L.+Timmermansauthor=F.+Vanderhoydoncauthor=L.+Deboelauthor=R.+Deruaauthor=E.+Waelkensauthor=K.+Brusselmansauthor=G.+Verhoevenauthor=J.+Swinnen&title=Methotrexate+Enhances+the+Antianabolic+and+Antiproliferative+Effects+of+5-Aminoimidazole-4-carboxamide+Riboside&doi=10.1158%2F1535-7163.MCT-06-0001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside</span></div><div class="casAuthors">Beckers, Annelies; Organe, Sophie; Timmermans, Leen; Vanderhoydonc, Frank; Deboel, Ludo; Derua, Rita; Waelkens, Etienne; Brusselmans, Koen; Verhoeven, Guido; Swinnen, Johannes V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2211-2217</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because of its ability to mimic a low energy status of the cell, the cell-permeable nucleoside 5-aminoimidazole-4-carboxamide (AICA) riboside was proposed as an antineoplastic agent switching off major energy-consuming processes assocd. with the malignant phenotype (lipid prodn., DNA synthesis, cell proliferation, cell migration, etc.).  Key to the antineoplastic action of AICA riboside is its conversion to ZMP, an AMP mimetic that at high concns. activates the AMP-activated protein kinase (AMPK).  Here, in an attempt to increase the efficacy of AICA riboside, we pretreated cancer cells with methotrexate, an antimetabolite blocking the metab. of ZMP.  Methotrexate enhanced the AICA riboside-induced accumulation of ZMP and led to a decrease in the levels of ATP, which functions as an intrasteric inhibitor of AMPK.  Consequently, methotrexate markedly sensitized AMPK for activation by AICA riboside and potentiated the inhibitory effects of AICA riboside on tumor-assocd. processes.  As cotreatment elicited antiproliferative effects already at concns. of compds. that were only marginally effective when used alone, our findings on the cooperation between methotrexate and AICA riboside provide new opportunities both for the application of classic antimetabolic chemotherapeutics, such as methotrexate, and for the exploitation of the energy-sensing machinery as a target for cancer intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Axd8n_NZmLVg90H21EOLACvtfcHk0liKtqsuVGG1kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1yns7g%253D&md5=88ceaf92888cf2cd32926a70bb412b58</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0001%26sid%3Dliteratum%253Aachs%26aulast%3DBeckers%26aufirst%3DA.%26aulast%3DOrgane%26aufirst%3DS.%26aulast%3DTimmermans%26aufirst%3DL.%26aulast%3DVanderhoydonc%26aufirst%3DF.%26aulast%3DDeboel%26aufirst%3DL.%26aulast%3DDerua%26aufirst%3DR.%26aulast%3DWaelkens%26aufirst%3DE.%26aulast%3DBrusselmans%26aufirst%3DK.%26aulast%3DVerhoeven%26aufirst%3DG.%26aulast%3DSwinnen%26aufirst%3DJ.%26atitle%3DMethotrexate%2520Enhances%2520the%2520Antianabolic%2520and%2520Antiproliferative%2520Effects%2520of%25205-Aminoimidazole-4-carboxamide%2520Riboside%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D2211%26epage%3D2217%26doi%3D10.1158%2F1535-7163.MCT-06-0001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cronstein, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naime, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostad</span><span> </span><span class="NLM_article-title">The Antiinflammatory Mechanism of Methotrexate. Increased Adenosine Release at Inflammed Sites Diminishes Leukocyte Accumulation in an In Vivo Model of Inflammation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">2675</span><span class="NLM_x">–</span> <span class="NLM_lpage">2682</span><span class="refDoi"> DOI: 10.1172/JCI116884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1172%2FJCI116884" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1993&pages=2675-2682&author=B.+N.+Cronsteinauthor=D.+Naimeauthor=+Ostad&title=The+Antiinflammatory+Mechanism+of+Methotrexate.+Increased+Adenosine+Release+at+Inflammed+Sites+Diminishes+Leukocyte+Accumulation+in+an+In+Vivo+Model+of+Inflammation&doi=10.1172%2FJCI116884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1172%2FJCI116884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI116884%26sid%3Dliteratum%253Aachs%26aulast%3DCronstein%26aufirst%3DB.%2BN.%26aulast%3DNaime%26aufirst%3DD.%26aulast%3DOstad%26atitle%3DThe%2520Antiinflammatory%2520Mechanism%2520of%2520Methotrexate.%2520Increased%2520Adenosine%2520Release%2520at%2520Inflammed%2520Sites%2520Diminishes%2520Leukocyte%2520Accumulation%2520in%2520an%2520In%2520Vivo%2520Model%2520of%2520Inflammation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1993%26volume%3D92%26spage%3D2675%26epage%3D2682%26doi%3D10.1172%2FJCI116884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cronstein, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberle, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, R. I.</span><span> </span><span class="NLM_article-title">Methotrexate Inhibits Neutrophil Function by Stimulating Adenosine Release From Connective Tissue Cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">2441</span><span class="NLM_x">–</span> <span class="NLM_lpage">2445</span><span class="refDoi"> DOI: 10.1073/pnas.88.6.2441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1073%2Fpnas.88.6.2441" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=2441-2445&author=B.+N.+Cronsteinauthor=M.+A.+Eberleauthor=H.+E.+Gruberauthor=R.+I.+Levin&title=Methotrexate+Inhibits+Neutrophil+Function+by+Stimulating+Adenosine+Release+From+Connective+Tissue+Cells&doi=10.1073%2Fpnas.88.6.2441"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.6.2441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.6.2441%26sid%3Dliteratum%253Aachs%26aulast%3DCronstein%26aufirst%3DB.%2BN.%26aulast%3DEberle%26aufirst%3DM.%2BA.%26aulast%3DGruber%26aufirst%3DH.%2BE.%26aulast%3DLevin%26aufirst%3DR.%2BI.%26atitle%3DMethotrexate%2520Inhibits%2520Neutrophil%2520Function%2520by%2520Stimulating%2520Adenosine%2520Release%2520From%2520Connective%2520Tissue%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D2441%26epage%3D2445%26doi%3D10.1073%2Fpnas.88.6.2441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Paintlia, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paintlia, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span> </span><span class="NLM_article-title">Immunomodulatory Effect of Combination Therapy with Lovastatin and 5-Aminoimidazaole-4-Carboxamide-1-β-D-Ribofuranoside Alleviates Neurodegeneration in Experimental Autoimmune Encephalomyelitis</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">1012</span><span class="NLM_x">–</span> <span class="NLM_lpage">1025</span><span class="refDoi"> DOI: 10.2353/ajpath.2006.051309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.2353%2Fajpath.2006.051309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=16936274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFWqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2006&pages=1012-1025&author=A.+S.+Paintliaauthor=M.+K.+Paintliaauthor=I.+Singhauthor=A.+K.+Singh&title=Immunomodulatory+Effect+of+Combination+Therapy+with+Lovastatin+and+5-Aminoimidazaole-4-Carboxamide-1-%CE%B2-D-Ribofuranoside+Alleviates+Neurodegeneration+in+Experimental+Autoimmune+Encephalomyelitis&doi=10.2353%2Fajpath.2006.051309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17eR"><div class="casContent"><span class="casTitleNuber">17e</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Paintlia, Ajaib S.; Paintlia, Manjeet K.; Singh, Inderjit; Singh, Avtar K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1012-1025</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Combination therapy with multiple sclerosis (MS) therapeutics is gaining momentum over monotherapy for improving MS.  Lovastatin, an HMG-CoA reductase inhibitor (statin), was immunomodulatory in an exptl. autoimmune encephalomyelitis (EAE) model of MS.  Lovastatin biases the immune response from Th1 to a protective Th2 response in EAE by a different mechanism than 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, an immunomodulating agent that activates AMP-activated protein kinase.  Here we tested these agents in combination in an EAE model of MS.  Suboptimal doses of these drugs in combination were additive in efficacy against the induction of EAE; clin. symptoms were delayed and severity and duration of disease was reduced.  In the central nervous system, the cellular infiltration and proinflammatory immune response was decreased while the anti-inflammatory immune response was increased.  Combination treatment biased the class of elicited myelin basic protein antibodies from IgG2a to IgG1 and IgG2b, suggesting a shift from Th1 to Th2 response.  In addn., combination therapy lessened inflammation-assocd. neurodegeneration in the central nervous system of EAE animals.  These effects were absent in EAE animals treated with either drug alone at the same dose.  Thus, our data suggest that agents with different mechanisms of action such as lovastatin and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, when used in combination, could improve therapy for central nervous system demyelinating diseases and provide a rationale for testing them in MS patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5uf8Sn0g7WLVg90H21EOLACvtfcHk0lg1NkkvUckAGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFWqs7w%253D&md5=624513e56a5ce4c61b59bf4ed79fcc72</span></div><a href="/servlet/linkout?suffix=cit17e&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2006.051309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2006.051309%26sid%3Dliteratum%253Aachs%26aulast%3DPaintlia%26aufirst%3DA.%2BS.%26aulast%3DPaintlia%26aufirst%3DM.%2BK.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26atitle%3DImmunomodulatory%2520Effect%2520of%2520Combination%2520Therapy%2520with%2520Lovastatin%2520and%25205-Aminoimidazaole-4-Carboxamide-1-%25CE%25B2-D-Ribofuranoside%2520Alleviates%2520Neurodegeneration%2520in%2520Experimental%2520Autoimmune%2520Encephalomyelitis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2006%26volume%3D169%26spage%3D1012%26epage%3D1025%26doi%3D10.2353%2Fajpath.2006.051309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Prasad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span> </span><span class="NLM_article-title">5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside Attenuates Experimental Autoimmune Encephalomyelitis Via Modulation of Endothelial-Monocyte Interaction</span> <span class="citation_source-journal">J. Neurosci. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1002/jnr.20953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1002%2Fjnr.20953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=16770773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD28Xotlymsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2006&pages=614-625&author=R.+Prasadauthor=S.+Giriauthor=N.+Nathauthor=I.+Singhauthor=A.+K.+Singh&title=5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside+Attenuates+Experimental+Autoimmune+Encephalomyelitis+Via+Modulation+of+Endothelial-Monocyte+Interaction&doi=10.1002%2Fjnr.20953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17fR"><div class="casContent"><span class="casTitleNuber">17f</span><div class="casTitle"><span class="NLM_cas:atitle">5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction</span></div><div class="casAuthors">Prasad, Ratna; Giri, Shailendra; Nath, Narender; Singh, Inderjit; Singh, Avtar K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">614-625</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Exptl. autoimmune encephalomyelitis (EAE) is a model for studying multiple sclerosis (MS), a chronic demyelinating disorder of the CNS.  5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR), an activator of AMP-activated protein kinase (AMPK), has been reported to show antiinflammatory and immunomodulatory effects in various models of inflammation.  Recently, we have reported AICAR-mediated attenuation of active and passive EAE in mouse model.  Here we used a rat model of acute EAE to show antiinflammatory effects of AICAR after daily treatment starting at onset of the disease.  By maintaining the blood-brain barrier (BBB), AICAR-administered animals showed lower clin. scores compared with untreated EAE animals.  AICAR inhibited the infiltration of inflammatory cells across the BBB, resulting in lowered expression of proinflammatory mediators in the CNS and protection from severe demyelination.  By using in vitro model of endothelial-leukocyte interaction, we showed that AICAR inhibited adhesion of monocytes to tumor necrosis factor-α-activated endothelial cells.  One of the mechanisms of this action is through down-regulation of expression of endothelial cell adhesion mols. via modulation of nuclear factor κB activation.  The data suggest that AICAR attenuates EAE progression by limiting infiltration of leukocytes across the BBB, thereby controlling the consequent inflammatory reaction in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO0pXpBYsR1LVg90H21EOLACvtfcHk0lg1NkkvUckAGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xotlymsro%253D&md5=29768d534ccac2ce1552ce22248c22f8</span></div><a href="/servlet/linkout?suffix=cit17f&amp;dbid=16384&amp;doi=10.1002%2Fjnr.20953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.20953%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad%26aufirst%3DR.%26aulast%3DGiri%26aufirst%3DS.%26aulast%3DNath%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26atitle%3D5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside%2520Attenuates%2520Experimental%2520Autoimmune%2520Encephalomyelitis%2520Via%2520Modulation%2520of%2520Endothelial-Monocyte%2520Interaction%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2006%26volume%3D84%26spage%3D614%26epage%3D625%26doi%3D10.1002%2Fjnr.20953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Giri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viollet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span> </span><span class="NLM_article-title">5-Aminoimidazaole-4-Carboxamide-1-β-4-Ribofuranoside Inhibits Proinflammatory Response in Glial Cells: A Possible Role of AMP-Activated Protein Kinase</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.4288-03.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1523%2FJNEUROSCI.4288-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=14724246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvVyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=479-487&author=S.+Giriauthor=N.+Nathauthor=B.+Smithauthor=B.+Violletauthor=A.+K.+Singhauthor=I.+Singh&title=5-Aminoimidazaole-4-Carboxamide-1-%CE%B2-4-Ribofuranoside+Inhibits+Proinflammatory+Response+in+Glial+Cells%3A+A+Possible+Role+of+AMP-Activated+Protein+Kinase&doi=10.1523%2FJNEUROSCI.4288-03.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17gR"><div class="casContent"><span class="casTitleNuber">17g</span><div class="casTitle"><span class="NLM_cas:atitle">5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside inhibits proinflammatory response in glial cells: A possible role of AMP-activated protein kinase</span></div><div class="casAuthors">Giri, Shailendra; Nath, Narendra; Smith, Brian; Viollet, Benoit; Singh, Avtar K.; Singh, Inderjit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">AMP-activated protein kinase (AMPK) is tightly regulated by the cellular AMP:ATP ratio and plays a central role in the regulation of energy homeostasis and metabolic stress.  A pharmacol. activator of AMPK, 5-amino-4-imidazole carboxamide riboside (AICAR) inhibited lipopolysaccharide (LPS)-induced expression of proinflammatory cytokines (tumor necrosis factor α, interleukin-1β, and interleukin-6) and inducible nitric oxide synthase in primary rat astrocytes, microglia, and peritoneal macrophages.  AICAR attenuates the LPS-induced activation of nuclear factor κB via downregulation of IκB kinase α/β activity.  It also inhibits nuclear translocation of CCAAT/enhancer-binding protein (C/EBP) transcription factor by inhibiting the expression of C/EBP-δ in brain glial cells.  The dominant neg. form of AMPKα2 (D157A) and its antisense documents a possible role of AMPK in the regulation of the cellular proinflammatory process.  AICAR also inhibited the prodn. of inflammatory mediators in serum and their expression in CNS of rats injected with a sublethal dose of LPS by i.p. injection.  These observations in cultured cells as well as in the animal model suggest that AICAR may be of therapeutic value in treating inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqagrtIqYmE87Vg90H21EOLACvtfcHk0lg1NkkvUckAGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvVyjsA%253D%253D&md5=c259a37787afb327b97c1afa7c220356</span></div><a href="/servlet/linkout?suffix=cit17g&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4288-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4288-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DGiri%26aufirst%3DS.%26aulast%3DNath%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DViollet%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DSingh%26aufirst%3DI.%26atitle%3D5-Aminoimidazaole-4-Carboxamide-1-%25CE%25B2-4-Ribofuranoside%2520Inhibits%2520Proinflammatory%2520Response%2520in%2520Glial%2520Cells%253A%2520A%2520Possible%2520Role%2520of%2520AMP-Activated%2520Protein%2520Kinase%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D479%26epage%3D487%26doi%3D10.1523%2FJNEUROSCI.4288-03.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Nath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangalam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makkar, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Meester, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viollet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S.</span><span> </span><span class="NLM_article-title">Loss of AMPK Exacerbates Experimental Autoimmune Encephalomyelitis Disease Severity</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2009.05.106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.bbrc.2009.05.106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2009&pages=16-20&author=N.+Nathauthor=M.+Khanauthor=R.+Rattanauthor=A.+Mangalamauthor=R.+S.+Makkarauthor=C.+de+Meesterauthor=L.+Bertrandauthor=I.+Singhauthor=Y.+Chenauthor=B.+Violletauthor=S.+Giri&title=Loss+of+AMPK+Exacerbates+Experimental+Autoimmune+Encephalomyelitis+Disease+Severity&doi=10.1016%2Fj.bbrc.2009.05.106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17h&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2009.05.106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2009.05.106%26sid%3Dliteratum%253Aachs%26aulast%3DNath%26aufirst%3DN.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DRattan%26aufirst%3DR.%26aulast%3DMangalam%26aufirst%3DA.%26aulast%3DMakkar%26aufirst%3DR.%2BS.%26aulast%3Dde%2BMeester%26aufirst%3DC.%26aulast%3DBertrand%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DViollet%26aufirst%3DB.%26aulast%3DGiri%26aufirst%3DS.%26atitle%3DLoss%2520of%2520AMPK%2520Exacerbates%2520Experimental%2520Autoimmune%2520Encephalomyelitis%2520Disease%2520Severity%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2009%26volume%3D386%26spage%3D16%26epage%3D20%26doi%3D10.1016%2Fj.bbrc.2009.05.106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Suzuki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeonova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morizane, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobrin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vavvas, D. G.</span><span> </span><span class="NLM_article-title">Aminoimidazole Carboxamide Ribonucleotide Ameliorates Experimental Autoimmune Uveitis</span> <span class="citation_source-journal">Invest. Ophthalmol. Visual Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4158</span><span class="NLM_x">–</span> <span class="NLM_lpage">4169</span><span class="refDoi"> DOI: 10.1167/iovs.11-9323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1167%2Fiovs.11-9323" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=4158-4169&author=J.+Suzukiauthor=T.+Yoshimuraauthor=M.+Simeonovaauthor=K.+Takeuchiauthor=K.+Murakamiauthor=Y.+Morizaneauthor=J.+W.+Millerauthor=L.+Sobrinauthor=D.+G.+Vavvas&title=Aminoimidazole+Carboxamide+Ribonucleotide+Ameliorates+Experimental+Autoimmune+Uveitis&doi=10.1167%2Fiovs.11-9323"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17i&amp;dbid=16384&amp;doi=10.1167%2Fiovs.11-9323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.11-9323%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DJ.%26aulast%3DYoshimura%26aufirst%3DT.%26aulast%3DSimeonova%26aufirst%3DM.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DK.%26aulast%3DMorizane%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DJ.%2BW.%26aulast%3DSobrin%26aufirst%3DL.%26aulast%3DVavvas%26aufirst%3DD.%2BG.%26atitle%3DAminoimidazole%2520Carboxamide%2520Ribonucleotide%2520Ameliorates%2520Experimental%2520Autoimmune%2520Uveitis%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2012%26volume%3D53%26spage%3D4158%26epage%3D4169%26doi%3D10.1167%2Fiovs.11-9323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Boon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosselaar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Praet, S. F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaak, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saris, W. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagenmakers, A. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tack, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargreaves, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Loon, L. J. C.</span><span> </span><span class="NLM_article-title">Intravenous AICAR Administration Reduces Hepatic Glucose Output and Inhibits Whole Body Lipolysis in Type 2 Diabetic Patients</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1893</span><span class="NLM_x">–</span> <span class="NLM_lpage">1900</span><span class="refDoi"> DOI: 10.1007/s00125-008-1108-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1007%2Fs00125-008-1108-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1893-1900&author=H.+Boonauthor=M.+Bosselaarauthor=S.+F.+E.+Praetauthor=E.+E.+Blaakauthor=W.+H.+M.+Sarisauthor=A.+J.+M.+Wagenmakersauthor=S.+L.+McGeeauthor=C.+J.+Tackauthor=P.+Smitsauthor=M.+Hargreavesauthor=L.+J.+C.+van+Loon&title=Intravenous+AICAR+Administration+Reduces+Hepatic+Glucose+Output+and+Inhibits+Whole+Body+Lipolysis+in+Type+2+Diabetic+Patients&doi=10.1007%2Fs00125-008-1108-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17j&amp;dbid=16384&amp;doi=10.1007%2Fs00125-008-1108-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-008-1108-7%26sid%3Dliteratum%253Aachs%26aulast%3DBoon%26aufirst%3DH.%26aulast%3DBosselaar%26aufirst%3DM.%26aulast%3DPraet%26aufirst%3DS.%2BF.%2BE.%26aulast%3DBlaak%26aufirst%3DE.%2BE.%26aulast%3DSaris%26aufirst%3DW.%2BH.%2BM.%26aulast%3DWagenmakers%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DMcGee%26aufirst%3DS.%2BL.%26aulast%3DTack%26aufirst%3DC.%2BJ.%26aulast%3DSmits%26aufirst%3DP.%26aulast%3DHargreaves%26aufirst%3DM.%26aulast%3Dvan%2BLoon%26aufirst%3DL.%2BJ.%2BC.%26atitle%3DIntravenous%2520AICAR%2520Administration%2520Reduces%2520Hepatic%2520Glucose%2520Output%2520and%2520Inhibits%2520Whole%2520Body%2520Lipolysis%2520in%2520Type%25202%2520Diabetic%2520Patients%26jtitle%3DDiabetologia%26date%3D2008%26volume%3D51%26spage%3D1893%26epage%3D1900%26doi%3D10.1007%2Fs00125-008-1108-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ducker, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinowitz, J. D.</span><span> </span><span class="NLM_article-title">ZMP: A Master Regulator of One-Carbon Metabolism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.1016/j.molcel.2015.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.molcel.2015.01.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2015&pages=203-204&author=G.+S.+Duckerauthor=J.+D.+Rabinowitz&title=ZMP%3A+A+Master+Regulator+of+One-Carbon+Metabolism&doi=10.1016%2Fj.molcel.2015.01.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DDucker%26aufirst%3DG.%2BS.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26atitle%3DZMP%253A%2520A%2520Master%2520Regulator%2520of%2520One-Carbon%2520Metabolism%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D57%26spage%3D203%26epage%3D204%26doi%3D10.1016%2Fj.molcel.2015.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breaker, R. R.</span><span> </span><span class="NLM_article-title">An Ancient Riboswitch Class in Bacteria Regulates Purine Biosynthesis and One-Carbon Metabolism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.1016/j.molcel.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.molcel.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=25616067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2015&pages=317-328&author=P.+B.+Kimauthor=J.+W.+Nelsonauthor=R.+R.+Breaker&title=An+Ancient+Riboswitch+Class+in+Bacteria+Regulates+Purine+Biosynthesis+and+One-Carbon+Metabolism&doi=10.1016%2Fj.molcel.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">An ancient riboswitch class in bacteria regulates purine biosynthesis and one-carbon metabolism</span></div><div class="casAuthors">Kim, Peter B.; Nelson, James W.; Breaker, Ronald R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Over 30 years ago, ZTP (5-aminoimidazole-4-carboxamide riboside 5'-triphosphate), a modified purine biosynthetic intermediate, was proposed to signal 10-formyl-tetrahydrofolate (10f-THF) deficiency in bacteria.  However, the mechanisms by which this putative alarmone or its precursor ZMP (5-aminoimidazole-4-carboxamide ribonucleotide, also known as AICAR) brings about any metabolic changes remain unexplained.  Here, the authors report the existence of a widespread riboswitch class that is most commonly assocd. with genes related to de novo purine biosynthesis and one-carbon metab.  Biochem. data confirm that members of this riboswitch class selectively bind ZMP and ZTP with nanomolar affinity while strongly rejecting numerous natural analogs.  Indeed, increases in the ZMP/ZTP pool, caused by folate stress in bacterial cells, trigger changes in the expression of a reporter gene fused to representative ZTP riboswitches in vivo.  The wide distribution of this riboswitch class suggests that ZMP/ZTP signaling is important for species in numerous bacterial lineages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdpQHIlDzVcbVg90H21EOLACvtfcHk0lhohaz3VMoQYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaltb8%253D&md5=179de504539f88b10e860fbc28aa8928</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DP.%2BB.%26aulast%3DNelson%26aufirst%3DJ.%2BW.%26aulast%3DBreaker%26aufirst%3DR.%2BR.%26atitle%3DAn%2520Ancient%2520Riboswitch%2520Class%2520in%2520Bacteria%2520Regulates%2520Purine%2520Biosynthesis%2520and%2520One-Carbon%2520Metabolism%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D57%26spage%3D317%26epage%3D328%26doi%3D10.1016%2Fj.molcel.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cronstein, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamen, B. A.</span><span> </span><span class="NLM_article-title">5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside (AICA-riboside) as a Targeting Agent for Therapy of Patients with Acute Lymphoblastic Leukemia: Are we There and are There Pitfalls?</span> <span class="citation_source-journal">J. Pediatr. Hematol./Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span><span class="refDoi"> DOI: 10.1097/MPH.0b013e31815bbb83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1097%2FMPH.0b013e31815bbb83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=18090925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVCitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=805-807&author=B.+N.+Cronsteinauthor=B.+A.+Kamen&title=5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside+%28AICA-riboside%29+as+a+Targeting+Agent+for+Therapy+of+Patients+with+Acute+Lymphoblastic+Leukemia%3A+Are+we+There+and+are+There+Pitfalls%3F&doi=10.1097%2FMPH.0b013e31815bbb83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICA-riboside) as a targeting agent for therapy of patients with acute lymphoblastic leukemia: are we there and are there pitfalls?</span></div><div class="casAuthors">Cronstein, Bruce N.; Kamen, Barton A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pediatric Hematology/Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">805-807</span>CODEN:
                <span class="NLM_cas:coden">JPHOFG</span>;
        ISSN:<span class="NLM_cas:issn">1077-4114</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The research of Sengupta and colleagues et al. (2007) entitled, "Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy" is reviewed with commentary and refs.  The authors revealed that AICA-riboside effects were assocd. with its metab. to acadesine monophosphate (ZMP) with the presence of iodotubericidin which blocks the cytotoxicity.  Their work also provides the expanding the importance of basic cell biol.-biochem. as relating to the pharmacol. of cytotoxic therapy, whether it is for a patient with cancer or an autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXecfLSi_j-rVg90H21EOLACvtfcHk0lhXoGVghZiN5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVCitw%253D%253D&md5=ff265537e42999e00c168d5ed91eb8d5</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1097%2FMPH.0b013e31815bbb83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMPH.0b013e31815bbb83%26sid%3Dliteratum%253Aachs%26aulast%3DCronstein%26aufirst%3DB.%2BN.%26aulast%3DKamen%26aufirst%3DB.%2BA.%26atitle%3D5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside%2520%2528AICA-riboside%2529%2520as%2520a%2520Targeting%2520Agent%2520for%2520Therapy%2520of%2520Patients%2520with%2520Acute%2520Lymphoblastic%2520Leukemia%253A%2520Are%2520we%2520There%2520and%2520are%2520There%2520Pitfalls%253F%26jtitle%3DJ.%2520Pediatr.%2520Hematol.%252FOncol.%26date%3D2007%26volume%3D29%26spage%3D805%26epage%3D807%26doi%3D10.1097%2FMPH.0b013e31815bbb83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sengupta, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leclerc, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh-Kinser, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leclerc, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barredo, J. C.</span><span> </span><span class="NLM_article-title">Cytotoxic Effect of 5-Aminoimidazaole-4-Carboxamide-1-β-4-Ribofuranoside (AICAR) on Childhood Acute Lymphoblastic Leukemia (ALL) Cells: Implication for Targeted Therapy</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1186/1476-4598-6-46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1186%2F1476-4598-6-46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=17623090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A280%3ADC%252BD2svnvFSluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=46-57&author=T.+K.+Senguptaauthor=G.+M.+Leclercauthor=T.+T.+Hsieh-Kinserauthor=G.+J.+Leclercauthor=I.+Singhauthor=J.+C.+Barredo&title=Cytotoxic+Effect+of+5-Aminoimidazaole-4-Carboxamide-1-%CE%B2-4-Ribofuranoside+%28AICAR%29+on+Childhood+Acute+Lymphoblastic+Leukemia+%28ALL%29+Cells%3A+Implication+for+Targeted+Therapy&doi=10.1186%2F1476-4598-6-46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy</span></div><div class="casAuthors">Sengupta Tapas K; Leclerc Gilles M; Hsieh-Kinser Ting Ting; Leclerc Guy J; Singh Inderjit; Barredo Julio C</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy affecting children.  Despite significant progress and success in the treatment of ALL, a significant number of children continue to relapse and for them, outcome remains poor.  Therefore, the search for novel therapeutic approaches is warranted.  The aim of this study was to investigate the AMP activated protein kinase (AMPK) as a potential target in childhood acute lymphoblastic leukemia (ALL) subtypes characterized by non-random translocation signature profiles.  We evaluated the effects of the AMPK activator AICAR on cell growth, cell cycle regulators and apoptosis of various childhood ALL cells.  RESULTS:  We found that treatment with AICAR inhibited cell proliferation, induced cell cycle arrest in G1-phase, and apoptosis in CCRF-CEM (T-ALL), NALM6 (Bp-ALL), REH (Bp-ALL, TEL/AML1) and SupB15 (Bp-ALL, BCR/ABL) cells.  These effects were abolished by treatment with the adenosine kinase inhibitor 5'-iodotubericidin prior to addition of AICAR indicating that AICAR's cytotoxicity is mediated through AMPK activation.  Moreover, we determined that growth inhibition exerted by AICAR was associated with activation of p38-MAPK and increased expression of the cell cycle regulators p27 and p53.  We also demonstrated that AICAR mediated apoptosis through the mitochondrial pathway as revealed by the release of cytochrome C and cleavage of caspase 9.  Additionally, AICAR treatment resulted in phosphorylation of Akt suggesting that activation of the PI3K/Akt pathway may represent a compensatory survival mechanism in response to apoptosis and/or cell cycle arrest.  Combined treatment with AICAR and the mTOR inhibitor rapamycin resulted in additive anti-proliferative activity ALL cells.  CONCLUSION:  AICAR-mediated AMPK activation was found to be a proficient cytotoxic agent in ALL cells and the mechanism of its anti-proliferative and apoptotic effect appear to be mediated via activation of p38-MAPK pathway, increased expression of cell cycle inhibitory proteins p27 and p53, and downstream effects on the mTOR pathway, hence exhibiting therapeutic potential as a molecular target for the treatment of childhood ALL.  Therefore, activation of AMPK by AICAR represents a novel approach to targeted therapy, and suggests a role for AICAR in combination therapy with inhibitors of the PI3K/Akt/mTOR pathways for the treatment of childhood in ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeVb-EeO_GZ3WEEzDrymxmfW6udTcc2eb213vnysQkvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svnvFSluw%253D%253D&md5=5dfd9429d790df4f0c3a5ce6285d2273</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-6-46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-6-46%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DT.%2BK.%26aulast%3DLeclerc%26aufirst%3DG.%2BM.%26aulast%3DHsieh-Kinser%26aufirst%3DT.%2BT.%26aulast%3DLeclerc%26aufirst%3DG.%2BJ.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DBarredo%26aufirst%3DJ.%2BC.%26atitle%3DCytotoxic%2520Effect%2520of%25205-Aminoimidazaole-4-Carboxamide-1-%25CE%25B2-4-Ribofuranoside%2520%2528AICAR%2529%2520on%2520Childhood%2520Acute%2520Lymphoblastic%2520Leukemia%2520%2528ALL%2529%2520Cells%253A%2520Implication%2520for%2520Targeted%2520Therapy%26jtitle%3DMol.%2520Cancer%26date%3D2007%26volume%3D6%26spage%3D46%26epage%3D57%26doi%3D10.1186%2F1476-4598-6-46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Cheong, C.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolan, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greasley, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beardsley, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. A.</span><span> </span><span class="NLM_article-title">Crystal Structures of Human Bifunctional Enzyme Aminoimidazole-4-carboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase in Complex with Potent Sulfonyl-containing Antifolates</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">18034</span><span class="NLM_x">–</span> <span class="NLM_lpage">18045</span><span class="refDoi"> DOI: 10.1074/jbc.M313691200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1074%2Fjbc.M313691200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=14966129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Gms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=18034-18045&author=C.-G.+Cheongauthor=D.+W.+Wolanauthor=S.+E.+Greasleyauthor=P.+A.+Hortonauthor=G.+P.+Beardsleyauthor=I.+A.+Wilson&title=Crystal+Structures+of+Human+Bifunctional+Enzyme+Aminoimidazole-4-carboxamide+Ribonucleotide+Transformylase%2FIMP+Cyclohydrolase+in+Complex+with+Potent+Sulfonyl-containing+Antifolates&doi=10.1074%2Fjbc.M313691200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Human Bifunctional Enzyme Aminoimidazole-4-carboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase in Complex with Potent Sulfonyl-containing Antifolates</span></div><div class="casAuthors">Cheong, Cheom-Gil; Wolan, Dennis W.; Greasley, Samantha E.; Horton, Patricia A.; Beardsley, G. Peter; Wilson, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">18034-18045</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase/IMP cyclohydrolase (ATIC) is a bifunctional enzyme with folate-dependent AICAR transformylase and IMP cyclohydrolase activities that catalyzes the last two steps of purine biosynthesis.  The AICAR transformylase inhibitors BW1540 and BW2315 are sulfamido-bridged 5,8-dideazafolate analogs with remarkably potent Ki values of 8 and 6 nM, resp., compared with most other antifolates.  Crystal structures of ATIC at 2.55 and 2.60 Å with each inhibitor, in the presence of substrate AICAR, revealed that the sulfonyl groups dominate inhibitor binding and orientation through interaction with the proposed oxyanion hole.  These agents then appear to mimic the anionic transition state and now implicate Asn431 in the reaction mechanism along with previously identified key catalytic residues Lys266 and His267.  Potent and selective inhibition of the AICAR transformylase active site, compared with other folate-dependent enzymes, should therefore be pursued by further design of sulfonyl-contg. antifolates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp3qimqqvhSrVg90H21EOLACvtfcHk0lhXoGVghZiN5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Gms7Y%253D&md5=4d61d94453eee4e6f22c42f3799436b2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M313691200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M313691200%26sid%3Dliteratum%253Aachs%26aulast%3DCheong%26aufirst%3DC.-G.%26aulast%3DWolan%26aufirst%3DD.%2BW.%26aulast%3DGreasley%26aufirst%3DS.%2BE.%26aulast%3DHorton%26aufirst%3DP.%2BA.%26aulast%3DBeardsley%26aufirst%3DG.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26atitle%3DCrystal%2520Structures%2520of%2520Human%2520Bifunctional%2520Enzyme%2520Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Transformylase%252FIMP%2520Cyclohydrolase%2520in%2520Complex%2520with%2520Potent%2520Sulfonyl-containing%2520Antifolates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D18034%26epage%3D18045%26doi%3D10.1074%2Fjbc.M313691200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Leamon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomfield, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emsweller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westrick, E.</span><span> </span><span class="NLM_article-title">Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span><span class="refDoi"> DOI: 10.1124/jpet.108.143206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1124%2Fjpet.108.143206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=18791065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=918-925&author=C.+P.+Leamonauthor=J.+A.+Reddyauthor=R.+Dortonauthor=A.+Bloomfieldauthor=K.+Emswellerauthor=N.+Parkerauthor=E.+Westrick&title=Impact+of+High+and+Low+Folate+Diets+on+Tissue+Folate+Receptor+Levels+and+Antitumor+Responses+Toward+Folate-Drug+Conjugates&doi=10.1124%2Fjpet.108.143206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates</span></div><div class="casAuthors">Leamon, Christopher P.; Reddy, Joseph A.; Dorton, Ryan; Bloomfield, Alicia; Emsweller, Kristen; Parker, Nikki; Westrick, Elaine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The effects of feeding diets high and low in folic acid (folate) on assocd. changes in blood serum and red blood cell (RBC) folate levels, tissue-derived folate receptor levels, and the ability of folate-drug conjugates (EC-145, EC-0225, EC-0305) to bind and exert activity against folate receptor (FR)-pos. KB tumor xenografts were studied in lab. mice.  Serum and RBC folate concns. sharply decreased immediately after the mice were switched to low folate diets, but both parameters reached steady-state ("human-like") levels after 6 wk.  The tissue-related folate binding capacities were also decreased during the dietary modulation period, whereas the net uptake of radiolabeled folate conjugate was simultaneously increased 2.6- and 5-fold in FR-pos. kidney and tumor tissues, resp.  The performances of several clin. and preclinically relevant folate-drug conjugates were evaluated against tumors in mice that were fed high or low folate diets.  Except when administered at doses 6-fold less than required to sat. endogenous FR, no significant loss of antitumor activity was obsd.  Thus, lowering the dietary intake of folates in mice had little impact on the biol. activity of repetitively dosed folate-targeted agents, but low folate diet regimens decreased blood serum and RBC folate levels down to levels that more closely approx. the normal human folate ranges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaevhtqP7xLbVg90H21EOLACvtfcHk0lixjzbnlDhivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtLnN&md5=231e3a4c1d4f940bd6521fcc91bf0d67</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.143206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.143206%26sid%3Dliteratum%253Aachs%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26aulast%3DReddy%26aufirst%3DJ.%2BA.%26aulast%3DDorton%26aufirst%3DR.%26aulast%3DBloomfield%26aufirst%3DA.%26aulast%3DEmsweller%26aufirst%3DK.%26aulast%3DParker%26aufirst%3DN.%26aulast%3DWestrick%26aufirst%3DE.%26atitle%3DImpact%2520of%2520High%2520and%2520Low%2520Folate%2520Diets%2520on%2520Tissue%2520Folate%2520Receptor%2520Levels%2520and%2520Antitumor%2520Responses%2520Toward%2520Folate-Drug%2520Conjugates%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D918%26epage%3D925%26doi%3D10.1124%2Fjpet.108.143206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Venn, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riddell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisholm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aitken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossaak, J. I.</span><span> </span><span class="NLM_article-title">Assessment of Three Levels of Folic Acid on Serum Folate and Plasma Homocysteine: a Randomised Placebo-Controlled Double-Blind Dietary InterventionTrial</span> <span class="citation_source-journal">Eur. J. Clin. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">748</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span><span class="refDoi"> DOI: 10.1038/sj.ejcn.1601388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1038%2Fsj.ejcn.1601388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=12122551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD38Xltlamur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2002&pages=748-754&author=B.+J.+Vennauthor=J.+I.+Mannauthor=S.+M.+Williamsauthor=L.+J.+Riddellauthor=A.+Chisholmauthor=M.+J.+Harperauthor=W.+Aitkenauthor=J.+I.+Rossaak&title=Assessment+of+Three+Levels+of+Folic+Acid+on+Serum+Folate+and+Plasma+Homocysteine%3A+a+Randomised+Placebo-Controlled+Double-Blind+Dietary+InterventionTrial&doi=10.1038%2Fsj.ejcn.1601388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomised placebo-controlled double-blind dietary intervention trial</span></div><div class="casAuthors">Venn, B. J.; Mann, J. I.; Williams, S. M.; Riddell, L. J.; Chisholm, A.; Harper, M. J.; Aitken, W.; Rossaak, J. I.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Nutrition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">EJCNEQ</span>;
        ISSN:<span class="NLM_cas:issn">0954-3007</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">OBJECTIVE: To det. the min. ED of folic acid required to appreciably increase serum folate and to produce a significant redn. in plasma total homocysteine (tHcy).  DESIGN: Double-blind, randomised placebo-controlled intervention trial.  SETTING: Community-based project in a New Zealand city.  SUBJECTS: Seventy free living men and women with tHcy≥10 μmol/l.  Mean age (range) was 58 (29-90) yr.  INTERVENTIONS: Daily consumption over 4 wk of 20 g breakfast cereal either unfortified (placebo) or fortified with 100, 200 or 300 μg folic acid.  Dietary intake was detd. by weighed diet records and consumption of com. fortified products was avoided.  MAIN OUTCOME MEASURES: Plasma tHcy and serum folate concns.  RESULTS: Av. serum folate concns. (95% CI) increased significantly in the treatment groups relative to the control group by 28(9-51)%, 60(37-87)% and 79(51-114)% for supplementation with 100, 200 and 300 μg folic acid, resp.  A redn. in tHcy was obsd., being 16(8-22)%, 12(4-18)% and 17(9-24)% in the three treatment groups, resp.  CONCLUSIONS: A regular intake of as little as 100 μg folic acid per day was sufficient to lower tHcy in persons at the upper end of the normal range for tHcy.  Low-level fortification may also be appropriate for lowering the risk of neural tube defects given that, when aggregated from all sources, the total intake of folic acid may be sufficiently high to adequately improve the folate status of young women.  FUNDING: The breakfast cereals were supplied and the study partially funded by Kellogg Company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEhns33z2Qw7Vg90H21EOLACvtfcHk0lixjzbnlDhivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xltlamur4%253D&md5=0ca59ded8834273949001c36c4c0e262</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fsj.ejcn.1601388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ejcn.1601388%26sid%3Dliteratum%253Aachs%26aulast%3DVenn%26aufirst%3DB.%2BJ.%26aulast%3DMann%26aufirst%3DJ.%2BI.%26aulast%3DWilliams%26aufirst%3DS.%2BM.%26aulast%3DRiddell%26aufirst%3DL.%2BJ.%26aulast%3DChisholm%26aufirst%3DA.%26aulast%3DHarper%26aufirst%3DM.%2BJ.%26aulast%3DAitken%26aufirst%3DW.%26aulast%3DRossaak%26aufirst%3DJ.%2BI.%26atitle%3DAssessment%2520of%2520Three%2520Levels%2520of%2520Folic%2520Acid%2520on%2520Serum%2520Folate%2520and%2520Plasma%2520Homocysteine%253A%2520a%2520Randomised%2520Placebo-Controlled%2520Double-Blind%2520Dietary%2520InterventionTrial%26jtitle%3DEur.%2520J.%2520Clin.%2520Nutr.%26date%3D2002%26volume%3D56%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fsj.ejcn.1601388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Brooks, H. B.; Dally, R. D.; Durham, T. B.; Fales, K. R.; Frimpong, K.; McCowan, J. R.; Njoroge, F. G.; Shepherd, T. A.; Si, C.; Thrasher, K. J.; Toth, J. L.; Wu, Z.</span><span> </span><span class="NLM_article-title">1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide Compounds, Formulations Containing Those Compounds, and Their Use as AICARFT Inhibitors in the Treatment of Cancers</span>. U.S. Patent 9,776,992,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span>Eli Lilly and Company.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=H.+B.+Brooks&author=R.+D.+Dally&author=T.+B.+Durham&author=K.+R.+Fales&author=K.+Frimpong&author=J.+R.+McCowan&author=F.+G.+Njoroge&author=T.+A.+Shepherd&author=C.+Si&author=K.+J.+Thrasher&author=J.+L.+Toth&author=Z.+Wu&title=1-Oxo-1%2C2-dihydroisoquinolin-7-yl-%285-substituted-thiophen-2-yl%29-sulfonamide+Compounds%2C+Formulations+Containing+Those+Compounds%2C+and+Their+Use+as+AICARFT+Inhibitors+in+the+Treatment+of+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26atitle%3D1-Oxo-1%252C2-dihydroisoquinolin-7-yl-%25285-substituted-thiophen-2-yl%2529-sulfonamide%2520Compounds%252C%2520Formulations%2520Containing%2520Those%2520Compounds%252C%2520and%2520Their%2520Use%2520as%2520AICARFT%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Cancers%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Si, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fales, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrado, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frimpong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaoudi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandeveer, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Enantioselective Synthesis of 3,3-Difluoropyrrolidin-4-ol, a Valuable Building Block in Medicinal Chemistry</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">4359</span><span class="NLM_x">–</span> <span class="NLM_lpage">4363</span><span class="refDoi"> DOI: 10.1021/acs.joc.6b00305</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.6b00305" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=4359-4363&author=C.+Siauthor=K.+R.+Falesauthor=A.+Torradoauthor=K.+Frimpongauthor=T.+Kaoudiauthor=H.+G.+Vandeveerauthor=F.+G.+Njoroge&title=Enantioselective+Synthesis+of+3%2C3-Difluoropyrrolidin-4-ol%2C+a+Valuable+Building+Block+in+Medicinal+Chemistry&doi=10.1021%2Facs.joc.6b00305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.6b00305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.6b00305%26sid%3Dliteratum%253Aachs%26aulast%3DSi%26aufirst%3DC.%26aulast%3DFales%26aufirst%3DK.%2BR.%26aulast%3DTorrado%26aufirst%3DA.%26aulast%3DFrimpong%26aufirst%3DK.%26aulast%3DKaoudi%26aufirst%3DT.%26aulast%3DVandeveer%26aufirst%3DH.%2BG.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DEnantioselective%2520Synthesis%2520of%25203%252C3-Difluoropyrrolidin-4-ol%252C%2520a%2520Valuable%2520Building%2520Block%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2016%26volume%3D81%26spage%3D4359%26epage%3D4363%26doi%3D10.1021%2Facs.joc.6b00305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Si, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fales, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">An Efficient Synthesis of 3,4-Dihydropyridone via a Tandem Olefin Isomerization-Ring-Closing Metathesis Reaction</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5529</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2014.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.tetlet.2014.08.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=5529-5532&author=C.+Siauthor=K.+R.+Falesauthor=R.+D.+Boyerauthor=F.+G.+Njoroge&title=An+Efficient+Synthesis+of+3%2C4-Dihydropyridone+via+a+Tandem+Olefin+Isomerization-Ring-Closing+Metathesis+Reaction&doi=10.1016%2Fj.tetlet.2014.08.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2014.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2014.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DSi%26aufirst%3DC.%26aulast%3DFales%26aufirst%3DK.%2BR.%26aulast%3DBoyer%26aufirst%3DR.%2BD.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DAn%2520Efficient%2520Synthesis%2520of%25203%252C4-Dihydropyridone%2520via%2520a%2520Tandem%2520Olefin%2520Isomerization-Ring-Closing%2520Metathesis%2520Reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2014%26volume%3D55%26spage%3D5529%26epage%3D5532%26doi%3D10.1016%2Fj.tetlet.2014.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">See <a href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf" class="ext-link">Supporting Information</a> for representative curves.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="note"><p class="first last">A table including the experimental results and experimental details is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Brooks, H. B.; Meier, T. I.; Geeganage, S.; Fales, K. R.; Thrasher, K. J.; Konicek, S. A.; Spencer, C. D.; Thibodeaux, S.; Foreman, R. T.; Hui, Y.-H.; Roth, K. D.; Qian, Y.-W.; Bui, H.; Wang, T.; Luo, S.; Torrado, A.; Si, C.; Toth, J. L.; McCowan, J. R.; Frimpong, K.; Lee, M. R.; Dally, R. D.; Shepherd, T. A.; Durham, T. B.; Wang, Y.; Wu, Z.; Iversen, P. W.; Starling, J. J.; Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models</span>. Unpublished work.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Brooks%2C+H.+B.%3B+Meier%2C+T.+I.%3B+Geeganage%2C+S.%3B+Fales%2C+K.+R.%3B+Thrasher%2C+K.+J.%3B+Konicek%2C+S.+A.%3B+Spencer%2C+C.+D.%3B+Thibodeaux%2C+S.%3B+Foreman%2C+R.+T.%3B+Hui%2C+Y.-H.%3B+Roth%2C+K.+D.%3B+Qian%2C+Y.-W.%3B+Bui%2C+H.%3B+Wang%2C+T.%3B+Luo%2C+S.%3B+Torrado%2C+A.%3B+Si%2C+C.%3B+Toth%2C+J.+L.%3B+McCowan%2C+J.+R.%3B+Frimpong%2C+K.%3B+Lee%2C+M.+R.%3B+Dally%2C+R.+D.%3B+Shepherd%2C+T.+A.%3B+Durham%2C+T.+B.%3B+Wang%2C+Y.%3B+Wu%2C+Z.%3B+Iversen%2C+P.+W.%3B+Starling%2C+J.+J.%3B+Njoroge%2C+F.+G.+Characterization+of+a+novel+AICARFT+inhibitor+which+potently+elevates+ZMP+and+has+anti-tumor+activity+in+murine+models.+Unpublished+work."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520AICARFT%2520inhibitor%2520which%2520potently%2520elevates%2520ZMP%2520and%2520has%2520anti-tumor%2520activity%2520in%2520murine%2520models" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Bauer, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cress, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parise, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caggiano, V.</span><span> </span><span class="NLM_article-title">Descriptive Analysis of Estrogen Receptor (ER)-Negative, Progestoerone Receptor (PR)-Negative, and HER2-Negative Invasive Breast Cancer, the So-called Triple-Negative Phenotype: A Population-Based Study From the California Cancer Registry</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">–</span> <span class="NLM_lpage">1728</span><span class="refDoi"> DOI: 10.1002/cncr.22618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1002%2Fcncr.22618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=1721-1728&author=K.+R.+Bauerauthor=M.+Brownauthor=R.+D.+Cressauthor=C.+A.+Pariseauthor=V.+Caggiano&title=Descriptive+Analysis+of+Estrogen+Receptor+%28ER%29-Negative%2C+Progestoerone+Receptor+%28PR%29-Negative%2C+and+HER2-Negative+Invasive+Breast+Cancer%2C+the+So-called+Triple-Negative+Phenotype%3A+A+Population-Based+Study+From+the+California+Cancer+Registry&doi=10.1002%2Fcncr.22618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22618%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DK.%2BR.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCress%26aufirst%3DR.%2BD.%26aulast%3DParise%26aufirst%3DC.%2BA.%26aulast%3DCaggiano%26aufirst%3DV.%26atitle%3DDescriptive%2520Analysis%2520of%2520Estrogen%2520Receptor%2520%2528ER%2529-Negative%252C%2520Progestoerone%2520Receptor%2520%2528PR%2529-Negative%252C%2520and%2520HER2-Negative%2520Invasive%2520Breast%2520Cancer%252C%2520the%2520So-called%2520Triple-Negative%2520Phenotype%253A%2520A%2520Population-Based%2520Study%2520From%2520the%2520California%2520Cancer%2520Registry%26jtitle%3DCancer%26date%3D2007%26volume%3D109%26spage%3D1721%26epage%3D1728%26doi%3D10.1002%2Fcncr.22618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Carey, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perou, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livasy, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressler, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaca, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troester, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmiston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deming, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geradts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheang, M. C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorman, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millikan, R. C.</span><span> </span><span class="NLM_article-title">Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">2492</span><span class="NLM_x">–</span> <span class="NLM_lpage">2502</span><span class="refDoi"> DOI: 10.1001/jama.295.21.2492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1001%2Fjama.295.21.2492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=16757721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsV2rtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2006&pages=2492-2502&author=L.+A.+Careyauthor=C.+M.+Perouauthor=C.+A.+Livasyauthor=L.+G.+Dresslerauthor=D.+Cowanauthor=K.+Conwayauthor=G.+Karacaauthor=M.+A.+Troesterauthor=C.+K.+Tseauthor=S.+Edmistonauthor=S.+L.+Demingauthor=J.+Geradtsauthor=M.+C.+U.+Cheangauthor=T.+O.+Nielsenauthor=P.+G.+Moormanauthor=H.+S.+Earpauthor=R.+C.+Millikan&title=Race%2C+Breast+Cancer+Subtypes%2C+and+Survival+in+the+Carolina+Breast+Cancer+Study&doi=10.1001%2Fjama.295.21.2492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study</span></div><div class="casAuthors">Carey, Lisa A.; Perou, Charles M.; Livasy, Chad A.; Dressler, Lynn G.; Cowan, David; Conway, Kathleen; Karaca, Gamze; Troester, Melissa A.; Tse, Chiu Kit; Edmiston, Sharon; Deming, Sandra L.; Geradts, Joseph; Cheang, Maggie C. U.; Nielsen, Torsten O.; Moorman, Patricia G.; Earp, H. Shelton; Millikan, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2492-2502</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Gene expression anal. has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 pos./estrogen receptor neg. (HER2+/ER-), luminal A, and luminal B.  Objectives: To det. population-based distributions and clin. assocns. for breast cancer subtypes.  Design, Setting, and Participants: Immunohistochem. surrogates for each sub-type were applied to 496 incident cases of invasive breast cancer from the Carolina Breast Cancer Study (ascertained between May 1993 and Dec. 1996), a population-based, case-control study that oversampled premenopausal and African American women.  Subtype definitions were as follows: luminal A (ER+ and/or progesterone receptor pos. [PR+], HER2-), luminal B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-, HER2-, cytokeratin 5/6 pos., and/or HER1+), HER2+/ER- (ER-, PR-, and HER2+), and unclassified (neg. for all 5 markers).  Main Outcome Measures We examd. the prevalence of breast cancer sub- types within racial and menopausal subsets and detd. their assocns. with tumor size, axillary nodal status, mitotic index, nuclear pleomorphism, combined grade, p53 mutation status, and breast cancer-specific survival.  Results: The basal-like breast cancer subtype was more prevalent among pre- menopausal African American women (39%) compared with postmenopausal African American women (14%) and non-African American women (16%) of any age (P < .001), whereas the luminal A subtype was less prevalent (36% vs 59% and 54%, resp.).  The HER2+/ER- subtype did not vary with race or menopausal status (6%-9%).  Compared with luminal A, basal-like tumors had more TP53 mutations (44% vs 15%, P < .001), higher mitotic index (odds ratio [OR], 11.0; 95% confidence interval [Cl], 5.6-21.7), more marked nuclear pleomorphism (OR, 9.7; 95% Cl, 5.3-18.0), and higher combined grade (OR, 8.3; 95% Cl, 4.4-15.6).  Breast cancer-specific survival differed by subtype (P < .001), with shortest survival among HER2+/ER- and basal-like subtypes.  Conclusions: Basal-like breast tumors occurred at a higher prevalence among pre-menopausal African American patients compared with postmenopausal African American and non-African American patients in this population-based study.  A higher prevalence of basal-like breast tumors and a lower prevalence of luminal A tumors could contribute to the poor prognosis of young African American women with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyFu0ZR8nYV7Vg90H21EOLACvtfcHk0lgC6CFU8bT52A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsV2rtLw%253D&md5=251f6baa529a4f22a39d5b236cf9b9c7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1001%2Fjama.295.21.2492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.295.21.2492%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DLivasy%26aufirst%3DC.%2BA.%26aulast%3DDressler%26aufirst%3DL.%2BG.%26aulast%3DCowan%26aufirst%3DD.%26aulast%3DConway%26aufirst%3DK.%26aulast%3DKaraca%26aufirst%3DG.%26aulast%3DTroester%26aufirst%3DM.%2BA.%26aulast%3DTse%26aufirst%3DC.%2BK.%26aulast%3DEdmiston%26aufirst%3DS.%26aulast%3DDeming%26aufirst%3DS.%2BL.%26aulast%3DGeradts%26aufirst%3DJ.%26aulast%3DCheang%26aufirst%3DM.%2BC.%2BU.%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26aulast%3DMoorman%26aufirst%3DP.%2BG.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DMillikan%26aufirst%3DR.%2BC.%26atitle%3DRace%252C%2520Breast%2520Cancer%2520Subtypes%252C%2520and%2520Survival%2520in%2520the%2520Carolina%2520Breast%2520Cancer%2520Study%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2006%26volume%3D295%26spage%3D2492%26epage%3D2502%26doi%3D10.1001%2Fjama.295.21.2492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Worm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkin, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dzhandzhugazyan, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guldberg, P.</span><span> </span><span class="NLM_article-title">Methylation-dependent Silencing of the Reduced Folate Carrier Gene in Inherently Methotrexate-resistant Human Breast Cancer Cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">39990</span><span class="NLM_x">–</span> <span class="NLM_lpage">40000</span><span class="refDoi"> DOI: 10.1074/jbc.M103181200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1074%2Fjbc.M103181200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=39990-40000&author=J.+Wormauthor=A.+F.+Kirkinauthor=K.+N.+Dzhandzhugazyanauthor=P.+Guldberg&title=Methylation-dependent+Silencing+of+the+Reduced+Folate+Carrier+Gene+in+Inherently+Methotrexate-resistant+Human+Breast+Cancer+Cells&doi=10.1074%2Fjbc.M103181200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M103181200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M103181200%26sid%3Dliteratum%253Aachs%26aulast%3DWorm%26aufirst%3DJ.%26aulast%3DKirkin%26aufirst%3DA.%2BF.%26aulast%3DDzhandzhugazyan%26aufirst%3DK.%2BN.%26aulast%3DGuldberg%26aufirst%3DP.%26atitle%3DMethylation-dependent%2520Silencing%2520of%2520the%2520Reduced%2520Folate%2520Carrier%2520Gene%2520in%2520Inherently%2520Methotrexate-resistant%2520Human%2520Breast%2520Cancer%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D39990%26epage%3D40000%26doi%3D10.1074%2Fjbc.M103181200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rowe, P. B.</span><span> </span><span class="NLM_article-title">The synthesis of N5,N10-methenyltetrahydrofolic acid</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">Part B</span><span class="NLM_x">) </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1016/S0076-6879(71)18145-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2FS0076-6879%2871%2918145-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1971&pages=733-735&issue=Part+B&author=P.+B.+Rowe&title=The+synthesis+of+N5%2CN10-methenyltetrahydrofolic+acid&doi=10.1016%2FS0076-6879%2871%2918145-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2871%2918145-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252871%252918145-1%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DP.%2BB.%26atitle%3DThe%2520synthesis%2520of%2520N5%252CN10-methenyltetrahydrofolic%2520acid%26jtitle%3DMethods%2520Enzymol.%26date%3D1971%26volume%3D18%26issue%3DPart%2520B%26spage%3D733%26epage%3D735%26doi%3D10.1016%2FS0076-6879%2871%2918145-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rabinowitz, J. C.</span><span> </span><span class="NLM_article-title">Preparation and Properties of 5,10-Methenyltetrahydrofolic Acid and 10-Formultetrahydrofolic acid</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1963</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">814</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span><span class="refDoi"> DOI: 10.1016/0076-6879(63)06256-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2F0076-6879%2863%2906256-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1963&pages=814-815&author=J.+C.+Rabinowitz&title=Preparation+and+Properties+of+5%2C10-Methenyltetrahydrofolic+Acid+and+10-Formultetrahydrofolic+acid&doi=10.1016%2F0076-6879%2863%2906256-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1016%2F0076-6879%2863%2906256-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0076-6879%252863%252906256-X%26sid%3Dliteratum%253Aachs%26aulast%3DRabinowitz%26aufirst%3DJ.%2BC.%26atitle%3DPreparation%2520and%2520Properties%2520of%25205%252C10-Methenyltetrahydrofolic%2520Acid%2520and%252010-Formultetrahydrofolic%2520acid%26jtitle%3DMethods%2520Enzymol.%26date%3D1963%26volume%3D6%26spage%3D814%26epage%3D815%26doi%3D10.1016%2F0076-6879%2863%2906256-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15a','cit15b'],'ref16':['cit16'],'ref17':['cit17a','cit17b','cit17c','cit17d','cit17e','cit17f','cit17g','cit17h','cit17i','cit17j'],'ref18':['cit18a','cit18b'],'ref19':['cit19a','cit19b'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':[],'ref27':[],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Saul Jaime-Figueroa, Michael J. Bond, J. Ignacio Vergara, Jake C. Swartzel, <span class="NLM_string-name hlFld-ContribAuthor">Craig M. Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Isoquinolones by Sequential Suzuki Coupling of 2-Halobenzonitriles with Vinyl Boronate Followed by Cyclization. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (12)
                                     , 8479-8488. <a href="https://doi.org/10.1021/acs.joc.1c00472" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00472%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BIsoquinolones%252Bby%252BSequential%252BSuzuki%252BCoupling%252Bof%252B2-Halobenzonitriles%252Bwith%252BVinyl%252BBoronate%252BFollowed%252Bby%252BCyclization%26aulast%3DJaime-Figueroa%26aufirst%3DSaul%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D25022021%26date%3D28052021%26volume%3D86%26issue%3D12%26spage%3D8479%26epage%3D8488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zaixiang Fang, Yi Wang, <span class="NLM_string-name hlFld-ContribAuthor">Yuanhua Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 4-Iodoisoquinolin-1(2H)-ones by a Dirhodium(II)-Catalyzed 1,4-Bisfunctionalization of Isoquinolinium Iodide Salts. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (2)
                                     , 434-438. <a href="https://doi.org/10.1021/acs.orglett.8b03614" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03614</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03614%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252B4-Iodoisoquinolin-1%2525282H%252529-ones%252Bby%252Ba%252BDirhodium%252528II%252529-Catalyzed%252B1%25252C4-Bisfunctionalization%252Bof%252BIsoquinolinium%252BIodide%252BSalts%26aulast%3DFang%26aufirst%3DZaixiang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D13112018%26date%3D07012019%26volume%3D21%26issue%3D2%26spage%3D434%26epage%3D438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">You-Quan Zhu, Jing-Li He, Yun-Xia Niu, Hui-Ying Kang, Ting-Feng Han, <span class="NLM_string-name hlFld-ContribAuthor">Hao-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">AgSbF6-Mediated Selective Thiolation and Selenylation at C-4 Position of Isoquinolin-1(2H)-ones. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (17)
                                     , 9958-9967. <a href="https://doi.org/10.1021/acs.joc.8b01361" title="DOI URL">https://doi.org/10.1021/acs.joc.8b01361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b01361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b01361%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAgSbF6-Mediated%252BSelective%252BThiolation%252Band%252BSelenylation%252Bat%252BC-4%252BPosition%252Bof%252BIsoquinolin-1%2525282H%252529-ones%26aulast%3DZhu%26aufirst%3DYou-Quan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D30052018%26date%3D20072018%26date%3D11072018%26volume%3D83%26issue%3D17%26spage%3D9958%26epage%3D9967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cai‐Yun  Yang</span>, <span class="hlFld-ContribAuthor ">Xia  Li</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Guo‐Li  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">I
              2
              ‐Promoted Direct C−H Sulfenylation of Isoquinolin‐1(2
              H
              )‐ones with Sulfonyl Chlorides. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (1)
                                     , 117-124. <a href="https://doi.org/10.1002/ejoc.202001371" title="DOI URL">https://doi.org/10.1002/ejoc.202001371</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202001371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202001371%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DI%252B2%252B%2525E2%252580%252590Promoted%252BDirect%252BC%2525E2%252588%252592H%252BSulfenylation%252Bof%252BIsoquinolin%2525E2%252580%2525901%2525282%252BH%252B%252529%2525E2%252580%252590ones%252Bwith%252BSulfonyl%252BChlorides%26aulast%3DYang%26aufirst%3DCai%25E2%2580%2590Yun%26date%3D2021%26date%3D2020%26volume%3D2021%26issue%3D1%26spage%3D117%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maciej E.  Domaradzki</span>, <span class="hlFld-ContribAuthor ">Xiaochen  Liu</span>, <span class="hlFld-ContribAuthor ">Jiye  Ong</span>, <span class="hlFld-ContribAuthor ">Gyeongah  Yu</span>, <span class="hlFld-ContribAuthor ">Gan  Zhang</span>, <span class="hlFld-ContribAuthor ">Ariel  Simantov</span>, <span class="hlFld-ContribAuthor ">Eliyahu  Perl</span>, <span class="hlFld-ContribAuthor ">Yu  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Triflic acid mediated sequential cyclization of ortho-alkynylarylesters with ammonium acetate. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (37)
                                     , 131437. <a href="https://doi.org/10.1016/j.tet.2020.131437" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131437%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DTriflic%252Bacid%252Bmediated%252Bsequential%252Bcyclization%252Bof%252Bortho-alkynylarylesters%252Bwith%252Bammonium%252Bacetate%26aulast%3DDomaradzki%26aufirst%3DMaciej%2BE.%26date%3D2020%26volume%3D76%26issue%3D37%26spage%3D131437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sumit  Agarwal</span>, <span class="hlFld-ContribAuthor ">Balabhadrapatruni V. S. K.  Chakravarthi</span>, <span class="hlFld-ContribAuthor ">Michael  Behring</span>, <span class="hlFld-ContribAuthor ">Hyung-Gyoon  Kim</span>, <span class="hlFld-ContribAuthor ">Darshan S.  Chandrashekar</span>, <span class="hlFld-ContribAuthor ">Nirzari  Gupta</span>, <span class="hlFld-ContribAuthor ">Prachi  Bajpai</span>, <span class="hlFld-ContribAuthor ">Amr  Elkholy</span>, <span class="hlFld-ContribAuthor ">Sai A. H.  Balasubramanya</span>, <span class="hlFld-ContribAuthor ">Cherlene  Hardy</span>, <span class="hlFld-ContribAuthor ">Sameer Al  Diffalha</span>, <span class="hlFld-ContribAuthor ">Sooryanarayana  Varambally</span>, <span class="hlFld-ContribAuthor ">Upender  Manne</span>. </span><span class="cited-content_cbyCitation_article-title">PAICS, a Purine Nucleotide Metabolic Enzyme, is Involved in Tumor Growth and the Metastasis of Colorectal Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (4)
                                     , 772. <a href="https://doi.org/10.3390/cancers12040772" title="DOI URL">https://doi.org/10.3390/cancers12040772</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12040772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12040772%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DPAICS%25252C%252Ba%252BPurine%252BNucleotide%252BMetabolic%252BEnzyme%25252C%252Bis%252BInvolved%252Bin%252BTumor%252BGrowth%252Band%252Bthe%252BMetastasis%252Bof%252BColorectal%252BCancer%26aulast%3DAgarwal%26aufirst%3DSumit%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D4%26spage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Chao  Tian</span>, <span class="hlFld-ContribAuthor ">Liangmin  Xue</span>, <span class="hlFld-ContribAuthor ">Hao  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Cong</span>, <span class="hlFld-ContribAuthor ">Fang  Fang</span>, <span class="hlFld-ContribAuthor ">Jiajia  Yang</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Yuan</span>, <span class="hlFld-ContribAuthor ">Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Ying  Guo</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Wang</span>, <span class="hlFld-ContribAuthor ">Junyi  Liu</span>, <span class="hlFld-ContribAuthor ">Zhili  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological activity of N-substituted tetrahydropteroate analogs as non-classical antifolates against cobalamin-dependent methionine synthase and potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>190 </em>, 112113. <a href="https://doi.org/10.1016/j.ejmech.2020.112113" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112113%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivity%252Bof%252BN-substituted%252Btetrahydropteroate%252Banalogs%252Bas%252Bnon-classical%252Bantifolates%252Bagainst%252Bcobalamin-dependent%252Bmethionine%252Bsynthase%252Band%252Bpotential%252Banticancer%252Bagents%26aulast%3DWang%26aufirst%3DMeng%26date%3D2020%26volume%3D190%26spage%3D112113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alyncia D.  Robinson</span>, <span class="hlFld-ContribAuthor ">Marie-Lisa  Eich</span>, <span class="hlFld-ContribAuthor ">Sooryanarayana  Varambally</span>. </span><span class="cited-content_cbyCitation_article-title">Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2020,</strong> <em>470 </em>, 134-140. <a href="https://doi.org/10.1016/j.canlet.2019.11.013" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.11.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.11.013%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DDysregulation%252Bof%252Bde%252Bnovo%252Bnucleotide%252Bbiosynthetic%252Bpathway%252Benzymes%252Bin%252Bcancer%252Band%252Btargeting%252Bopportunities%26aulast%3DRobinson%26aufirst%3DAlyncia%2BD.%26date%3D2020%26volume%3D470%26spage%3D134%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fernández-Villa</span>, <span class="hlFld-ContribAuthor ">Aguilar</span>, <span class="hlFld-ContribAuthor ">Rojo</span>. </span><span class="cited-content_cbyCitation_article-title">Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (20)
                                     , 4996. <a href="https://doi.org/10.3390/ijms20204996" title="DOI URL">https://doi.org/10.3390/ijms20204996</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20204996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20204996%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DFolic%252BAcid%252BAntagonists%25253A%252BAntimicrobial%252Band%252BImmunomodulating%252BMechanisms%252Band%252BApplications%26aulast%3DFern%25C3%25A1ndez-Villa%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D20%26spage%3D4996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harold B.  Brooks</span>, <span class="hlFld-ContribAuthor ">Timothy I.  Meier</span>, <span class="hlFld-ContribAuthor ">Sandaruwan  Geeganage</span>, <span class="hlFld-ContribAuthor ">Kevin R.  Fales</span>, <span class="hlFld-ContribAuthor ">Kenneth J.  Thrasher</span>, <span class="hlFld-ContribAuthor ">Susan A.  Konicek</span>, <span class="hlFld-ContribAuthor ">Charles D.  Spencer</span>, <span class="hlFld-ContribAuthor ">Stefan  Thibodeaux</span>, <span class="hlFld-ContribAuthor ">Robert T.  Foreman</span>, <span class="hlFld-ContribAuthor ">Yu-Hua  Hui</span>, <span class="hlFld-ContribAuthor ">Kenneth D.  Roth</span>, <span class="hlFld-ContribAuthor ">Yue-Wei  Qian</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Shuang  Luo</span>, <span class="hlFld-ContribAuthor ">Alicia  Torrado</span>, <span class="hlFld-ContribAuthor ">Chong  Si</span>, <span class="hlFld-ContribAuthor ">James L.  Toth</span>, <span class="hlFld-ContribAuthor ">Jefferson R.  Mc Cowan</span>, <span class="hlFld-ContribAuthor ">Kwame  Frimpong</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Lee</span>, <span class="hlFld-ContribAuthor ">Robert D.  Dally</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Shepherd</span>, <span class="hlFld-ContribAuthor ">Timothy B.  Durham</span>, <span class="hlFld-ContribAuthor ">Yong  Wang</span>, <span class="hlFld-ContribAuthor ">Zhipei  Wu</span>, <span class="hlFld-ContribAuthor ">Philip W.  Iversen</span>, <span class="hlFld-ContribAuthor ">F. George  Njoroge</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-33453-4" title="DOI URL">https://doi.org/10.1038/s41598-018-33453-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-33453-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-33453-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DCharacterization%252Bof%252Ba%252Bnovel%252BAICARFT%252Binhibitor%252Bwhich%252Bpotently%252Belevates%252BZMP%252Band%252Bhas%252Banti-tumor%252Bactivity%252Bin%252Bmurine%252Bmodels%26aulast%3DBrooks%26aufirst%3DHarold%2BB.%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingliang  Liu</span>, <span class="hlFld-ContribAuthor ">Wanchun  Gong</span>, <span class="hlFld-ContribAuthor ">Erli  You</span>, <span class="hlFld-ContribAuthor ">Haizhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Shi</span>, <span class="hlFld-ContribAuthor ">Weiguo  Cao</span>, <span class="hlFld-ContribAuthor ">Jingjing  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Isoquinolines through Ir
              III
              -Catalyzed C-H Activation/Annulation from Benzimidates with Hydroxylisopropylalkynes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (36)
                                     , 4991-4995. <a href="https://doi.org/10.1002/ejoc.201800410" title="DOI URL">https://doi.org/10.1002/ejoc.201800410</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201800410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201800410%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BIsoquinolines%252Bthrough%252BIr%252BIII%252B-Catalyzed%252BC-H%252BActivation%25252FAnnulation%252Bfrom%252BBenzimidates%252Bwith%252BHydroxylisopropylalkynes%26aulast%3DLiu%26aufirst%3DMingliang%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D36%26spage%3D4991%26epage%3D4995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Di  Zhang</span>, <span class="hlFld-ContribAuthor ">Chenyan  Shu</span>, <span class="hlFld-ContribAuthor ">Xiaoyuan  Lian</span>, <span class="hlFld-ContribAuthor ">Zhizhen  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">New Antibacterial Bagremycins F and G from the Marine-Derived Streptomyces sp. ZZ745. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2018,</strong> <em>16 </em>
                                    (9)
                                     , 330. <a href="https://doi.org/10.3390/md16090330" title="DOI URL">https://doi.org/10.3390/md16090330</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md16090330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd16090330%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DNew%252BAntibacterial%252BBagremycins%252BF%252Band%252BG%252Bfrom%252Bthe%252BMarine-Derived%252BStreptomyces%252Bsp.%252BZZ745%26aulast%3DZhang%26aufirst%3DDi%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D9%26spage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Purine biosynthetic pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Reported AICARFT inhibitors and binding regions of <b>11</b>. (a) Crystal structure of <b>11</b> was obtained from PDB (code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1pl0">1pl0</a>; BW2315U89UC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Initial leads.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) triphosgene, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N (0 °C) followed by AlCl<sub>3</sub> (0 °C to rt); (b) H<sub>2</sub>SO<sub>4</sub>, KNO<sub>3</sub> (0 °C); (c) MnO<sub>2</sub>, dichloroethane (120 °C); (d) Pd/C, H<sub>2</sub>, MeOH.</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Crystal structure of <b>28a</b> (white) and ZMP (yellow) in complex with ATIC (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UZ0">5UZ0</a>). (b) Top: Overlay of <b>11</b> (yellow) from PDB (code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1pl0">1pl0</a>) with <b>28a</b> (cyan) and ZMP (majenta) in the AICARFT domain. Middle: <b>28a</b> in the AICARFT domain. Bottom: Two-dimensional representation of key binding interactions. (c) Pteridine binding region detailed interactions. (d) Oxyanion hole detailed interactions. (e) ZMP π-stack and glutamate binding regions detailed interactions. (f) Protein surface representation of the ZMP π-stack and glutamate binding regions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) sulfonyl chloride, pyridine; (b) amine, CuBr, CsCO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub>, DMSO, 100 °C, 16 h; (c) amine, pyridine, 110 °C, 40 h; (d) pyridone-boronate, Pd(dppf), K<sub>2</sub>CO<sub>3</sub>, dioxane, water, 140 °C, microwave, 90 min; (e) 2-thienylzinc bromide, Pd(dppf), THF, 60 °C, 17 h; (f) chlorosulfuric acid, dichloromethane, 0 °C to ambient, 90 min; (g) pyridine, 16 h.</p></p></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Binding interactions of <b>32b</b> in complex with ATIC (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UY8">5UY8</a>). (b) Protein surface representation of <b>32b</b> in complex with ATIC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Results from in vivo target inhibition studies using H460 xenografts in mice maintained on low folate diet: (a) tumor ZMP concentrations at increasing dose levels of compounds <b>28a</b>, <b>28f</b>, <b>28i</b>, and <b>32a</b>; (b) plasma AICAr concentrations at increasing dose levels of compounds <b>28a</b>, <b>28f</b>, <b>28i</b>, and <b>32a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/medium/jm-2017-01046b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Antiproliferative effects of <b>28a</b> on MDA-MB-231met2. Group size was <i>n</i> = 6 for all dose groups studied. (b) End of study intratumoral metabolite levels.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01046/20171215/images/large/jm-2017-01046b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01046&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i60">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52708" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52708" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ealick, S. E.</span><span> </span><span class="NLM_article-title">Structural Biology of the Purine Biosynthetic Pathway</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3699</span><span class="NLM_x">–</span> <span class="NLM_lpage">3724</span><span class="refDoi"> DOI: 10.1007/s00018-008-8295-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1007%2Fs00018-008-8295-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=18712276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGgs7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=3699-3724&author=Y.+Zhangauthor=M.+Morarauthor=S.+E.+Ealick&title=Structural+Biology+of+the+Purine+Biosynthetic+Pathway&doi=10.1007%2Fs00018-008-8295-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Structural biology of the purine biosynthetic pathway</span></div><div class="casAuthors">Zhang, Y.; Morar, M.; Ealick, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3699-3724</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Purine biosynthesis requires 10 enzymic transformations to generate IMP.  Enzymes PurF, PurD, PurL, PurM, PurC, and PurB are common to all pathways, whereas PurN or PurT, PurK/PurE-I or PurE-II, PurH or PurP, and PurJ or PurO catalyze the same steps in different organisms.  X-ray crystal structures are available for all 15 purine biosynthetic enzymes, including 7 ATP-dependent enzymes, 2 amidotransferases, and 2 tetrahydrofolate-dependent enzymes.  Here, the authors summarize the structures of the purine biosynthetic enzymes, discuss similarities and differences, and present arguments for pathway evolution.  Four of the ATP-dependent enzymes belong to the ATP-grasp superfamily and 2 to the PurM superfamily.  The amidotransferases are unrelated, with one utilizing an N-terminal nucleophile-glutaminase and the other utilizing a triad glutaminase.  Likewise, the tetrahydrofolate-dependent enzymes are unrelated.  Ancestral proteins may have included a broad specificity enzyme instead of PurD, PurT, PurK, PurC, and PurP, and a sep. enzyme instead of PurM and PurL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUjcyeLGRkBLVg90H21EOLACvtfcHk0lgrfMEOskH-Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGgs7jM&md5=da182c0690aa7642a26dcd9f2573afbe</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs00018-008-8295-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-008-8295-8%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMorar%26aufirst%3DM.%26aulast%3DEalick%26aufirst%3DS.%2BE.%26atitle%3DStructural%2520Biology%2520of%2520the%2520Purine%2520Biosynthetic%2520Pathway%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2008%26volume%3D65%26spage%3D3699%26epage%3D3724%26doi%3D10.1007%2Fs00018-008-8295-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Buchanan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, S. C.</span><span> </span><span class="NLM_article-title">Enzymic Reactions in the Synthesis of the Purines</span> <span class="citation_source-journal">Adv. Enzymol. Relat. Areas Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1002/9780470122662.ch5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1002%2F9780470122662.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=199-261&author=J.+M.+Buchananauthor=S.+C.+Hartman&title=Enzymic+Reactions+in+the+Synthesis+of+the+Purines&doi=10.1002%2F9780470122662.ch5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2F9780470122662.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9780470122662.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BC.%26atitle%3DEnzymic%2520Reactions%2520in%2520the%2520Synthesis%2520of%2520the%2520Purines%26jtitle%3DAdv.%2520Enzymol.%2520Relat.%2520Areas%2520Mol.%2520Biol.%26date%3D2006%26volume%3D21%26spage%3D199%26epage%3D261%26doi%3D10.1002%2F9780470122662.ch5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Baggott, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, B. B.</span><span> </span><span class="NLM_article-title">Inhibition of 5-Aminoimidazole-4-carboxamide Ribotide Transformylase, Adenosine Deaminase and 5′-Adenylate Deaminase by Polyglutamates of Methotrexate and Oxidized Folates and by 5-Aminoimidazole-4-carboxamide Riboside and Ribotide</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span><span class="refDoi"> DOI: 10.1042/bj2360193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1042%2Fbj2360193" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=1986&pages=193-200&author=J.+E.+Baggottauthor=W.+H.+Vaughnauthor=B.+B.+Hudson&title=Inhibition+of+5-Aminoimidazole-4-carboxamide+Ribotide+Transformylase%2C+Adenosine+Deaminase+and+5%E2%80%B2-Adenylate+Deaminase+by+Polyglutamates+of+Methotrexate+and+Oxidized+Folates+and+by+5-Aminoimidazole-4-carboxamide+Riboside+and+Ribotide&doi=10.1042%2Fbj2360193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2Fbj2360193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj2360193%26sid%3Dliteratum%253Aachs%26aulast%3DBaggott%26aufirst%3DJ.%2BE.%26aulast%3DVaughn%26aufirst%3DW.%2BH.%26aulast%3DHudson%26aufirst%3DB.%2BB.%26atitle%3DInhibition%2520of%25205-Aminoimidazole-4-carboxamide%2520Ribotide%2520Transformylase%252C%2520Adenosine%2520Deaminase%2520and%25205%25E2%2580%25B2-Adenylate%2520Deaminase%2520by%2520Polyglutamates%2520of%2520Methotrexate%2520and%2520Oxidized%2520Folates%2520and%2520by%25205-Aminoimidazole-4-carboxamide%2520Riboside%2520and%2520Ribotide%26jtitle%3DBiochem.%2520J.%26date%3D1986%26volume%3D236%26spage%3D193%26epage%3D200%26doi%3D10.1042%2Fbj2360193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mitchell-Ryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravindra, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matherly, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">Discovery of 5-Substituted Pyrrolo[2,3-<i>d</i>]pyrimidine Antifolates as Dual-Acting Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase in De Novo Purine Nucleotide Biosynthesis: Implications of Inhibiting 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase to AMPK Activation and Antitumor Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">10016</span><span class="NLM_x">–</span> <span class="NLM_lpage">10032</span><span class="refDoi"> DOI: 10.1021/jm401328u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401328u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVajur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=10016-10032&author=S.+Mitchell-Ryanauthor=Y.+Wangauthor=S.+Raghavanauthor=M.+P.+Ravindraauthor=E.+Halesauthor=S.+Orrauthor=C.+Cherianauthor=Z.+Houauthor=L.+H.+Matherlyauthor=A.+Gangjee&title=Discovery+of+5-Substituted+Pyrrolo%5B2%2C3-d%5Dpyrimidine+Antifolates+as+Dual-Acting+Inhibitors+of+Glycinamide+Ribonucleotide+Formyltransferase+and+5-Aminoimidazole-4-carboxamide+Ribonucleotide+Formyltransferase+in+De+Novo+Purine+Nucleotide+Biosynthesis%3A+Implications+of+Inhibiting+5-Aminoimidazole-4-carboxamide+Ribonucleotide+Formyltransferase+to+AMPK+Activation+and+Antitumor+Activity&doi=10.1021%2Fjm401328u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates as Dual-Acting Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase in De Novo Purine Nucleotide Biosynthesis: Implications of Inhibiting 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase to AMPK Activation and Antitumor Activity</span></div><div class="casAuthors">Mitchell-Ryan, Shermaine; Wang, Yiqiang; Raghavan, Sudhir; Ravindra, Manasa Punaha; Hales, Eric; Orr, Steven; Cherian, Christina; Hou, Zhanjun; Matherly, Larry H.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10016-10032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We synthesized 5-substituted pyrrolo-[2,3-d]-pyrimidine antifolates (compds. 5-10) with one-to-six bridge carbons and a benozyl ring in the side chain as antitumor agents.  Compd. 8 with a 4-carbon bridge was the most active analog and potently inhibited proliferation of folate receptor (FR) α-expressing Chinese hamster ovary and KB human tumor cells.  Growth inhibition was reversed completely or in part by excess folic acid, indicating that FRα is involved in cellular uptake, and resulted in S-phase accumulation and apoptosis.  Antiproliferative effects of compd. 8 toward KB cells were protected by excess adenosine but not thymidine, establishing de novo purine nucleotide biosynthesis as the targeted pathway.  However, 5-aminoimidazole-4-carboxamide (AICA) protection was incomplete, suggesting inhibition of both AICA ribonucleotide formyltransferase (AICARFTase) and glycinamide ribonucleotide formyltransferase (GARFTase).  Inhibition of GARFTase and AICARFTase by compd. 8 was confirmed by cellular metabolic assays and resulted in ATP pool depletion.  To our knowledge, this is the first example of an antifolate that acts as a dual inhibitor of GARFTase and AICARFTase as its principal mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCWR5x3a4Wo7Vg90H21EOLACvtfcHk0ljn9EQ-hlwu_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVajur7I&md5=0870603cc284cf81c44388c7c3cd162f</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1021%2Fjm401328u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401328u%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell-Ryan%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRavindra%26aufirst%3DM.%2BP.%26aulast%3DHales%26aufirst%3DE.%26aulast%3DOrr%26aufirst%3DS.%26aulast%3DCherian%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DZ.%26aulast%3DMatherly%26aufirst%3DL.%2BH.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25205-Substituted%2520Pyrrolo%255B2%252C3-d%255Dpyrimidine%2520Antifolates%2520as%2520Dual-Acting%2520Inhibitors%2520of%2520Glycinamide%2520Ribonucleotide%2520Formyltransferase%2520and%25205-Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Formyltransferase%2520in%2520De%2520Novo%2520Purine%2520Nucleotide%2520Biosynthesis%253A%2520Implications%2520of%2520Inhibiting%25205-Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Formyltransferase%2520to%2520AMPK%2520Activation%2520and%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D10016%26epage%3D10032%26doi%3D10.1021%2Fjm401328u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell-Ryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghavan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matherly, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">Novel 5-Substituted Pyrrolo[2,3-<i>d</i>]pyrimidines as Dual Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase and as Potential Antitumor Agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span><span class="refDoi"> DOI: 10.1021/jm501787c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501787c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1479-1493&author=Y.+Wangauthor=S.+Mitchell-Ryanauthor=S.+Raghavanauthor=C.+Georgeauthor=S.+Orrauthor=Z.+Houauthor=L.+H.+Matherlyauthor=A.+Gangjee&title=Novel+5-Substituted+Pyrrolo%5B2%2C3-d%5Dpyrimidines+as+Dual+Inhibitors+of+Glycinamide+Ribonucleotide+Formyltransferase+and+5-Aminoimidazole-4-carboxamide+Ribonucleotide+Formyltransferase+and+as+Potential+Antitumor+Agents&doi=10.1021%2Fjm501787c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1021%2Fjm501787c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501787c%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMitchell-Ryan%26aufirst%3DS.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DOrr%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DZ.%26aulast%3DMatherly%26aufirst%3DL.%2BH.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DNovel%25205-Substituted%2520Pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520Dual%2520Inhibitors%2520of%2520Glycinamide%2520Ribonucleotide%2520Formyltransferase%2520and%25205-Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Formyltransferase%2520and%2520as%2520Potential%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1479%26epage%3D1493%26doi%3D10.1021%2Fjm501787c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, L.</span><span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 6-Substituted Pyrrolo[2,3-d]pyrimidines as Dual Inhibitors of TS and AICARFTase and as Potential Antitumor Agents</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.ejmech.2016.03.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2016&pages=245-256&author=Y.+Liuauthor=M.+Liauthor=H.+Zhangauthor=J.+Yuanauthor=C.+Zhangauthor=K.+Zhangauthor=H.+Guoauthor=L.+Zhaoauthor=Y.+Duauthor=L.+Wangauthor=L.+Ren&title=Design%2C+Synthesis+and+Biological+Evaluation+of+6-Substituted+Pyrrolo%5B2%2C3-d%5Dpyrimidines+as+Dual+Inhibitors+of+TS+and+AICARFTase+and+as+Potential+Antitumor+Agents&doi=10.1016%2Fj.ejmech.2016.03.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DL.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25206-Substituted%2520Pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520Dual%2520Inhibitors%2520of%2520TS%2520and%2520AICARFTase%2520and%2520as%2520Potential%2520Antitumor%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D115%26spage%3D245%26epage%3D256%26doi%3D10.1016%2Fj.ejmech.2016.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Cheong, C.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolan, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greasley, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beardsley, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. A.</span><span> </span><span class="NLM_article-title">Crystal Structures of Human Bifunctional Enzyme Aminoimidazole-4-carboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase in Complex with Potent Sulfonyl-Containing Antifolates</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">18034</span><span class="NLM_x">–</span> <span class="NLM_lpage">18045</span><span class="refDoi"> DOI: 10.1074/jbc.M313691200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1074%2Fjbc.M313691200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=14966129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Gms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=18034-18045&author=C.-G.+Cheongauthor=D.+W.+Wolanauthor=S.+E.+Greasleyauthor=P.+A.+Hortonauthor=G.+P.+Beardsleyauthor=I.+A.+Wilson&title=Crystal+Structures+of+Human+Bifunctional+Enzyme+Aminoimidazole-4-carboxamide+Ribonucleotide+Transformylase%2FIMP+Cyclohydrolase+in+Complex+with+Potent+Sulfonyl-Containing+Antifolates&doi=10.1074%2Fjbc.M313691200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Human Bifunctional Enzyme Aminoimidazole-4-carboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase in Complex with Potent Sulfonyl-containing Antifolates</span></div><div class="casAuthors">Cheong, Cheom-Gil; Wolan, Dennis W.; Greasley, Samantha E.; Horton, Patricia A.; Beardsley, G. Peter; Wilson, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">18034-18045</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase/IMP cyclohydrolase (ATIC) is a bifunctional enzyme with folate-dependent AICAR transformylase and IMP cyclohydrolase activities that catalyzes the last two steps of purine biosynthesis.  The AICAR transformylase inhibitors BW1540 and BW2315 are sulfamido-bridged 5,8-dideazafolate analogs with remarkably potent Ki values of 8 and 6 nM, resp., compared with most other antifolates.  Crystal structures of ATIC at 2.55 and 2.60 Å with each inhibitor, in the presence of substrate AICAR, revealed that the sulfonyl groups dominate inhibitor binding and orientation through interaction with the proposed oxyanion hole.  These agents then appear to mimic the anionic transition state and now implicate Asn431 in the reaction mechanism along with previously identified key catalytic residues Lys266 and His267.  Potent and selective inhibition of the AICAR transformylase active site, compared with other folate-dependent enzymes, should therefore be pursued by further design of sulfonyl-contg. antifolates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp3qimqqvhSrVg90H21EOLACvtfcHk0ljweOEDy0AiZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Gms7Y%253D&md5=4d61d94453eee4e6f22c42f3799436b2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M313691200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M313691200%26sid%3Dliteratum%253Aachs%26aulast%3DCheong%26aufirst%3DC.-G.%26aulast%3DWolan%26aufirst%3DD.%2BW.%26aulast%3DGreasley%26aufirst%3DS.%2BE.%26aulast%3DHorton%26aufirst%3DP.%2BA.%26aulast%3DBeardsley%26aufirst%3DG.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26atitle%3DCrystal%2520Structures%2520of%2520Human%2520Bifunctional%2520Enzyme%2520Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Transformylase%252FIMP%2520Cyclohydrolase%2520in%2520Complex%2520with%2520Potent%2520Sulfonyl-Containing%2520Antifolates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D18034%26epage%3D18045%26doi%3D10.1074%2Fjbc.M313691200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Wall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benkovic, S. J.</span><span> </span><span class="NLM_article-title">A Multisubstrate Adduct Inhibitor of AICAR Transformylase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3421</span><span class="NLM_x">–</span> <span class="NLM_lpage">3424</span><span class="refDoi"> DOI: 10.1021/jm990323+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990323%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3421-3424&author=M.+Wallauthor=J.+H.+Shimauthor=S.+J.+Benkovic&title=A+Multisubstrate+Adduct+Inhibitor+of+AICAR+Transformylase&doi=10.1021%2Fjm990323%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm990323%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990323%252B%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DM.%26aulast%3DShim%26aufirst%3DJ.%2BH.%26aulast%3DBenkovic%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Multisubstrate%2520Adduct%2520Inhibitor%2520of%2520AICAR%2520Transformylase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3421%26epage%3D3424%26doi%3D10.1021%2Fjm990323%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Spurr, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birts, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benkovic, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaydes, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavassoli, A.</span><span> </span><span class="NLM_article-title">Targeting Tumour Proliferation with a Small-Molecule Inhibitor of AICAR Transformylase Homodimerization</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1628</span><span class="NLM_x">–</span> <span class="NLM_lpage">1634</span><span class="refDoi"> DOI: 10.1002/cbic.201200279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1002%2Fcbic.201200279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=22764122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVelt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1628-1634&author=I.+B.+Spurrauthor=C.+N.+Birtsauthor=F.+Cudaauthor=S.+J.+Benkovicauthor=J.+P.+Blaydesauthor=A.+Tavassoli&title=Targeting+Tumour+Proliferation+with+a+Small-Molecule+Inhibitor+of+AICAR+Transformylase+Homodimerization&doi=10.1002%2Fcbic.201200279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting tumor proliferation with a small-molecule inhibitor of AICAR transformylase homodimerization</span></div><div class="casAuthors">Spurr, Ian B.; Birts, Charles N.; Cuda, Francesco; Benkovic, Stephen J.; Blaydes, Jeremy P.; Tavassoli, Ali</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1628-1634, S1628/1-S1628/44</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) is a bifunctional homodimeric enzyme that catalyzes the last two steps of de novo purine biosynthesis.  Homodimerization of ATIC, a protein-protein interaction with an interface of over 5000 Å2, is required for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity, with the active sites forming at the interface of the interacting proteins.  Here, we report the development of a small-mol. inhibitor of AICAR transformylase that functions by preventing the homodimerization of ATIC.  The compd. is derived from a previously reported cyclic hexapeptide inhibitor of AICAR transformylase (with a Ki of 17 μM), identified by high-throughput screening.  The active motif of the cyclic peptide is identified as an arginine-tyrosine dipeptide, a capped analog of which inhibits AICAR transformylase with a Ki value of 84 μM.  A library of nonnatural analogs of this dipeptide was designed, synthesized, and assayed.  The most potent compd. inhibits AICAR transformylase with a Ki value of 685 nM, a 25-fold improvement in activity from the parent cyclic peptide.  The potential for this AICAR transformylase inhibitor in cancer therapy was assessed by studying its effect on the proliferation of a model breast cancer cell line.  Using a nonradioactive proliferation assay and live cell imaging, a dose-dependent redn. in cell nos. and cell division rates was obsd. in cells treated with our ATIC dimerization inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbzH_QElMmLbVg90H21EOLACvtfcHk0ljweOEDy0AiZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVelt7k%253D&md5=4c1437a368f2fd3ac0303918b8b30a73</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201200279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201200279%26sid%3Dliteratum%253Aachs%26aulast%3DSpurr%26aufirst%3DI.%2BB.%26aulast%3DBirts%26aufirst%3DC.%2BN.%26aulast%3DCuda%26aufirst%3DF.%26aulast%3DBenkovic%26aufirst%3DS.%2BJ.%26aulast%3DBlaydes%26aufirst%3DJ.%2BP.%26aulast%3DTavassoli%26aufirst%3DA.%26atitle%3DTargeting%2520Tumour%2520Proliferation%2520with%2520a%2520Small-Molecule%2520Inhibitor%2520of%2520AICAR%2520Transformylase%2520Homodimerization%26jtitle%3DChemBioChem%26date%3D2012%26volume%3D13%26spage%3D1628%26epage%3D1634%26doi%3D10.1002%2Fcbic.201200279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tatlock, J. H.; Linton, M. A.; Condon, B.; Davies, J. F.,  II; Escobar, J. A.; Kumpf, R. A.; Lundgren, K.; Price, S.; Romines, W. H.,  III; Sisson, W.; Varney, M. D.; Worland, S. T.</span><span> </span><span class="NLM_article-title">Design, Synthesis and Evaluation of Novel 6-Arylsulfonylamino-3-chloro-benzo[b]thiophene-2-carboxylic Acid Amides: Potent, Lipophilic Inhibitors of 5-Aminoimidazole-4-carboxamide Ribonucleotide Transformylase</span>. Presented at the 217th National Meeting of the American Chemical Society, Anaheim, CA, March<span class="NLM_x"> </span><span class="NLM_year">1999</span><span class="NLM_x">; </span>Poster MEDI-041.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=J.+H.+Tatlock&author=M.+A.+Linton&author=B.+Condon&author=J.+F.+Davies&author=J.+A.+Escobar&author=R.+A.+Kumpf&author=K.+Lundgren&author=S.+Price&author=W.+H.+Romines&author=W.+Sisson&author=M.+D.+Varney&author=S.+T.+Worland&title=Design%2C+Synthesis+and+Evaluation+of+Novel+6-Arylsulfonylamino-3-chloro-benzo%5Bb%5Dthiophene-2-carboxylic+Acid+Amides%3A+Potent%2C+Lipophilic+Inhibitors+of+5-Aminoimidazole-4-carboxamide+Ribonucleotide+Transformylase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DTatlock%26aufirst%3DJ.%2BH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Evaluation%2520of%2520Novel%25206-Arylsulfonylamino-3-chloro-benzo%255Bb%255Dthiophene-2-carboxylic%2520Acid%2520Amides%253A%2520Potent%252C%2520Lipophilic%2520Inhibitors%2520of%25205-Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Transformylase%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Pearce, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. A.</span><span> </span><span class="NLM_article-title">The Evolution of Cancer Research and Drug Discovery at Lilly Research Laboratories</span> <span class="citation_source-journal">Adv. Enzyme Regul.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1016/j.advenzreg.2005.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.advenzreg.2005.02.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=229-255&author=H.+L.+Pearceauthor=M.+A.+Miller&title=The+Evolution+of+Cancer+Research+and+Drug+Discovery+at+Lilly+Research+Laboratories&doi=10.1016%2Fj.advenzreg.2005.02.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.advenzreg.2005.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.advenzreg.2005.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DPearce%26aufirst%3DH.%2BL.%26aulast%3DMiller%26aufirst%3DM.%2BA.%26atitle%3DThe%2520Evolution%2520of%2520Cancer%2520Research%2520and%2520Drug%2520Discovery%2520at%2520Lilly%2520Research%2520Laboratories%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D2005%26volume%3D45%26spage%3D229%26epage%3D255%26doi%3D10.1016%2Fj.advenzreg.2005.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Racanelli, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothbart, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R. G.</span><span> </span><span class="NLM_article-title">Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">5467</span><span class="NLM_x">–</span> <span class="NLM_lpage">5474</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1158%2F0008-5472.CAN-08-4979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=19549896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFajsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=5467-5474&author=A.+C.+Racanelliauthor=S.+B.+Rothbartauthor=C.+L.+Heyerauthor=R.+G.+Moran&title=Therapeutics+by+Cytotoxic+Metabolite+Accumulation%3A+Pemetrexed+Causes+ZMP+Accumulation%2C+AMPK+Activation%2C+and+Mammalian+Target+of+Rapamycin+Inhibition&doi=10.1158%2F0008-5472.CAN-08-4979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition</span></div><div class="casAuthors">Racanelli, Alexandra C.; Rothbart, Scott B.; Heyer, Cortney L.; Moran, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5467-5474</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Pemetrexed represents the first antifolate cancer drug to be approved by the Food and Drug Administration in 20 years; it is currently in widespread use for first line therapy of mesothelioma and non-small cell lung cancer.  Pemetrexed has more than one site of action; the primary site is thymidylate synthase.  We now report that the secondary target is the downstream folate-dependent enzyme in de novo purine synthesis, aminoimidazolecarboxamide ribonucleotide formyltransferase (AICART).  The substrate of the AICART reaction, ZMP, accumulated in intact pemetrexed-inhibited tumor cells, identifying AICART as the step in purine synthesis that becomes rate-limiting after drug treatment.  The accumulating ZMP causes an activation of AMP-activated protein kinase with subsequent inhibition of the mammalian target of rapamycin (mTOR) and hypophosphorylation of the downstream targets of mTOR that control initiation of protein synthesis and cell growth.  We suggest that the activity of pemetrexed against human cancers is a reflection of its direct inhibition of folate-dependent target proteins combined with prolonged inhibition of the mTOR pathway secondary to accumulation of ZMP.  [Cancer Res 2009;69(13):5467-74].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlnjGOCRvlVLVg90H21EOLACvtfcHk0liOptbwSyYq-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFajsrc%253D&md5=6cd2a5e107455ab99524d8ed2ed3fc2d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4979%26sid%3Dliteratum%253Aachs%26aulast%3DRacanelli%26aufirst%3DA.%2BC.%26aulast%3DRothbart%26aufirst%3DS.%2BB.%26aulast%3DHeyer%26aufirst%3DC.%2BL.%26aulast%3DMoran%26aufirst%3DR.%2BG.%26atitle%3DTherapeutics%2520by%2520Cytotoxic%2520Metabolite%2520Accumulation%253A%2520Pemetrexed%2520Causes%2520ZMP%2520Accumulation%252C%2520AMPK%2520Activation%252C%2520and%2520Mammalian%2520Target%2520of%2520Rapamycin%2520Inhibition%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D5467%26epage%3D5474%26doi%3D10.1158%2F0008-5472.CAN-08-4979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Rothbart, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racanelli, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R. G.</span><span> </span><span class="NLM_article-title">Pemetrexed Indirectly Activates the Metabolic Kinase AMPK in Human Carcinomas</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">10299</span><span class="NLM_x">–</span> <span class="NLM_lpage">10309</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1158%2F0008-5472.CAN-10-1873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=21159649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10299-10309&author=S.+B.+Rothbartauthor=A.+C.+Racanelliauthor=R.+G.+Moran&title=Pemetrexed+Indirectly+Activates+the+Metabolic+Kinase+AMPK+in+Human+Carcinomas&doi=10.1158%2F0008-5472.CAN-10-1873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pemetrexed Indirectly Activates the Metabolic Kinase AMPK in Human Carcinomas</span></div><div class="casAuthors">Rothbart, Scott B.; Racanelli, Alexandra C.; Moran, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10299-10309</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The chemotherapeutic drug pemetrexed, an inhibitor of thymidylate synthase, has an important secondary target in human leukemic cells, aminoimidazolecarboxamide ribonucleotide formyltransferase (AICART), the second folate-dependent enzyme of purine biosynthesis.  The purine intermediate aminoimidazolecarboxamide ribonucleotide (ZMP), which accumulates behind this block, transmits an inhibitory signal to the mTORC1 complex via activation of the cellular energy sensor AMP-activated kinase (AMPK).  Given that the PI3K-AKT-mTOR pathway is frequently deregulated during carcinogenesis, we asked whether the indirect activation of AMPK by pemetrexed offers an effective therapeutic strategy for carcinomas with defects in this pathway.  Activation of AMPK by ZMP in pemetrexed-treated colon and lung carcinoma cells and the downstream consequences of this activation were strikingly more robust than previously seen in leukemic cells.  Genetic expts. demonstrated the intermediacy of AICART inhibition and the centrality of AMPK activation in these effects.  Whereas AMPK activation resulted in marked inhibition of mTORC1, other targets of AMPK were phosphorylated that were not mTORC1-dependent.  Whereas AMPK activation is thought to require AMPKα T172 phosphorylation, pemetrexed also activated AMPK in carcinoma cells null for LKB1, the predominant AMPKα T172 kinase whose deficiency is common in lung adenocarcinomas.  Like rapamycin analogs, pemetrexed relieved feedback suppression of PI3K and AKT, but the prolonged accumulation of unphosphorylated 4E-BP1, a tight-binding inhibitor of cap-dependent translation, was seen following AMPK activation.  Our findings indicate that AMPK activation by pemetrexed inhibits mTORC1-dependent and -independent processes that control translation and lipid metab., identifying pemetrexed as a targeted therapeutic agent for this pathway that differs significantly from rapamycin analogs.  Cancer Res; 70(24); 10299-309.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS06UXoSFlg7Vg90H21EOLACvtfcHk0liOptbwSyYq-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7fF&md5=06fb664e3b1713aff6bdde1ccbadf23a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1873%26sid%3Dliteratum%253Aachs%26aulast%3DRothbart%26aufirst%3DS.%2BB.%26aulast%3DRacanelli%26aufirst%3DA.%2BC.%26aulast%3DMoran%26aufirst%3DR.%2BG.%26atitle%3DPemetrexed%2520Indirectly%2520Activates%2520the%2520Metabolic%2520Kinase%2520AMPK%2520in%2520Human%2520Carcinomas%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10299%26epage%3D10309%26doi%3D10.1158%2F0008-5472.CAN-10-1873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Goldman, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chattopadhyay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R.</span><span> </span><span class="NLM_article-title">The Antifolates: Evolution, New Agents in the Clinic, and how Targeting Delivery via Specific Membrane Transporters is Driving the Development of a Next Generation of Folate Analogs</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1423</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1409-1423&author=I.+D.+Goldmanauthor=S.+Chattopadhyayauthor=R.+Zhaoauthor=R.+Moran&title=The+Antifolates%3A+Evolution%2C+New+Agents+in+the+Clinic%2C+and+how+Targeting+Delivery+via+Specific+Membrane+Transporters+is+Driving+the+Development+of+a+Next+Generation+of+Folate+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DI.%2BD.%26aulast%3DChattopadhyay%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DMoran%26aufirst%3DR.%26atitle%3DThe%2520Antifolates%253A%2520Evolution%252C%2520New%2520Agents%2520in%2520the%2520Clinic%252C%2520and%2520how%2520Targeting%2520Delivery%2520via%2520Specific%2520Membrane%2520Transporters%2520is%2520Driving%2520the%2520Development%2520of%2520a%2520Next%2520Generation%2520of%2520Folate%2520Analogs%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D11%26spage%3D1409%26epage%3D1423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Visentin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, I. D.</span><span> </span><span class="NLM_article-title">The Antifolates</span> <span class="citation_source-journal">Hematol. Oncol. Clin. N. Am.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">629</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span><span class="refDoi"> DOI: 10.1016/j.hoc.2012.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.hoc.2012.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=22520983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A280%3ADC%252BC38rmslyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=629-648&author=M.+Visentinauthor=R.+Zhaoauthor=I.+D.+Goldman&title=The+Antifolates&doi=10.1016%2Fj.hoc.2012.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">The antifolates</span></div><div class="casAuthors">Visentin Michele; Zhao Rongbao; Goldman I David</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-48, ix</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics.  New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTs6Vk1KGWrT_h3YQQtAhNufW6udTcc2eb2TiZU7Rw2Prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rmslyiuw%253D%253D&md5=516c6432e647418b245aba234c1dd545</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.hoc.2012.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hoc.2012.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DVisentin%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DGoldman%26aufirst%3DI.%2BD.%26atitle%3DThe%2520Antifolates%26jtitle%3DHematol.%2520Oncol.%2520Clin.%2520N.%2520Am.%26date%3D2012%26volume%3D26%26spage%3D629%26epage%3D648%26doi%3D10.1016%2Fj.hoc.2012.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Visentin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diop-Bove, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, D. I.</span><span> </span><span class="NLM_article-title">The Intestinal Absorption of Folates</span> <span class="citation_source-journal">Annu. Rev. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span><span class="refDoi"> DOI: 10.1146/annurev-physiol-020911-153251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1146%2Fannurev-physiol-020911-153251" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=251-274&author=M.+Visentinauthor=N.+Diop-Boveauthor=R.+Zhaoauthor=D.+I.+Goldman&title=The+Intestinal+Absorption+of+Folates&doi=10.1146%2Fannurev-physiol-020911-153251"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1146%2Fannurev-physiol-020911-153251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-physiol-020911-153251%26sid%3Dliteratum%253Aachs%26aulast%3DVisentin%26aufirst%3DM.%26aulast%3DDiop-Bove%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DGoldman%26aufirst%3DD.%2BI.%26atitle%3DThe%2520Intestinal%2520Absorption%2520of%2520Folates%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2014%26volume%3D76%26spage%3D251%26epage%3D274%26doi%3D10.1146%2Fannurev-physiol-020911-153251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Faessel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slocum, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boritzki, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustum, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, W. R.</span><span> </span><span class="NLM_article-title">Super <i>in Vitro</i> Synergy Between Inhibitors of Dihydrofolate Reductase and Inhibitors of Other Folate-requiring Enzymes: The Critical Role of Polyglutamylation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3036</span><span class="NLM_x">–</span> <span class="NLM_lpage">3050</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=3036-3050&author=H.+M.+Faesselauthor=H.+K.+Slocumauthor=R.+C.+Jacksonauthor=T.+J.+Boritzkiauthor=R.+M.+Rustumauthor=M.+G.+Nairauthor=W.+R.+Greco&title=Super+in+Vitro+Synergy+Between+Inhibitors+of+Dihydrofolate+Reductase+and+Inhibitors+of+Other+Folate-requiring+Enzymes%3A+The+Critical+Role+of+Polyglutamylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaessel%26aufirst%3DH.%2BM.%26aulast%3DSlocum%26aufirst%3DH.%2BK.%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DBoritzki%26aufirst%3DT.%2BJ.%26aulast%3DRustum%26aufirst%3DR.%2BM.%26aulast%3DNair%26aufirst%3DM.%2BG.%26aulast%3DGreco%26aufirst%3DW.%2BR.%26atitle%3DSuper%2520in%2520Vitro%2520Synergy%2520Between%2520Inhibitors%2520of%2520Dihydrofolate%2520Reductase%2520and%2520Inhibitors%2520of%2520Other%2520Folate-requiring%2520Enzymes%253A%2520The%2520Critical%2520Role%2520of%2520Polyglutamylation%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D3036%26epage%3D3050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Allegra, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drake, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolivet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabner, B. A.</span><span> </span><span class="NLM_article-title">Inhibition of Phosphoribosylaminoimidazolecarboxamide Transformylase by Methotrexate and Dihydrofolic Acid Polyglutamates</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">4881</span><span class="NLM_x">–</span> <span class="NLM_lpage">4885</span><span class="refDoi"> DOI: 10.1073/pnas.82.15.4881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1073%2Fpnas.82.15.4881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=3860829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADyaL2MXltFGrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=4881-4885&author=C.+J.+Allegraauthor=J.+C.+Drakeauthor=J.+Jolivetauthor=B.+A.+Chabner&title=Inhibition+of+Phosphoribosylaminoimidazolecarboxamide+Transformylase+by+Methotrexate+and+Dihydrofolic+Acid+Polyglutamates&doi=10.1073%2Fpnas.82.15.4881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates</span></div><div class="casAuthors">Allegra, Carmen J.; Drake, James C.; Jolivet, Jacques; Chabner, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4881-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The enhanced inhibitory potency of methotrexate polyglutamate (MTX polyglutamate)  [82334-40-5] and dihydrofolate pentaglutamate  [98204-33-2] on the catalytic activity of phosphoribosylaminoimidazolecarboxamide transformylase (AICAR transformylase)  [9032-03-5] purified from MCF-7 human breast cancer cells was detd.  MTX  [59-05-2] and dihydrofolate  [4033-27-6] both monoglutamates, were weak competitive inhibitors of AICAR transformylase with Ki of 143 and 63 μM, resp., and their inhibitory capacity was largely unaffected by the glutamated state of the folate cosubstrate.  In contrast, MTX polyglutamates were potent competitive inhibitors, with an ≈10-fold increase in inhibitory potency with the addn. of each glutamate group up to 4 (i.e., the pentaglutamate deriv.  [80801-53-2]).  MTX tetraglutamate  [80801-54-3] and MTX pentaglutamates were the most potent, with equiv. Kis of 5.6 × 10-8 M; they were 2500-fold more potent than MTX.  Dihydrofolate pentaglutamate was as potent an inhibitor as MTX pentaglutamate, with a Ki of 4.3 × 10-8 M.  The potent inhibitory effects demonstrated by the polyglutamate compds., when tested against the folate monoglutamate substrate were sharply curtailed when folate pentaglutamate was used as the substrate.  MTX and dehydrofolate pentaglutamates were only 7- and 25-fold more potent than their monoglutamate counterparts under these conditions.  A model depicting these complex interactions is postulated.  These findings have significant implications regarding the antitumor mechanism of action of MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsdj6Jb-DzFrVg90H21EOLACvtfcHk0lis5fVkcJItsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltFGrt7k%253D&md5=2e89e65beda64b5972a7dd689b928311</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.82.15.4881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.82.15.4881%26sid%3Dliteratum%253Aachs%26aulast%3DAllegra%26aufirst%3DC.%2BJ.%26aulast%3DDrake%26aufirst%3DJ.%2BC.%26aulast%3DJolivet%26aufirst%3DJ.%26aulast%3DChabner%26aufirst%3DB.%2BA.%26atitle%3DInhibition%2520of%2520Phosphoribosylaminoimidazolecarboxamide%2520Transformylase%2520by%2520Methotrexate%2520and%2520Dihydrofolic%2520Acid%2520Polyglutamates%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1985%26volume%3D82%26spage%3D4881%26epage%3D4885%26doi%3D10.1073%2Fpnas.82.15.4881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span> </span><span class="NLM_article-title">Molecular Basis of Antifolate Resistance</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1007/s10555-007-9049-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1007%2Fs10555-007-9049-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=17333344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1KqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=153-181&author=Y.+G.+Assaraf&title=Molecular+Basis+of+Antifolate+Resistance&doi=10.1007%2Fs10555-007-9049-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of antifolate resistance</span></div><div class="casAuthors">Assaraf, Yehuda G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">153-181</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Folates play a key role in one-carbon metab. essential for the biosynthesis of purines, thymidylate and hence DNA replication.  The antifolate methotrexate has been rationally-designed nearly 60 years ago to potently block the folate-dependent enzyme dihydrofolate reductase (DHFR) thereby achieving temporary remissions in childhood acute leukemia.  Recently, the novel antifolates raltitrexed and pemetrexed that target thymidylate synthase (TS) and glycineamide ribonucleotide transformylase (GARTF) were introduced for the treatment of colorectal cancer and malignant pleural mesothelioma. (Anti)folates are divalent anions which predominantly use the reduced folate carrier (RFC) for their cellular uptake. (Anti)folates are retained intracellularly via polyglutamylation catalyzed by folylpoly-γ-glutamate synthetase (FPGS).  As the intracellular concn. of antifolates is crit. for their pharmacol. activity, polyglutamylation is a key determinant of antifolate cytotoxicity.  However, anticancer drug resistance phenomena pose major obstacles towards curative cancer chemotherapy.  Pre-clin. and clin. studies have identified a plethora of mechanisms of antifolate-resistance; these are frequently assocd. with qual. and/or quant. alterations in influx and/or efflux transporters of (anti)folates as well as in folate-dependent enzymes.  These include inactivating mutations and/or down-regulation of the RFC and various alterations in the target enzymes DHFR, TS and FPGS.  Furthermore, it has been recently shown that members of the ATP-binding cassette (ABC) superfamily including multidrug resistance proteins (MRP/ABCC) and breast cancer resistance protein (BCRP/ABCG2) are low affinity, high capacity ATP-driven (anti)folate efflux transporters.  This transport activity is in addn. to their established facility to extrude multiple cytotoxic agents.  Hence, by actively extruding antifolates, overexpressed MRPs and/or BCRP confer antifolate resistance.  Moreover, down-regulation of MRPs and/or BCRP results in decreased folate efflux thereby leading to expansion of the intracellular folate pool and antifolate resistance.  This chapter reviews and discusses the panoply of mol. modalities of antifolate-resistance in pre-clin. tumor cell systems in vitro and in vivo as well as in cancer patients.  Currently emerging novel strategies for the overcoming of antifolate-resistance are presented.  Finally, exptl. evidence is provided that the identification and characterization of the mol. mechanisms of antifolate-resistance may prove instrumental in the future development of rationally-based novel antifolates and strategies that could conceivably overcome drug-resistance phenomena.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4aMyulwdVTrVg90H21EOLACvtfcHk0lis5fVkcJItsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1KqtL8%253D&md5=bb228ef0ef439e83c57d606d17ad216c</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1007%2Fs10555-007-9049-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-007-9049-z%26sid%3Dliteratum%253Aachs%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26atitle%3DMolecular%2520Basis%2520of%2520Antifolate%2520Resistance%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2007%26volume%3D26%26spage%3D153%26epage%3D181%26doi%3D10.1007%2Fs10555-007-9049-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gonen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assaraf, Y. G.</span><span> </span><span class="NLM_article-title">Antifolates in Cancer Therapy: Structure, Activity, and Mechanisms of Drug Resistance</span> <span class="citation_source-journal">Drug Resist. Updates</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1016/j.drup.2012.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.drup.2012.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=22921318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWqsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=183-210&author=N.+Gonenauthor=Y.+G.+Assaraf&title=Antifolates+in+Cancer+Therapy%3A+Structure%2C+Activity%2C+and+Mechanisms+of+Drug+Resistance&doi=10.1016%2Fj.drup.2012.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance</span></div><div class="casAuthors">Gonen, Nitzan; Assaraf, Yehuda G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">183-210</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In the past 65 years, antifolates targeting folate metab. played a pivotal role in drug treatment of malignant, microbial, parasitic and chronic inflammatory diseases.  Drug discovery of novel antifolates with improved properties and superior activities remains an attractive strategy both in academia and in the pharmaceutical industry.  Among novel antifolates are pemetrexed which primarily targets thymidylate synthase as well as pralatrexate which blocks dihydrofolate reductase, and displays enhanced transport and cellular retention properties.  The present review describes the evolution and pharmacol. activity of antifolates and prospects for the development of the next generation antifolates.  Pre-clin. and clin. studies identified a plethora of mechanisms of antifolate resistance that are a primary hindrance to curative cancer chemotherapy; these are frequently assocd. with qual. and/or quant. alterations in influx and/or efflux transporters of antifolates and in folate-dependent enzymes.  Current advances including for example the deciphering of the dominant folate transporter proton-coupled folate transporter (PCFT/SLC46A1) facilitated the synthesis of exptl. antifolates aimed at selectively targeting solid tumor cells, which reside in an acidic microenvironment where PCFT supposedly functions optimally.  Moreover, drugs that are structurally and mechanistically distinct from folates were conjugated to folic acid (e.g.  Vintafolide/EC145, a folic acid desacetylvinblastine conjugate) to facilitate endocytosis via the folate receptor (FR) which is markedly overexpressed in various solid tumors.  In an alternative approach, novel antifolates selectively targeting the FR but not other folate transporters are being developed (e.g.  BGC 945). Hence, targeting mechanisms of antifolate-resistance could facilitate the development of rationally-based novel antifolates and strategies that overcome chemoresistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVjP1iploMdbVg90H21EOLACvtfcHk0lis5fVkcJItsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWqsrnO&md5=e9f7f1742c26c72a96a2fdeb2d118f1a</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2012.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2012.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DGonen%26aufirst%3DN.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26atitle%3DAntifolates%2520in%2520Cancer%2520Therapy%253A%2520Structure%252C%2520Activity%252C%2520and%2520Mechanisms%2520of%2520Drug%2520Resistance%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2012%26volume%3D15%26spage%3D183%26epage%3D210%26doi%3D10.1016%2Fj.drup.2012.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurup, S.</span><span> </span><span class="NLM_article-title">Recent Advances in Classical and Non-Classical Antifolates as Antitumor and Antiopportunistic Infection Agents: Part I</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">524</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.2174/187152007781668724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.2174%2F187152007781668724" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=524-542&author=A.+Gangjeeauthor=H.+D.+Jainauthor=S.+Kurup&title=Recent+Advances+in+Classical+and+Non-Classical+Antifolates+as+Antitumor+and+Antiopportunistic+Infection+Agents%3A+Part+I&doi=10.2174%2F187152007781668724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F187152007781668724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152007781668724%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DH.%2BD.%26aulast%3DKurup%26aufirst%3DS.%26atitle%3DRecent%2520Advances%2520in%2520Classical%2520and%2520Non-Classical%2520Antifolates%2520as%2520Antitumor%2520and%2520Antiopportunistic%2520Infection%2520Agents%253A%2520Part%2520I%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D524%26epage%3D542%26doi%3D10.2174%2F187152007781668724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Daignan-Fornier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinson, B.</span><span> </span><span class="NLM_article-title">5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl 5′-Monophosphate (AICAR), a Highly Conserved Purine Intermediate with Multiple Effects</span> <span class="citation_source-journal">Metabolites</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.3390/metabo2020292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.3390%2Fmetabo2020292" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=292-302&author=B.+Daignan-Fornierauthor=B.+Pinson&title=5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl+5%E2%80%B2-Monophosphate+%28AICAR%29%2C+a+Highly+Conserved+Purine+Intermediate+with+Multiple+Effects&doi=10.3390%2Fmetabo2020292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.3390%2Fmetabo2020292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmetabo2020292%26sid%3Dliteratum%253Aachs%26aulast%3DDaignan-Fornier%26aufirst%3DB.%26aulast%3DPinson%26aufirst%3DB.%26atitle%3D5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl%25205%25E2%2580%25B2-Monophosphate%2520%2528AICAR%2529%252C%2520a%2520Highly%2520Conserved%2520Purine%2520Intermediate%2520with%2520Multiple%2520Effects%26jtitle%3DMetabolites%26date%3D2012%26volume%3D2%26spage%3D292%26epage%3D302%26doi%3D10.3390%2Fmetabo2020292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Beckers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Organe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmermans, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderhoydonc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deboel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waelkens, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brusselmans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoeven, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinnen, J.</span><span> </span><span class="NLM_article-title">Methotrexate Enhances the Antianabolic and Antiproliferative Effects of 5-Aminoimidazole-4-carboxamide Riboside</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2217</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1158%2F1535-7163.MCT-06-0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=16985054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1yns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=2211-2217&author=A.+Beckersauthor=S.+Organeauthor=L.+Timmermansauthor=F.+Vanderhoydoncauthor=L.+Deboelauthor=R.+Deruaauthor=E.+Waelkensauthor=K.+Brusselmansauthor=G.+Verhoevenauthor=J.+Swinnen&title=Methotrexate+Enhances+the+Antianabolic+and+Antiproliferative+Effects+of+5-Aminoimidazole-4-carboxamide+Riboside&doi=10.1158%2F1535-7163.MCT-06-0001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside</span></div><div class="casAuthors">Beckers, Annelies; Organe, Sophie; Timmermans, Leen; Vanderhoydonc, Frank; Deboel, Ludo; Derua, Rita; Waelkens, Etienne; Brusselmans, Koen; Verhoeven, Guido; Swinnen, Johannes V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2211-2217</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because of its ability to mimic a low energy status of the cell, the cell-permeable nucleoside 5-aminoimidazole-4-carboxamide (AICA) riboside was proposed as an antineoplastic agent switching off major energy-consuming processes assocd. with the malignant phenotype (lipid prodn., DNA synthesis, cell proliferation, cell migration, etc.).  Key to the antineoplastic action of AICA riboside is its conversion to ZMP, an AMP mimetic that at high concns. activates the AMP-activated protein kinase (AMPK).  Here, in an attempt to increase the efficacy of AICA riboside, we pretreated cancer cells with methotrexate, an antimetabolite blocking the metab. of ZMP.  Methotrexate enhanced the AICA riboside-induced accumulation of ZMP and led to a decrease in the levels of ATP, which functions as an intrasteric inhibitor of AMPK.  Consequently, methotrexate markedly sensitized AMPK for activation by AICA riboside and potentiated the inhibitory effects of AICA riboside on tumor-assocd. processes.  As cotreatment elicited antiproliferative effects already at concns. of compds. that were only marginally effective when used alone, our findings on the cooperation between methotrexate and AICA riboside provide new opportunities both for the application of classic antimetabolic chemotherapeutics, such as methotrexate, and for the exploitation of the energy-sensing machinery as a target for cancer intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Axd8n_NZmLVg90H21EOLACvtfcHk0liHCB4dHPLmmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1yns7g%253D&md5=88ceaf92888cf2cd32926a70bb412b58</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0001%26sid%3Dliteratum%253Aachs%26aulast%3DBeckers%26aufirst%3DA.%26aulast%3DOrgane%26aufirst%3DS.%26aulast%3DTimmermans%26aufirst%3DL.%26aulast%3DVanderhoydonc%26aufirst%3DF.%26aulast%3DDeboel%26aufirst%3DL.%26aulast%3DDerua%26aufirst%3DR.%26aulast%3DWaelkens%26aufirst%3DE.%26aulast%3DBrusselmans%26aufirst%3DK.%26aulast%3DVerhoeven%26aufirst%3DG.%26aulast%3DSwinnen%26aufirst%3DJ.%26atitle%3DMethotrexate%2520Enhances%2520the%2520Antianabolic%2520and%2520Antiproliferative%2520Effects%2520of%25205-Aminoimidazole-4-carboxamide%2520Riboside%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D2211%26epage%3D2217%26doi%3D10.1158%2F1535-7163.MCT-06-0001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cronstein, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naime, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostad</span><span> </span><span class="NLM_article-title">The Antiinflammatory Mechanism of Methotrexate. Increased Adenosine Release at Inflammed Sites Diminishes Leukocyte Accumulation in an In Vivo Model of Inflammation</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">2675</span><span class="NLM_x">–</span> <span class="NLM_lpage">2682</span><span class="refDoi"> DOI: 10.1172/JCI116884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1172%2FJCI116884" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1993&pages=2675-2682&author=B.+N.+Cronsteinauthor=D.+Naimeauthor=+Ostad&title=The+Antiinflammatory+Mechanism+of+Methotrexate.+Increased+Adenosine+Release+at+Inflammed+Sites+Diminishes+Leukocyte+Accumulation+in+an+In+Vivo+Model+of+Inflammation&doi=10.1172%2FJCI116884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1172%2FJCI116884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI116884%26sid%3Dliteratum%253Aachs%26aulast%3DCronstein%26aufirst%3DB.%2BN.%26aulast%3DNaime%26aufirst%3DD.%26aulast%3DOstad%26atitle%3DThe%2520Antiinflammatory%2520Mechanism%2520of%2520Methotrexate.%2520Increased%2520Adenosine%2520Release%2520at%2520Inflammed%2520Sites%2520Diminishes%2520Leukocyte%2520Accumulation%2520in%2520an%2520In%2520Vivo%2520Model%2520of%2520Inflammation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1993%26volume%3D92%26spage%3D2675%26epage%3D2682%26doi%3D10.1172%2FJCI116884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cronstein, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberle, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, R. I.</span><span> </span><span class="NLM_article-title">Methotrexate Inhibits Neutrophil Function by Stimulating Adenosine Release From Connective Tissue Cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">2441</span><span class="NLM_x">–</span> <span class="NLM_lpage">2445</span><span class="refDoi"> DOI: 10.1073/pnas.88.6.2441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1073%2Fpnas.88.6.2441" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=2441-2445&author=B.+N.+Cronsteinauthor=M.+A.+Eberleauthor=H.+E.+Gruberauthor=R.+I.+Levin&title=Methotrexate+Inhibits+Neutrophil+Function+by+Stimulating+Adenosine+Release+From+Connective+Tissue+Cells&doi=10.1073%2Fpnas.88.6.2441"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.6.2441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.6.2441%26sid%3Dliteratum%253Aachs%26aulast%3DCronstein%26aufirst%3DB.%2BN.%26aulast%3DEberle%26aufirst%3DM.%2BA.%26aulast%3DGruber%26aufirst%3DH.%2BE.%26aulast%3DLevin%26aufirst%3DR.%2BI.%26atitle%3DMethotrexate%2520Inhibits%2520Neutrophil%2520Function%2520by%2520Stimulating%2520Adenosine%2520Release%2520From%2520Connective%2520Tissue%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D2441%26epage%3D2445%26doi%3D10.1073%2Fpnas.88.6.2441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Paintlia, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paintlia, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span> </span><span class="NLM_article-title">Immunomodulatory Effect of Combination Therapy with Lovastatin and 5-Aminoimidazaole-4-Carboxamide-1-β-D-Ribofuranoside Alleviates Neurodegeneration in Experimental Autoimmune Encephalomyelitis</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">1012</span><span class="NLM_x">–</span> <span class="NLM_lpage">1025</span><span class="refDoi"> DOI: 10.2353/ajpath.2006.051309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.2353%2Fajpath.2006.051309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=16936274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFWqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2006&pages=1012-1025&author=A.+S.+Paintliaauthor=M.+K.+Paintliaauthor=I.+Singhauthor=A.+K.+Singh&title=Immunomodulatory+Effect+of+Combination+Therapy+with+Lovastatin+and+5-Aminoimidazaole-4-Carboxamide-1-%CE%B2-D-Ribofuranoside+Alleviates+Neurodegeneration+in+Experimental+Autoimmune+Encephalomyelitis&doi=10.2353%2Fajpath.2006.051309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17eR"><div class="casContent"><span class="casTitleNuber">17e</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Paintlia, Ajaib S.; Paintlia, Manjeet K.; Singh, Inderjit; Singh, Avtar K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1012-1025</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Combination therapy with multiple sclerosis (MS) therapeutics is gaining momentum over monotherapy for improving MS.  Lovastatin, an HMG-CoA reductase inhibitor (statin), was immunomodulatory in an exptl. autoimmune encephalomyelitis (EAE) model of MS.  Lovastatin biases the immune response from Th1 to a protective Th2 response in EAE by a different mechanism than 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, an immunomodulating agent that activates AMP-activated protein kinase.  Here we tested these agents in combination in an EAE model of MS.  Suboptimal doses of these drugs in combination were additive in efficacy against the induction of EAE; clin. symptoms were delayed and severity and duration of disease was reduced.  In the central nervous system, the cellular infiltration and proinflammatory immune response was decreased while the anti-inflammatory immune response was increased.  Combination treatment biased the class of elicited myelin basic protein antibodies from IgG2a to IgG1 and IgG2b, suggesting a shift from Th1 to Th2 response.  In addn., combination therapy lessened inflammation-assocd. neurodegeneration in the central nervous system of EAE animals.  These effects were absent in EAE animals treated with either drug alone at the same dose.  Thus, our data suggest that agents with different mechanisms of action such as lovastatin and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, when used in combination, could improve therapy for central nervous system demyelinating diseases and provide a rationale for testing them in MS patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5uf8Sn0g7WLVg90H21EOLACvtfcHk0lioeznPIblJJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFWqs7w%253D&md5=624513e56a5ce4c61b59bf4ed79fcc72</span></div><a href="/servlet/linkout?suffix=cit17e&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2006.051309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2006.051309%26sid%3Dliteratum%253Aachs%26aulast%3DPaintlia%26aufirst%3DA.%2BS.%26aulast%3DPaintlia%26aufirst%3DM.%2BK.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26atitle%3DImmunomodulatory%2520Effect%2520of%2520Combination%2520Therapy%2520with%2520Lovastatin%2520and%25205-Aminoimidazaole-4-Carboxamide-1-%25CE%25B2-D-Ribofuranoside%2520Alleviates%2520Neurodegeneration%2520in%2520Experimental%2520Autoimmune%2520Encephalomyelitis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2006%26volume%3D169%26spage%3D1012%26epage%3D1025%26doi%3D10.2353%2Fajpath.2006.051309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Prasad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span> </span><span class="NLM_article-title">5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside Attenuates Experimental Autoimmune Encephalomyelitis Via Modulation of Endothelial-Monocyte Interaction</span> <span class="citation_source-journal">J. Neurosci. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1002/jnr.20953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1002%2Fjnr.20953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=16770773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD28Xotlymsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2006&pages=614-625&author=R.+Prasadauthor=S.+Giriauthor=N.+Nathauthor=I.+Singhauthor=A.+K.+Singh&title=5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside+Attenuates+Experimental+Autoimmune+Encephalomyelitis+Via+Modulation+of+Endothelial-Monocyte+Interaction&doi=10.1002%2Fjnr.20953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17fR"><div class="casContent"><span class="casTitleNuber">17f</span><div class="casTitle"><span class="NLM_cas:atitle">5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction</span></div><div class="casAuthors">Prasad, Ratna; Giri, Shailendra; Nath, Narender; Singh, Inderjit; Singh, Avtar K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">614-625</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Exptl. autoimmune encephalomyelitis (EAE) is a model for studying multiple sclerosis (MS), a chronic demyelinating disorder of the CNS.  5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR), an activator of AMP-activated protein kinase (AMPK), has been reported to show antiinflammatory and immunomodulatory effects in various models of inflammation.  Recently, we have reported AICAR-mediated attenuation of active and passive EAE in mouse model.  Here we used a rat model of acute EAE to show antiinflammatory effects of AICAR after daily treatment starting at onset of the disease.  By maintaining the blood-brain barrier (BBB), AICAR-administered animals showed lower clin. scores compared with untreated EAE animals.  AICAR inhibited the infiltration of inflammatory cells across the BBB, resulting in lowered expression of proinflammatory mediators in the CNS and protection from severe demyelination.  By using in vitro model of endothelial-leukocyte interaction, we showed that AICAR inhibited adhesion of monocytes to tumor necrosis factor-α-activated endothelial cells.  One of the mechanisms of this action is through down-regulation of expression of endothelial cell adhesion mols. via modulation of nuclear factor κB activation.  The data suggest that AICAR attenuates EAE progression by limiting infiltration of leukocytes across the BBB, thereby controlling the consequent inflammatory reaction in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO0pXpBYsR1LVg90H21EOLACvtfcHk0lioeznPIblJJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xotlymsro%253D&md5=29768d534ccac2ce1552ce22248c22f8</span></div><a href="/servlet/linkout?suffix=cit17f&amp;dbid=16384&amp;doi=10.1002%2Fjnr.20953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.20953%26sid%3Dliteratum%253Aachs%26aulast%3DPrasad%26aufirst%3DR.%26aulast%3DGiri%26aufirst%3DS.%26aulast%3DNath%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26atitle%3D5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside%2520Attenuates%2520Experimental%2520Autoimmune%2520Encephalomyelitis%2520Via%2520Modulation%2520of%2520Endothelial-Monocyte%2520Interaction%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2006%26volume%3D84%26spage%3D614%26epage%3D625%26doi%3D10.1002%2Fjnr.20953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Giri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viollet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span> </span><span class="NLM_article-title">5-Aminoimidazaole-4-Carboxamide-1-β-4-Ribofuranoside Inhibits Proinflammatory Response in Glial Cells: A Possible Role of AMP-Activated Protein Kinase</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.4288-03.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1523%2FJNEUROSCI.4288-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=14724246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvVyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=479-487&author=S.+Giriauthor=N.+Nathauthor=B.+Smithauthor=B.+Violletauthor=A.+K.+Singhauthor=I.+Singh&title=5-Aminoimidazaole-4-Carboxamide-1-%CE%B2-4-Ribofuranoside+Inhibits+Proinflammatory+Response+in+Glial+Cells%3A+A+Possible+Role+of+AMP-Activated+Protein+Kinase&doi=10.1523%2FJNEUROSCI.4288-03.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17gR"><div class="casContent"><span class="casTitleNuber">17g</span><div class="casTitle"><span class="NLM_cas:atitle">5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside inhibits proinflammatory response in glial cells: A possible role of AMP-activated protein kinase</span></div><div class="casAuthors">Giri, Shailendra; Nath, Narendra; Smith, Brian; Viollet, Benoit; Singh, Avtar K.; Singh, Inderjit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">AMP-activated protein kinase (AMPK) is tightly regulated by the cellular AMP:ATP ratio and plays a central role in the regulation of energy homeostasis and metabolic stress.  A pharmacol. activator of AMPK, 5-amino-4-imidazole carboxamide riboside (AICAR) inhibited lipopolysaccharide (LPS)-induced expression of proinflammatory cytokines (tumor necrosis factor α, interleukin-1β, and interleukin-6) and inducible nitric oxide synthase in primary rat astrocytes, microglia, and peritoneal macrophages.  AICAR attenuates the LPS-induced activation of nuclear factor κB via downregulation of IκB kinase α/β activity.  It also inhibits nuclear translocation of CCAAT/enhancer-binding protein (C/EBP) transcription factor by inhibiting the expression of C/EBP-δ in brain glial cells.  The dominant neg. form of AMPKα2 (D157A) and its antisense documents a possible role of AMPK in the regulation of the cellular proinflammatory process.  AICAR also inhibited the prodn. of inflammatory mediators in serum and their expression in CNS of rats injected with a sublethal dose of LPS by i.p. injection.  These observations in cultured cells as well as in the animal model suggest that AICAR may be of therapeutic value in treating inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqagrtIqYmE87Vg90H21EOLACvtfcHk0lioeznPIblJJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvVyjsA%253D%253D&md5=c259a37787afb327b97c1afa7c220356</span></div><a href="/servlet/linkout?suffix=cit17g&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4288-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4288-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DGiri%26aufirst%3DS.%26aulast%3DNath%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DViollet%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DSingh%26aufirst%3DI.%26atitle%3D5-Aminoimidazaole-4-Carboxamide-1-%25CE%25B2-4-Ribofuranoside%2520Inhibits%2520Proinflammatory%2520Response%2520in%2520Glial%2520Cells%253A%2520A%2520Possible%2520Role%2520of%2520AMP-Activated%2520Protein%2520Kinase%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D479%26epage%3D487%26doi%3D10.1523%2FJNEUROSCI.4288-03.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Nath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangalam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makkar, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Meester, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viollet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, S.</span><span> </span><span class="NLM_article-title">Loss of AMPK Exacerbates Experimental Autoimmune Encephalomyelitis Disease Severity</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2009.05.106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.bbrc.2009.05.106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2009&pages=16-20&author=N.+Nathauthor=M.+Khanauthor=R.+Rattanauthor=A.+Mangalamauthor=R.+S.+Makkarauthor=C.+de+Meesterauthor=L.+Bertrandauthor=I.+Singhauthor=Y.+Chenauthor=B.+Violletauthor=S.+Giri&title=Loss+of+AMPK+Exacerbates+Experimental+Autoimmune+Encephalomyelitis+Disease+Severity&doi=10.1016%2Fj.bbrc.2009.05.106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17h&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2009.05.106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2009.05.106%26sid%3Dliteratum%253Aachs%26aulast%3DNath%26aufirst%3DN.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DRattan%26aufirst%3DR.%26aulast%3DMangalam%26aufirst%3DA.%26aulast%3DMakkar%26aufirst%3DR.%2BS.%26aulast%3Dde%2BMeester%26aufirst%3DC.%26aulast%3DBertrand%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DViollet%26aufirst%3DB.%26aulast%3DGiri%26aufirst%3DS.%26atitle%3DLoss%2520of%2520AMPK%2520Exacerbates%2520Experimental%2520Autoimmune%2520Encephalomyelitis%2520Disease%2520Severity%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2009%26volume%3D386%26spage%3D16%26epage%3D20%26doi%3D10.1016%2Fj.bbrc.2009.05.106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Suzuki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeonova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morizane, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobrin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vavvas, D. G.</span><span> </span><span class="NLM_article-title">Aminoimidazole Carboxamide Ribonucleotide Ameliorates Experimental Autoimmune Uveitis</span> <span class="citation_source-journal">Invest. Ophthalmol. Visual Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4158</span><span class="NLM_x">–</span> <span class="NLM_lpage">4169</span><span class="refDoi"> DOI: 10.1167/iovs.11-9323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1167%2Fiovs.11-9323" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=4158-4169&author=J.+Suzukiauthor=T.+Yoshimuraauthor=M.+Simeonovaauthor=K.+Takeuchiauthor=K.+Murakamiauthor=Y.+Morizaneauthor=J.+W.+Millerauthor=L.+Sobrinauthor=D.+G.+Vavvas&title=Aminoimidazole+Carboxamide+Ribonucleotide+Ameliorates+Experimental+Autoimmune+Uveitis&doi=10.1167%2Fiovs.11-9323"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17i&amp;dbid=16384&amp;doi=10.1167%2Fiovs.11-9323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.11-9323%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DJ.%26aulast%3DYoshimura%26aufirst%3DT.%26aulast%3DSimeonova%26aufirst%3DM.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DK.%26aulast%3DMorizane%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DJ.%2BW.%26aulast%3DSobrin%26aufirst%3DL.%26aulast%3DVavvas%26aufirst%3DD.%2BG.%26atitle%3DAminoimidazole%2520Carboxamide%2520Ribonucleotide%2520Ameliorates%2520Experimental%2520Autoimmune%2520Uveitis%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2012%26volume%3D53%26spage%3D4158%26epage%3D4169%26doi%3D10.1167%2Fiovs.11-9323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Boon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosselaar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Praet, S. F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaak, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saris, W. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagenmakers, A. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tack, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargreaves, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Loon, L. J. C.</span><span> </span><span class="NLM_article-title">Intravenous AICAR Administration Reduces Hepatic Glucose Output and Inhibits Whole Body Lipolysis in Type 2 Diabetic Patients</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1893</span><span class="NLM_x">–</span> <span class="NLM_lpage">1900</span><span class="refDoi"> DOI: 10.1007/s00125-008-1108-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1007%2Fs00125-008-1108-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1893-1900&author=H.+Boonauthor=M.+Bosselaarauthor=S.+F.+E.+Praetauthor=E.+E.+Blaakauthor=W.+H.+M.+Sarisauthor=A.+J.+M.+Wagenmakersauthor=S.+L.+McGeeauthor=C.+J.+Tackauthor=P.+Smitsauthor=M.+Hargreavesauthor=L.+J.+C.+van+Loon&title=Intravenous+AICAR+Administration+Reduces+Hepatic+Glucose+Output+and+Inhibits+Whole+Body+Lipolysis+in+Type+2+Diabetic+Patients&doi=10.1007%2Fs00125-008-1108-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17j&amp;dbid=16384&amp;doi=10.1007%2Fs00125-008-1108-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-008-1108-7%26sid%3Dliteratum%253Aachs%26aulast%3DBoon%26aufirst%3DH.%26aulast%3DBosselaar%26aufirst%3DM.%26aulast%3DPraet%26aufirst%3DS.%2BF.%2BE.%26aulast%3DBlaak%26aufirst%3DE.%2BE.%26aulast%3DSaris%26aufirst%3DW.%2BH.%2BM.%26aulast%3DWagenmakers%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DMcGee%26aufirst%3DS.%2BL.%26aulast%3DTack%26aufirst%3DC.%2BJ.%26aulast%3DSmits%26aufirst%3DP.%26aulast%3DHargreaves%26aufirst%3DM.%26aulast%3Dvan%2BLoon%26aufirst%3DL.%2BJ.%2BC.%26atitle%3DIntravenous%2520AICAR%2520Administration%2520Reduces%2520Hepatic%2520Glucose%2520Output%2520and%2520Inhibits%2520Whole%2520Body%2520Lipolysis%2520in%2520Type%25202%2520Diabetic%2520Patients%26jtitle%3DDiabetologia%26date%3D2008%26volume%3D51%26spage%3D1893%26epage%3D1900%26doi%3D10.1007%2Fs00125-008-1108-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ducker, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinowitz, J. D.</span><span> </span><span class="NLM_article-title">ZMP: A Master Regulator of One-Carbon Metabolism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.1016/j.molcel.2015.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.molcel.2015.01.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2015&pages=203-204&author=G.+S.+Duckerauthor=J.+D.+Rabinowitz&title=ZMP%3A+A+Master+Regulator+of+One-Carbon+Metabolism&doi=10.1016%2Fj.molcel.2015.01.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DDucker%26aufirst%3DG.%2BS.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26atitle%3DZMP%253A%2520A%2520Master%2520Regulator%2520of%2520One-Carbon%2520Metabolism%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D57%26spage%3D203%26epage%3D204%26doi%3D10.1016%2Fj.molcel.2015.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breaker, R. R.</span><span> </span><span class="NLM_article-title">An Ancient Riboswitch Class in Bacteria Regulates Purine Biosynthesis and One-Carbon Metabolism</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.1016/j.molcel.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.molcel.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=25616067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFaltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2015&pages=317-328&author=P.+B.+Kimauthor=J.+W.+Nelsonauthor=R.+R.+Breaker&title=An+Ancient+Riboswitch+Class+in+Bacteria+Regulates+Purine+Biosynthesis+and+One-Carbon+Metabolism&doi=10.1016%2Fj.molcel.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">An ancient riboswitch class in bacteria regulates purine biosynthesis and one-carbon metabolism</span></div><div class="casAuthors">Kim, Peter B.; Nelson, James W.; Breaker, Ronald R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Over 30 years ago, ZTP (5-aminoimidazole-4-carboxamide riboside 5'-triphosphate), a modified purine biosynthetic intermediate, was proposed to signal 10-formyl-tetrahydrofolate (10f-THF) deficiency in bacteria.  However, the mechanisms by which this putative alarmone or its precursor ZMP (5-aminoimidazole-4-carboxamide ribonucleotide, also known as AICAR) brings about any metabolic changes remain unexplained.  Here, the authors report the existence of a widespread riboswitch class that is most commonly assocd. with genes related to de novo purine biosynthesis and one-carbon metab.  Biochem. data confirm that members of this riboswitch class selectively bind ZMP and ZTP with nanomolar affinity while strongly rejecting numerous natural analogs.  Indeed, increases in the ZMP/ZTP pool, caused by folate stress in bacterial cells, trigger changes in the expression of a reporter gene fused to representative ZTP riboswitches in vivo.  The wide distribution of this riboswitch class suggests that ZMP/ZTP signaling is important for species in numerous bacterial lineages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdpQHIlDzVcbVg90H21EOLACvtfcHk0lhSWadvmiAzhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFaltb8%253D&md5=179de504539f88b10e860fbc28aa8928</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DP.%2BB.%26aulast%3DNelson%26aufirst%3DJ.%2BW.%26aulast%3DBreaker%26aufirst%3DR.%2BR.%26atitle%3DAn%2520Ancient%2520Riboswitch%2520Class%2520in%2520Bacteria%2520Regulates%2520Purine%2520Biosynthesis%2520and%2520One-Carbon%2520Metabolism%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D57%26spage%3D317%26epage%3D328%26doi%3D10.1016%2Fj.molcel.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cronstein, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamen, B. A.</span><span> </span><span class="NLM_article-title">5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside (AICA-riboside) as a Targeting Agent for Therapy of Patients with Acute Lymphoblastic Leukemia: Are we There and are There Pitfalls?</span> <span class="citation_source-journal">J. Pediatr. Hematol./Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span><span class="refDoi"> DOI: 10.1097/MPH.0b013e31815bbb83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1097%2FMPH.0b013e31815bbb83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=18090925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVCitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2007&pages=805-807&author=B.+N.+Cronsteinauthor=B.+A.+Kamen&title=5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside+%28AICA-riboside%29+as+a+Targeting+Agent+for+Therapy+of+Patients+with+Acute+Lymphoblastic+Leukemia%3A+Are+we+There+and+are+There+Pitfalls%3F&doi=10.1097%2FMPH.0b013e31815bbb83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICA-riboside) as a targeting agent for therapy of patients with acute lymphoblastic leukemia: are we there and are there pitfalls?</span></div><div class="casAuthors">Cronstein, Bruce N.; Kamen, Barton A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pediatric Hematology/Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">805-807</span>CODEN:
                <span class="NLM_cas:coden">JPHOFG</span>;
        ISSN:<span class="NLM_cas:issn">1077-4114</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The research of Sengupta and colleagues et al. (2007) entitled, "Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy" is reviewed with commentary and refs.  The authors revealed that AICA-riboside effects were assocd. with its metab. to acadesine monophosphate (ZMP) with the presence of iodotubericidin which blocks the cytotoxicity.  Their work also provides the expanding the importance of basic cell biol.-biochem. as relating to the pharmacol. of cytotoxic therapy, whether it is for a patient with cancer or an autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXecfLSi_j-rVg90H21EOLACvtfcHk0lhSWadvmiAzhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVCitw%253D%253D&md5=ff265537e42999e00c168d5ed91eb8d5</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1097%2FMPH.0b013e31815bbb83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMPH.0b013e31815bbb83%26sid%3Dliteratum%253Aachs%26aulast%3DCronstein%26aufirst%3DB.%2BN.%26aulast%3DKamen%26aufirst%3DB.%2BA.%26atitle%3D5-Aminoimidazaole-4-Carboxamide-1-Beta-4-Ribofuranoside%2520%2528AICA-riboside%2529%2520as%2520a%2520Targeting%2520Agent%2520for%2520Therapy%2520of%2520Patients%2520with%2520Acute%2520Lymphoblastic%2520Leukemia%253A%2520Are%2520we%2520There%2520and%2520are%2520There%2520Pitfalls%253F%26jtitle%3DJ.%2520Pediatr.%2520Hematol.%252FOncol.%26date%3D2007%26volume%3D29%26spage%3D805%26epage%3D807%26doi%3D10.1097%2FMPH.0b013e31815bbb83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sengupta, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leclerc, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh-Kinser, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leclerc, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barredo, J. C.</span><span> </span><span class="NLM_article-title">Cytotoxic Effect of 5-Aminoimidazaole-4-Carboxamide-1-β-4-Ribofuranoside (AICAR) on Childhood Acute Lymphoblastic Leukemia (ALL) Cells: Implication for Targeted Therapy</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1186/1476-4598-6-46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1186%2F1476-4598-6-46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=17623090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A280%3ADC%252BD2svnvFSluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=46-57&author=T.+K.+Senguptaauthor=G.+M.+Leclercauthor=T.+T.+Hsieh-Kinserauthor=G.+J.+Leclercauthor=I.+Singhauthor=J.+C.+Barredo&title=Cytotoxic+Effect+of+5-Aminoimidazaole-4-Carboxamide-1-%CE%B2-4-Ribofuranoside+%28AICAR%29+on+Childhood+Acute+Lymphoblastic+Leukemia+%28ALL%29+Cells%3A+Implication+for+Targeted+Therapy&doi=10.1186%2F1476-4598-6-46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy</span></div><div class="casAuthors">Sengupta Tapas K; Leclerc Gilles M; Hsieh-Kinser Ting Ting; Leclerc Guy J; Singh Inderjit; Barredo Julio C</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy affecting children.  Despite significant progress and success in the treatment of ALL, a significant number of children continue to relapse and for them, outcome remains poor.  Therefore, the search for novel therapeutic approaches is warranted.  The aim of this study was to investigate the AMP activated protein kinase (AMPK) as a potential target in childhood acute lymphoblastic leukemia (ALL) subtypes characterized by non-random translocation signature profiles.  We evaluated the effects of the AMPK activator AICAR on cell growth, cell cycle regulators and apoptosis of various childhood ALL cells.  RESULTS:  We found that treatment with AICAR inhibited cell proliferation, induced cell cycle arrest in G1-phase, and apoptosis in CCRF-CEM (T-ALL), NALM6 (Bp-ALL), REH (Bp-ALL, TEL/AML1) and SupB15 (Bp-ALL, BCR/ABL) cells.  These effects were abolished by treatment with the adenosine kinase inhibitor 5'-iodotubericidin prior to addition of AICAR indicating that AICAR's cytotoxicity is mediated through AMPK activation.  Moreover, we determined that growth inhibition exerted by AICAR was associated with activation of p38-MAPK and increased expression of the cell cycle regulators p27 and p53.  We also demonstrated that AICAR mediated apoptosis through the mitochondrial pathway as revealed by the release of cytochrome C and cleavage of caspase 9.  Additionally, AICAR treatment resulted in phosphorylation of Akt suggesting that activation of the PI3K/Akt pathway may represent a compensatory survival mechanism in response to apoptosis and/or cell cycle arrest.  Combined treatment with AICAR and the mTOR inhibitor rapamycin resulted in additive anti-proliferative activity ALL cells.  CONCLUSION:  AICAR-mediated AMPK activation was found to be a proficient cytotoxic agent in ALL cells and the mechanism of its anti-proliferative and apoptotic effect appear to be mediated via activation of p38-MAPK pathway, increased expression of cell cycle inhibitory proteins p27 and p53, and downstream effects on the mTOR pathway, hence exhibiting therapeutic potential as a molecular target for the treatment of childhood ALL.  Therefore, activation of AMPK by AICAR represents a novel approach to targeted therapy, and suggests a role for AICAR in combination therapy with inhibitors of the PI3K/Akt/mTOR pathways for the treatment of childhood in ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeVb-EeO_GZ3WEEzDrymxmfW6udTcc2eZu5maBEisMJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svnvFSluw%253D%253D&md5=5dfd9429d790df4f0c3a5ce6285d2273</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-6-46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-6-46%26sid%3Dliteratum%253Aachs%26aulast%3DSengupta%26aufirst%3DT.%2BK.%26aulast%3DLeclerc%26aufirst%3DG.%2BM.%26aulast%3DHsieh-Kinser%26aufirst%3DT.%2BT.%26aulast%3DLeclerc%26aufirst%3DG.%2BJ.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DBarredo%26aufirst%3DJ.%2BC.%26atitle%3DCytotoxic%2520Effect%2520of%25205-Aminoimidazaole-4-Carboxamide-1-%25CE%25B2-4-Ribofuranoside%2520%2528AICAR%2529%2520on%2520Childhood%2520Acute%2520Lymphoblastic%2520Leukemia%2520%2528ALL%2529%2520Cells%253A%2520Implication%2520for%2520Targeted%2520Therapy%26jtitle%3DMol.%2520Cancer%26date%3D2007%26volume%3D6%26spage%3D46%26epage%3D57%26doi%3D10.1186%2F1476-4598-6-46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Cheong, C.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolan, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greasley, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horton, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beardsley, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. A.</span><span> </span><span class="NLM_article-title">Crystal Structures of Human Bifunctional Enzyme Aminoimidazole-4-carboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase in Complex with Potent Sulfonyl-containing Antifolates</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">18034</span><span class="NLM_x">–</span> <span class="NLM_lpage">18045</span><span class="refDoi"> DOI: 10.1074/jbc.M313691200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1074%2Fjbc.M313691200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=14966129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Gms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=18034-18045&author=C.-G.+Cheongauthor=D.+W.+Wolanauthor=S.+E.+Greasleyauthor=P.+A.+Hortonauthor=G.+P.+Beardsleyauthor=I.+A.+Wilson&title=Crystal+Structures+of+Human+Bifunctional+Enzyme+Aminoimidazole-4-carboxamide+Ribonucleotide+Transformylase%2FIMP+Cyclohydrolase+in+Complex+with+Potent+Sulfonyl-containing+Antifolates&doi=10.1074%2Fjbc.M313691200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Human Bifunctional Enzyme Aminoimidazole-4-carboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase in Complex with Potent Sulfonyl-containing Antifolates</span></div><div class="casAuthors">Cheong, Cheom-Gil; Wolan, Dennis W.; Greasley, Samantha E.; Horton, Patricia A.; Beardsley, G. Peter; Wilson, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">18034-18045</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase/IMP cyclohydrolase (ATIC) is a bifunctional enzyme with folate-dependent AICAR transformylase and IMP cyclohydrolase activities that catalyzes the last two steps of purine biosynthesis.  The AICAR transformylase inhibitors BW1540 and BW2315 are sulfamido-bridged 5,8-dideazafolate analogs with remarkably potent Ki values of 8 and 6 nM, resp., compared with most other antifolates.  Crystal structures of ATIC at 2.55 and 2.60 Å with each inhibitor, in the presence of substrate AICAR, revealed that the sulfonyl groups dominate inhibitor binding and orientation through interaction with the proposed oxyanion hole.  These agents then appear to mimic the anionic transition state and now implicate Asn431 in the reaction mechanism along with previously identified key catalytic residues Lys266 and His267.  Potent and selective inhibition of the AICAR transformylase active site, compared with other folate-dependent enzymes, should therefore be pursued by further design of sulfonyl-contg. antifolates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp3qimqqvhSrVg90H21EOLACvtfcHk0lh0ogQyFuA2SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Gms7Y%253D&md5=4d61d94453eee4e6f22c42f3799436b2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M313691200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M313691200%26sid%3Dliteratum%253Aachs%26aulast%3DCheong%26aufirst%3DC.-G.%26aulast%3DWolan%26aufirst%3DD.%2BW.%26aulast%3DGreasley%26aufirst%3DS.%2BE.%26aulast%3DHorton%26aufirst%3DP.%2BA.%26aulast%3DBeardsley%26aufirst%3DG.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26atitle%3DCrystal%2520Structures%2520of%2520Human%2520Bifunctional%2520Enzyme%2520Aminoimidazole-4-carboxamide%2520Ribonucleotide%2520Transformylase%252FIMP%2520Cyclohydrolase%2520in%2520Complex%2520with%2520Potent%2520Sulfonyl-containing%2520Antifolates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D18034%26epage%3D18045%26doi%3D10.1074%2Fjbc.M313691200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Leamon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomfield, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emsweller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westrick, E.</span><span> </span><span class="NLM_article-title">Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span><span class="refDoi"> DOI: 10.1124/jpet.108.143206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1124%2Fjpet.108.143206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=18791065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=918-925&author=C.+P.+Leamonauthor=J.+A.+Reddyauthor=R.+Dortonauthor=A.+Bloomfieldauthor=K.+Emswellerauthor=N.+Parkerauthor=E.+Westrick&title=Impact+of+High+and+Low+Folate+Diets+on+Tissue+Folate+Receptor+Levels+and+Antitumor+Responses+Toward+Folate-Drug+Conjugates&doi=10.1124%2Fjpet.108.143206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates</span></div><div class="casAuthors">Leamon, Christopher P.; Reddy, Joseph A.; Dorton, Ryan; Bloomfield, Alicia; Emsweller, Kristen; Parker, Nikki; Westrick, Elaine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The effects of feeding diets high and low in folic acid (folate) on assocd. changes in blood serum and red blood cell (RBC) folate levels, tissue-derived folate receptor levels, and the ability of folate-drug conjugates (EC-145, EC-0225, EC-0305) to bind and exert activity against folate receptor (FR)-pos. KB tumor xenografts were studied in lab. mice.  Serum and RBC folate concns. sharply decreased immediately after the mice were switched to low folate diets, but both parameters reached steady-state ("human-like") levels after 6 wk.  The tissue-related folate binding capacities were also decreased during the dietary modulation period, whereas the net uptake of radiolabeled folate conjugate was simultaneously increased 2.6- and 5-fold in FR-pos. kidney and tumor tissues, resp.  The performances of several clin. and preclinically relevant folate-drug conjugates were evaluated against tumors in mice that were fed high or low folate diets.  Except when administered at doses 6-fold less than required to sat. endogenous FR, no significant loss of antitumor activity was obsd.  Thus, lowering the dietary intake of folates in mice had little impact on the biol. activity of repetitively dosed folate-targeted agents, but low folate diet regimens decreased blood serum and RBC folate levels down to levels that more closely approx. the normal human folate ranges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaevhtqP7xLbVg90H21EOLACvtfcHk0lh0ogQyFuA2SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtLnN&md5=231e3a4c1d4f940bd6521fcc91bf0d67</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.143206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.143206%26sid%3Dliteratum%253Aachs%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26aulast%3DReddy%26aufirst%3DJ.%2BA.%26aulast%3DDorton%26aufirst%3DR.%26aulast%3DBloomfield%26aufirst%3DA.%26aulast%3DEmsweller%26aufirst%3DK.%26aulast%3DParker%26aufirst%3DN.%26aulast%3DWestrick%26aufirst%3DE.%26atitle%3DImpact%2520of%2520High%2520and%2520Low%2520Folate%2520Diets%2520on%2520Tissue%2520Folate%2520Receptor%2520Levels%2520and%2520Antitumor%2520Responses%2520Toward%2520Folate-Drug%2520Conjugates%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D918%26epage%3D925%26doi%3D10.1124%2Fjpet.108.143206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Venn, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riddell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisholm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aitken, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossaak, J. I.</span><span> </span><span class="NLM_article-title">Assessment of Three Levels of Folic Acid on Serum Folate and Plasma Homocysteine: a Randomised Placebo-Controlled Double-Blind Dietary InterventionTrial</span> <span class="citation_source-journal">Eur. J. Clin. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">748</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span><span class="refDoi"> DOI: 10.1038/sj.ejcn.1601388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1038%2Fsj.ejcn.1601388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=12122551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD38Xltlamur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2002&pages=748-754&author=B.+J.+Vennauthor=J.+I.+Mannauthor=S.+M.+Williamsauthor=L.+J.+Riddellauthor=A.+Chisholmauthor=M.+J.+Harperauthor=W.+Aitkenauthor=J.+I.+Rossaak&title=Assessment+of+Three+Levels+of+Folic+Acid+on+Serum+Folate+and+Plasma+Homocysteine%3A+a+Randomised+Placebo-Controlled+Double-Blind+Dietary+InterventionTrial&doi=10.1038%2Fsj.ejcn.1601388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomised placebo-controlled double-blind dietary intervention trial</span></div><div class="casAuthors">Venn, B. J.; Mann, J. I.; Williams, S. M.; Riddell, L. J.; Chisholm, A.; Harper, M. J.; Aitken, W.; Rossaak, J. I.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Nutrition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">EJCNEQ</span>;
        ISSN:<span class="NLM_cas:issn">0954-3007</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">OBJECTIVE: To det. the min. ED of folic acid required to appreciably increase serum folate and to produce a significant redn. in plasma total homocysteine (tHcy).  DESIGN: Double-blind, randomised placebo-controlled intervention trial.  SETTING: Community-based project in a New Zealand city.  SUBJECTS: Seventy free living men and women with tHcy≥10 μmol/l.  Mean age (range) was 58 (29-90) yr.  INTERVENTIONS: Daily consumption over 4 wk of 20 g breakfast cereal either unfortified (placebo) or fortified with 100, 200 or 300 μg folic acid.  Dietary intake was detd. by weighed diet records and consumption of com. fortified products was avoided.  MAIN OUTCOME MEASURES: Plasma tHcy and serum folate concns.  RESULTS: Av. serum folate concns. (95% CI) increased significantly in the treatment groups relative to the control group by 28(9-51)%, 60(37-87)% and 79(51-114)% for supplementation with 100, 200 and 300 μg folic acid, resp.  A redn. in tHcy was obsd., being 16(8-22)%, 12(4-18)% and 17(9-24)% in the three treatment groups, resp.  CONCLUSIONS: A regular intake of as little as 100 μg folic acid per day was sufficient to lower tHcy in persons at the upper end of the normal range for tHcy.  Low-level fortification may also be appropriate for lowering the risk of neural tube defects given that, when aggregated from all sources, the total intake of folic acid may be sufficiently high to adequately improve the folate status of young women.  FUNDING: The breakfast cereals were supplied and the study partially funded by Kellogg Company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEhns33z2Qw7Vg90H21EOLACvtfcHk0lh0ogQyFuA2SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xltlamur4%253D&md5=0ca59ded8834273949001c36c4c0e262</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fsj.ejcn.1601388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ejcn.1601388%26sid%3Dliteratum%253Aachs%26aulast%3DVenn%26aufirst%3DB.%2BJ.%26aulast%3DMann%26aufirst%3DJ.%2BI.%26aulast%3DWilliams%26aufirst%3DS.%2BM.%26aulast%3DRiddell%26aufirst%3DL.%2BJ.%26aulast%3DChisholm%26aufirst%3DA.%26aulast%3DHarper%26aufirst%3DM.%2BJ.%26aulast%3DAitken%26aufirst%3DW.%26aulast%3DRossaak%26aufirst%3DJ.%2BI.%26atitle%3DAssessment%2520of%2520Three%2520Levels%2520of%2520Folic%2520Acid%2520on%2520Serum%2520Folate%2520and%2520Plasma%2520Homocysteine%253A%2520a%2520Randomised%2520Placebo-Controlled%2520Double-Blind%2520Dietary%2520InterventionTrial%26jtitle%3DEur.%2520J.%2520Clin.%2520Nutr.%26date%3D2002%26volume%3D56%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fsj.ejcn.1601388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Brooks, H. B.; Dally, R. D.; Durham, T. B.; Fales, K. R.; Frimpong, K.; McCowan, J. R.; Njoroge, F. G.; Shepherd, T. A.; Si, C.; Thrasher, K. J.; Toth, J. L.; Wu, Z.</span><span> </span><span class="NLM_article-title">1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide Compounds, Formulations Containing Those Compounds, and Their Use as AICARFT Inhibitors in the Treatment of Cancers</span>. U.S. Patent 9,776,992,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span>Eli Lilly and Company.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=H.+B.+Brooks&author=R.+D.+Dally&author=T.+B.+Durham&author=K.+R.+Fales&author=K.+Frimpong&author=J.+R.+McCowan&author=F.+G.+Njoroge&author=T.+A.+Shepherd&author=C.+Si&author=K.+J.+Thrasher&author=J.+L.+Toth&author=Z.+Wu&title=1-Oxo-1%2C2-dihydroisoquinolin-7-yl-%285-substituted-thiophen-2-yl%29-sulfonamide+Compounds%2C+Formulations+Containing+Those+Compounds%2C+and+Their+Use+as+AICARFT+Inhibitors+in+the+Treatment+of+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26atitle%3D1-Oxo-1%252C2-dihydroisoquinolin-7-yl-%25285-substituted-thiophen-2-yl%2529-sulfonamide%2520Compounds%252C%2520Formulations%2520Containing%2520Those%2520Compounds%252C%2520and%2520Their%2520Use%2520as%2520AICARFT%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Cancers%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Si, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fales, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torrado, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frimpong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaoudi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandeveer, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Enantioselective Synthesis of 3,3-Difluoropyrrolidin-4-ol, a Valuable Building Block in Medicinal Chemistry</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">4359</span><span class="NLM_x">–</span> <span class="NLM_lpage">4363</span><span class="refDoi"> DOI: 10.1021/acs.joc.6b00305</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.6b00305" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=4359-4363&author=C.+Siauthor=K.+R.+Falesauthor=A.+Torradoauthor=K.+Frimpongauthor=T.+Kaoudiauthor=H.+G.+Vandeveerauthor=F.+G.+Njoroge&title=Enantioselective+Synthesis+of+3%2C3-Difluoropyrrolidin-4-ol%2C+a+Valuable+Building+Block+in+Medicinal+Chemistry&doi=10.1021%2Facs.joc.6b00305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.6b00305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.6b00305%26sid%3Dliteratum%253Aachs%26aulast%3DSi%26aufirst%3DC.%26aulast%3DFales%26aufirst%3DK.%2BR.%26aulast%3DTorrado%26aufirst%3DA.%26aulast%3DFrimpong%26aufirst%3DK.%26aulast%3DKaoudi%26aufirst%3DT.%26aulast%3DVandeveer%26aufirst%3DH.%2BG.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DEnantioselective%2520Synthesis%2520of%25203%252C3-Difluoropyrrolidin-4-ol%252C%2520a%2520Valuable%2520Building%2520Block%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2016%26volume%3D81%26spage%3D4359%26epage%3D4363%26doi%3D10.1021%2Facs.joc.6b00305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Si, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fales, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">An Efficient Synthesis of 3,4-Dihydropyridone via a Tandem Olefin Isomerization-Ring-Closing Metathesis Reaction</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5529</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2014.08.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2Fj.tetlet.2014.08.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=5529-5532&author=C.+Siauthor=K.+R.+Falesauthor=R.+D.+Boyerauthor=F.+G.+Njoroge&title=An+Efficient+Synthesis+of+3%2C4-Dihydropyridone+via+a+Tandem+Olefin+Isomerization-Ring-Closing+Metathesis+Reaction&doi=10.1016%2Fj.tetlet.2014.08.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2014.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2014.08.025%26sid%3Dliteratum%253Aachs%26aulast%3DSi%26aufirst%3DC.%26aulast%3DFales%26aufirst%3DK.%2BR.%26aulast%3DBoyer%26aufirst%3DR.%2BD.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DAn%2520Efficient%2520Synthesis%2520of%25203%252C4-Dihydropyridone%2520via%2520a%2520Tandem%2520Olefin%2520Isomerization-Ring-Closing%2520Metathesis%2520Reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2014%26volume%3D55%26spage%3D5529%26epage%3D5532%26doi%3D10.1016%2Fj.tetlet.2014.08.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">See <a href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf" class="ext-link">Supporting Information</a> for representative curves.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="note"><p class="first last">A table including the experimental results and experimental details is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Brooks, H. B.; Meier, T. I.; Geeganage, S.; Fales, K. R.; Thrasher, K. J.; Konicek, S. A.; Spencer, C. D.; Thibodeaux, S.; Foreman, R. T.; Hui, Y.-H.; Roth, K. D.; Qian, Y.-W.; Bui, H.; Wang, T.; Luo, S.; Torrado, A.; Si, C.; Toth, J. L.; McCowan, J. R.; Frimpong, K.; Lee, M. R.; Dally, R. D.; Shepherd, T. A.; Durham, T. B.; Wang, Y.; Wu, Z.; Iversen, P. W.; Starling, J. J.; Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models</span>. Unpublished work.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Brooks%2C+H.+B.%3B+Meier%2C+T.+I.%3B+Geeganage%2C+S.%3B+Fales%2C+K.+R.%3B+Thrasher%2C+K.+J.%3B+Konicek%2C+S.+A.%3B+Spencer%2C+C.+D.%3B+Thibodeaux%2C+S.%3B+Foreman%2C+R.+T.%3B+Hui%2C+Y.-H.%3B+Roth%2C+K.+D.%3B+Qian%2C+Y.-W.%3B+Bui%2C+H.%3B+Wang%2C+T.%3B+Luo%2C+S.%3B+Torrado%2C+A.%3B+Si%2C+C.%3B+Toth%2C+J.+L.%3B+McCowan%2C+J.+R.%3B+Frimpong%2C+K.%3B+Lee%2C+M.+R.%3B+Dally%2C+R.+D.%3B+Shepherd%2C+T.+A.%3B+Durham%2C+T.+B.%3B+Wang%2C+Y.%3B+Wu%2C+Z.%3B+Iversen%2C+P.+W.%3B+Starling%2C+J.+J.%3B+Njoroge%2C+F.+G.+Characterization+of+a+novel+AICARFT+inhibitor+which+potently+elevates+ZMP+and+has+anti-tumor+activity+in+murine+models.+Unpublished+work."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520AICARFT%2520inhibitor%2520which%2520potently%2520elevates%2520ZMP%2520and%2520has%2520anti-tumor%2520activity%2520in%2520murine%2520models" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Bauer, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cress, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parise, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caggiano, V.</span><span> </span><span class="NLM_article-title">Descriptive Analysis of Estrogen Receptor (ER)-Negative, Progestoerone Receptor (PR)-Negative, and HER2-Negative Invasive Breast Cancer, the So-called Triple-Negative Phenotype: A Population-Based Study From the California Cancer Registry</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">–</span> <span class="NLM_lpage">1728</span><span class="refDoi"> DOI: 10.1002/cncr.22618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1002%2Fcncr.22618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=1721-1728&author=K.+R.+Bauerauthor=M.+Brownauthor=R.+D.+Cressauthor=C.+A.+Pariseauthor=V.+Caggiano&title=Descriptive+Analysis+of+Estrogen+Receptor+%28ER%29-Negative%2C+Progestoerone+Receptor+%28PR%29-Negative%2C+and+HER2-Negative+Invasive+Breast+Cancer%2C+the+So-called+Triple-Negative+Phenotype%3A+A+Population-Based+Study+From+the+California+Cancer+Registry&doi=10.1002%2Fcncr.22618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22618%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DK.%2BR.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCress%26aufirst%3DR.%2BD.%26aulast%3DParise%26aufirst%3DC.%2BA.%26aulast%3DCaggiano%26aufirst%3DV.%26atitle%3DDescriptive%2520Analysis%2520of%2520Estrogen%2520Receptor%2520%2528ER%2529-Negative%252C%2520Progestoerone%2520Receptor%2520%2528PR%2529-Negative%252C%2520and%2520HER2-Negative%2520Invasive%2520Breast%2520Cancer%252C%2520the%2520So-called%2520Triple-Negative%2520Phenotype%253A%2520A%2520Population-Based%2520Study%2520From%2520the%2520California%2520Cancer%2520Registry%26jtitle%3DCancer%26date%3D2007%26volume%3D109%26spage%3D1721%26epage%3D1728%26doi%3D10.1002%2Fcncr.22618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Carey, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perou, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livasy, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressler, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaca, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troester, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmiston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deming, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geradts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheang, M. C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorman, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millikan, R. C.</span><span> </span><span class="NLM_article-title">Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">2492</span><span class="NLM_x">–</span> <span class="NLM_lpage">2502</span><span class="refDoi"> DOI: 10.1001/jama.295.21.2492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1001%2Fjama.295.21.2492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=16757721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsV2rtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2006&pages=2492-2502&author=L.+A.+Careyauthor=C.+M.+Perouauthor=C.+A.+Livasyauthor=L.+G.+Dresslerauthor=D.+Cowanauthor=K.+Conwayauthor=G.+Karacaauthor=M.+A.+Troesterauthor=C.+K.+Tseauthor=S.+Edmistonauthor=S.+L.+Demingauthor=J.+Geradtsauthor=M.+C.+U.+Cheangauthor=T.+O.+Nielsenauthor=P.+G.+Moormanauthor=H.+S.+Earpauthor=R.+C.+Millikan&title=Race%2C+Breast+Cancer+Subtypes%2C+and+Survival+in+the+Carolina+Breast+Cancer+Study&doi=10.1001%2Fjama.295.21.2492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study</span></div><div class="casAuthors">Carey, Lisa A.; Perou, Charles M.; Livasy, Chad A.; Dressler, Lynn G.; Cowan, David; Conway, Kathleen; Karaca, Gamze; Troester, Melissa A.; Tse, Chiu Kit; Edmiston, Sharon; Deming, Sandra L.; Geradts, Joseph; Cheang, Maggie C. U.; Nielsen, Torsten O.; Moorman, Patricia G.; Earp, H. Shelton; Millikan, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2492-2502</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Gene expression anal. has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 pos./estrogen receptor neg. (HER2+/ER-), luminal A, and luminal B.  Objectives: To det. population-based distributions and clin. assocns. for breast cancer subtypes.  Design, Setting, and Participants: Immunohistochem. surrogates for each sub-type were applied to 496 incident cases of invasive breast cancer from the Carolina Breast Cancer Study (ascertained between May 1993 and Dec. 1996), a population-based, case-control study that oversampled premenopausal and African American women.  Subtype definitions were as follows: luminal A (ER+ and/or progesterone receptor pos. [PR+], HER2-), luminal B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-, HER2-, cytokeratin 5/6 pos., and/or HER1+), HER2+/ER- (ER-, PR-, and HER2+), and unclassified (neg. for all 5 markers).  Main Outcome Measures We examd. the prevalence of breast cancer sub- types within racial and menopausal subsets and detd. their assocns. with tumor size, axillary nodal status, mitotic index, nuclear pleomorphism, combined grade, p53 mutation status, and breast cancer-specific survival.  Results: The basal-like breast cancer subtype was more prevalent among pre- menopausal African American women (39%) compared with postmenopausal African American women (14%) and non-African American women (16%) of any age (P < .001), whereas the luminal A subtype was less prevalent (36% vs 59% and 54%, resp.).  The HER2+/ER- subtype did not vary with race or menopausal status (6%-9%).  Compared with luminal A, basal-like tumors had more TP53 mutations (44% vs 15%, P < .001), higher mitotic index (odds ratio [OR], 11.0; 95% confidence interval [Cl], 5.6-21.7), more marked nuclear pleomorphism (OR, 9.7; 95% Cl, 5.3-18.0), and higher combined grade (OR, 8.3; 95% Cl, 4.4-15.6).  Breast cancer-specific survival differed by subtype (P < .001), with shortest survival among HER2+/ER- and basal-like subtypes.  Conclusions: Basal-like breast tumors occurred at a higher prevalence among pre-menopausal African American patients compared with postmenopausal African American and non-African American patients in this population-based study.  A higher prevalence of basal-like breast tumors and a lower prevalence of luminal A tumors could contribute to the poor prognosis of young African American women with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyFu0ZR8nYV7Vg90H21EOLACvtfcHk0lhmv3YMQ0aueA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsV2rtLw%253D&md5=251f6baa529a4f22a39d5b236cf9b9c7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1001%2Fjama.295.21.2492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.295.21.2492%26sid%3Dliteratum%253Aachs%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DLivasy%26aufirst%3DC.%2BA.%26aulast%3DDressler%26aufirst%3DL.%2BG.%26aulast%3DCowan%26aufirst%3DD.%26aulast%3DConway%26aufirst%3DK.%26aulast%3DKaraca%26aufirst%3DG.%26aulast%3DTroester%26aufirst%3DM.%2BA.%26aulast%3DTse%26aufirst%3DC.%2BK.%26aulast%3DEdmiston%26aufirst%3DS.%26aulast%3DDeming%26aufirst%3DS.%2BL.%26aulast%3DGeradts%26aufirst%3DJ.%26aulast%3DCheang%26aufirst%3DM.%2BC.%2BU.%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26aulast%3DMoorman%26aufirst%3DP.%2BG.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DMillikan%26aufirst%3DR.%2BC.%26atitle%3DRace%252C%2520Breast%2520Cancer%2520Subtypes%252C%2520and%2520Survival%2520in%2520the%2520Carolina%2520Breast%2520Cancer%2520Study%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2006%26volume%3D295%26spage%3D2492%26epage%3D2502%26doi%3D10.1001%2Fjama.295.21.2492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Worm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkin, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dzhandzhugazyan, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guldberg, P.</span><span> </span><span class="NLM_article-title">Methylation-dependent Silencing of the Reduced Folate Carrier Gene in Inherently Methotrexate-resistant Human Breast Cancer Cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">39990</span><span class="NLM_x">–</span> <span class="NLM_lpage">40000</span><span class="refDoi"> DOI: 10.1074/jbc.M103181200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1074%2Fjbc.M103181200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=39990-40000&author=J.+Wormauthor=A.+F.+Kirkinauthor=K.+N.+Dzhandzhugazyanauthor=P.+Guldberg&title=Methylation-dependent+Silencing+of+the+Reduced+Folate+Carrier+Gene+in+Inherently+Methotrexate-resistant+Human+Breast+Cancer+Cells&doi=10.1074%2Fjbc.M103181200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M103181200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M103181200%26sid%3Dliteratum%253Aachs%26aulast%3DWorm%26aufirst%3DJ.%26aulast%3DKirkin%26aufirst%3DA.%2BF.%26aulast%3DDzhandzhugazyan%26aufirst%3DK.%2BN.%26aulast%3DGuldberg%26aufirst%3DP.%26atitle%3DMethylation-dependent%2520Silencing%2520of%2520the%2520Reduced%2520Folate%2520Carrier%2520Gene%2520in%2520Inherently%2520Methotrexate-resistant%2520Human%2520Breast%2520Cancer%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D39990%26epage%3D40000%26doi%3D10.1074%2Fjbc.M103181200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rowe, P. B.</span><span> </span><span class="NLM_article-title">The synthesis of N5,N10-methenyltetrahydrofolic acid</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">Part B</span><span class="NLM_x">) </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">735</span><span class="refDoi"> DOI: 10.1016/S0076-6879(71)18145-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2FS0076-6879%2871%2918145-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1971&pages=733-735&issue=Part+B&author=P.+B.+Rowe&title=The+synthesis+of+N5%2CN10-methenyltetrahydrofolic+acid&doi=10.1016%2FS0076-6879%2871%2918145-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2871%2918145-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252871%252918145-1%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DP.%2BB.%26atitle%3DThe%2520synthesis%2520of%2520N5%252CN10-methenyltetrahydrofolic%2520acid%26jtitle%3DMethods%2520Enzymol.%26date%3D1971%26volume%3D18%26issue%3DPart%2520B%26spage%3D733%26epage%3D735%26doi%3D10.1016%2FS0076-6879%2871%2918145-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rabinowitz, J. C.</span><span> </span><span class="NLM_article-title">Preparation and Properties of 5,10-Methenyltetrahydrofolic Acid and 10-Formultetrahydrofolic acid</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1963</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">814</span><span class="NLM_x">–</span> <span class="NLM_lpage">815</span><span class="refDoi"> DOI: 10.1016/0076-6879(63)06256-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;key=10.1016%2F0076-6879%2863%2906256-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1963&pages=814-815&author=J.+C.+Rabinowitz&title=Preparation+and+Properties+of+5%2C10-Methenyltetrahydrofolic+Acid+and+10-Formultetrahydrofolic+acid&doi=10.1016%2F0076-6879%2863%2906256-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1016%2F0076-6879%2863%2906256-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0076-6879%252863%252906256-X%26sid%3Dliteratum%253Aachs%26aulast%3DRabinowitz%26aufirst%3DJ.%2BC.%26atitle%3DPreparation%2520and%2520Properties%2520of%25205%252C10-Methenyltetrahydrofolic%2520Acid%2520and%252010-Formultetrahydrofolic%2520acid%26jtitle%3DMethods%2520Enzymol.%26date%3D1963%26volume%3D6%26spage%3D814%26epage%3D815%26doi%3D10.1016%2F0076-6879%2863%2906256-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1pl0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1pl0','PDB','1pl0'); return false;">PDB: 1pl0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UZ0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UZ0','PDB','5UZ0'); return false;">PDB: 5UZ0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=lp10" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=lp10','PDB','lp10'); return false;">PDB: lp10</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UY8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UY8','PDB','5UY8'); return false;">PDB: 5UY8</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i56"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01046">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_54714"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01046">10.1021/acs.jmedchem.7b01046</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">In vitro assays used to characterize the enzymatic selectivity of AICARFT inhibitors, ZMP response for compound <b>28a</b> showing effect of low vs high folate in NCI-H460 cells, Alamar Blue response of compound <b>28a</b> after 7 days of treatment in NCI-H460 and MDA-MB-231 cells, dose–response in vivo target inhibition results (H460, low folate diet, 4 h), and protein expression and purification of AICARFT (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_001.pdf">jm7b01046_si_001.pdf (351.07 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01046/suppl_file/jm7b01046_si_002.csv">jm7b01046_si_002.csv (2.34 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes for <b>28a</b> and <b>32b</b> in complex with human ATIC are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UZ0">5UZ0</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UY8">5UY8</a>. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01046&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01046%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01046" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c2d17ee7221c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
